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DEDICATION 
To all HPV vaccine-eligible persons, may they never have to face a preventable cancer 
diagnosis.  
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ABSTRACT 
 
Background: The HPV vaccine is a primary prevention method available to reduce the burden 
of HPV-related cancers and genital warts. The vaccine is currently approved for catch-up 
vaccination among women 18 to 26 years of age. Despite this recommendation, the rate of 
vaccine uptake among this group is considerably low (~34% uptake). One demographic 
characteristic that is consistently reported as a risk factor for non-vaccination is relationship 
status, specifically married or monogamous relationships. While the epidemiological data 
confirm this association, there is a lack of understanding how this risk factor operates. By 
elucidating the mechanism for this risk factor, HPV vaccine uptake among this consistently 
unvaccinated group could be improved.  
Purpose: The purpose of this study was to understand how young adult women’s relationship 
status influence informational needs, motivations, and behavioral skills related to HPV 
vaccination. This objective was achieved through the following specific aims: (1) assess how 
relationship status affects primary reasons for non-vaccination among 18 to 26 year old women; 
and (2) understand how relationship status frames HPV vaccine decision-making among 18 to 26 
year old women. 
Methods: To effectively achieve these specific aims, a concurrent mixed-methods study design 
was conducted. In Phase I, a secondary data analysis using the 2010 National Health Interview 
Survey was employed to determine if women in relationships are less likely to be interested in 
vaccination and identify the primary reasons (e.g., misinformation, motivations, behavioral 
skills) for non-vaccination among different relationship status categories. In Phase II, in-depth 
x 
interviews were conducted with a sample (N=50) of 18 to 26 year old women at the University 
of South Florida, stratified by relationship status and vaccination status. A comparative thematic 
analysis was conducted to determine if there were differences in informational needs, 
motivations, behavioral skills, and HPV vaccine decision-making between the groups. 
Results: Using NHIS 2010 data, women who were living with a partner (PR 1.44 95%CI 1.07-
1.87) and never married (PR 1.41 95%CI 1.12-1.73) were less likely to be interested in HPV 
vaccination compared women who were married. Moreover, primary reasons for non-vaccination 
differed significantly by relationship status group (p<0.01) Findings from the qualitative phase 
from the study indicated that women’s risk perceptions for HPV were impacted by current 
relationship status. Women in long-term relationships reported that monogamy and number of 
sexual partners reduced their risk of HPV and perceived need of the HPV vaccine. Women in all 
relationship status groups reported similar HPV knowledge levels (e.g., recognition that HPV is 
sexually transmitted, less clarity on the outcomes associated with HPV), behavioral skills (e.g., 
procedural knowledge to get the HPV vaccine, perceived facilitators, perceived barriers), and 
influential macro factors (e.g., anti-vaccination culture, television advertisement) related to HPV 
vaccination. 
Conclusion: This study found that relationship status impacts HPV vaccine decision-making 
among young adult women. Specifically, it operates by modifying risk perceptions for HPV, 
which serve as barriers to vaccination. Young adult women have the knowledge and behavioral 
skills necessary to access and understand the importance of HPV vaccination; however, women 
were unable to accurately perceive their risk for HPV, resulting in impaired motivation for 
vaccination. A potential approach to address this issue is the use of health literacy. Future 
research should integrate health literacy techniques with healthcare providers serving this 
xi 
population to assist in the evaluation process for risk of HPV. This will facilitate shared 
decision-making and patient-provider communication surrounding the HPV vaccine. This can 
ultimately promote HPV vaccination among young adult women and reduce the morbidity and 
mortality of HPV-related diseases. 
1 
 
 
CHAPTER 1: INTRODUCTION 
 
Background 
Human papillomavirus (HPV) is the most incident and prevalent sexually transmitted 
infection (STI) in the United States; it is estimated there are nearly 14 million new cases and a 
total of 79 million cases a year (Satterwhite et al., 2013). The public health significance of this 
STI is highlighted by the fact that HPV is a necessary cause for some cancers. There are two 
grades of HPV infections: high-risk and low-risk. High-risk HPV, such as types 16 and 18, are 
known to cause cancers, including cervical, vulvar, vaginal, penile, anal, and oropharyngeal 
(Munoz et al., 2003; zur Hausen, 2002). While low-risk HPV, such as types 6 and 11, are known 
to cause genital warts and recurrent respiratory papillomatosis (Lacey, Lowndes, & Shah, 2006). 
HPV is transmitted primarily through genital sexual contact, but can also be transmitted via oral 
to genital  contact or skin to skin genital contact (Burchell, Winer, de Sanjose, & Franco, 2006). 
As a primary prevention strategy for HPV, in 2006, the United States’ Advisory 
Committee on Immunization Practices (ACIP) recommended routine vaccination for the 3-dose 
quadrivalent HPV vaccine series for females 11 to 12 years of age (Markowitz et al., 2007). 
Additionally, the quadrivalent vaccine, licensed as Gardasil ®, was approved for use in females 
until age 26, if not previously vaccinated, as a “catch-up” group for vaccination. The 
quadrivalent HPV vaccine (HPV4) protects against four strains of HPV; low risk types 6 and 11, 
and high risk types 16 and 18 (Food and Drug Administration, 2014b). HPV4 serves as a primary 
prevention method against genital warts and HPV-related cancers (Lacey et al., 2006; Munoz et 
2 
al., 2003; zur Hausen, 2002). In 2009, this ACIP recommendation was expanded to include a 
bivalent HPV vaccine (HPV2), licensed as Cervarix ®, that protects against HPV strains 16 and 
18 (Centers for Disease Control and Prevention, 2010a; Food and Drug Administration, 2014a). 
In 2015, the ACIP recommendation expanded to a third vaccine, Gardasil 9 ®, which protects 
against the four strains in Gardasil and five additional strains (31, 33, 45, 52, and 58). The 
recommendations were consistent with those currently in place for the Gardasil vaccine (Food 
and Drug Administration, 2015; Petrosky et al., 2015). 
 
Table 1: HPV Vaccine Rates among Females 18-26 Years 
Year HPV Vaccine Uptake* 
2008 11.6% (9.7, 13.6) 
2009 19.0% (16.6, 21.4) 
2010 21.5% (19.2, 23.8) 
2011 29.7% (27.3, 32.2) 
2012 34.1% (31.6, 36.7) 
*Uptake is having received at least one HPV vaccine dose; **NHIS 2008-2010 data source 
 
Given the earlier approval of the HPV vaccine for females, national public health 
priorities for HPV vaccination have focused primarily on females. Yet, current HPV vaccination 
statistics in the United States reveal vaccine completion rates (16.6%) below the target of 80% 
for females by the age of 13 to 15 years old (Healthy People 2020, 2015c). As a result, 
unvaccinated adolescent females transition into the catch-up age range of 18 to 26 years, and are 
consequently considered a priority population for vaccination. This time period is the last 
opportunity for females to receive the vaccine; therefore, intervening during young adulthood is 
essential for this primary preventive behavior and to ultimately decrease HPV-related disease. 
3 
Unfortunately, rates in the catch-up age range among young adult women are also low.  
Data from nationally-representative samples provide the most accurate and generalizable 
representation of the HPV vaccination coverage among females 18 to 26 years old. The National 
Health Interview Survey (NHIS) currently has data available from 2008 to 2012 for HPV vaccine 
uptake (reported as: ever receiving at least one HPV vaccine dose). Rates have significantly 
increased over time, and as of 2012 were at 34.1% (Table 1) (Schmidt & Parsons, 2014). The 
latest NHIS 2013 data indicate 36.9% of women 19 to 26 years old received at least one dose of 
the HPV vaccine; among these women, 27.6% received the first dose during this age range 
(Williams et al., 2015). Despite these increases, these rates are dramatically low given that the 
vaccine has been available for nine years. 
 
Statement of Need 
Young adulthood is a period for autonomous decision-making regarding sexual and 
reproductive health choices. As such, it is necessary to understand the complex factors that may 
contribute to these health decisions, such as receiving the HPV vaccine. Barriers and facilitators 
to HPV vaccination among young adult (18 to 26 year olds) females have been widely reported 
(e.g., low knowledge, perceived barriers, perceived benefits, self-efficacy, subjective norms, 
healthcare provider recommendation and risk perception) (Allen et al., 2009; Bendik, Mayo, & 
Parker, 2011; Bennett, Buchanan, & Adams, 2012; Bynum, Brandt, Sharpe, Williams, & Kerr, 
2011; Daley, Vamos, et al., 2010; Dillard, 2011; Hodge, Itty, Cardoza, & Samuel-Nakamura, 
2011; Joseph et al., 2014; Licht et al., 2010; Marchand, Glenn, & Bastani, 2012; Ratanasiripong, 
Cheng, & Enriquez, 2013; Rosenthal et al., 2011; Schaefer Ziemer & Hoffman, 2013; Zimet, 
Weiss, Rosenthal, Good, & Vichnin, 2010). Additionally, a limited number of interventions have 
4 
been developed targeting this age group to improve HPV vaccination uptake and completion (Fu, 
Bonhomme, Cooper, Joseph, & Zimet, 2014). One of the potential limitations with these studies 
is that the entire group of female 18 to 26 years olds is being regarded as the same (i.e., there is a 
lack of tailored health interventions or health research). This ignores the potential variability 
within sub-groups of this population (e.g., different stages of readiness or demographic 
characteristics) that may encounter different barriers or facilitators to vaccination. Thus, given 
the minimal improvements in HPV vaccination among this age category nine years post-vaccine 
licensure, research efforts should focus, not only on the broad population of 18 to 26 year olds, 
but rather on sub-groups  who are consistently less likely to be vaccinated over this time period. 
One of these demographic characteristics that is consistently reported as a risk factor for 
non-vaccination among young adult women is relationship status, specifically married or 
monogamous relationships (Anhang Price, Tiro, Saraiya, Meissner, & Breen, 2011; Bernat, 
Gerend, Chevallier, Zimmerman, & Bauermeister, 2013; Ford, 2011; Joseph et al., 2014; Laz, 
Rahman, & Berenson, 2013; Liddon, Hood, & Leichliter, 2012; Liddon, Leichliter, & 
Markowitz, 2012; Lindley, Elkind, Landi, & Brandt, 2013; Rahman, Laz, & Berenson, 2013; 
Schmidt & Parsons, 2014; Wei, Moore, & Green, 2013; Williams et al., 2013; Zimet et al., 
2010). For example, according to 2010 NHIS data, unmarried or single women were 
significantly more likely to be vaccinated compared to married women (OR=3.10, 95% CI 1.71-
5.60) (Laz et al., 2013). Moreover, this is a risk factor for non-HPV vaccination that is specific to 
female young adults, rather than young adult males (Bernat et al., 2013; Newman, Logie, 
Doukas, & Asakura, 2013).  
Thus far, no research has been conducted to understand why this is occurring and how to 
remove this disparity. Women in long-term or monogamous relationships may be framing their 
5 
perceived risk of HPV according to their current relationship status and as a result declining 
vaccination. Interestingly, traditionally considered sexually high-risk women (e.g., more sexual 
partners, history of HPV, lower age at sexual debut) were more likely to be vaccinated for HPV 
compared to low-risk counterparts (Bednarczyk, Birkhead, Morse, Doleyres, & McNutt, 2011; 
Bendik et al., 2011; Bernat et al., 2013; Gerend & Shepherd, 2011; Lindley et al., 2013; Manhart 
et al., 2011; Mills, Vanderpool, & Crosby, 2011; Tiro et al., 2012). Moreover, healthcare 
providers may also have biases toward evaluating risk for HPV and perceived vaccine need 
based on relationship status of young adult women. Zimet et al., (2011) reported physicians 
giving a lower priority to vaccinating female patients who were married or in monogamous 
relationships compared to women who were single or dating. In contrast, these physicians 
surveyed did not alter priority perceptions based on women’s sexual history (e.g., HPV infection, 
abnormal Pap test) (Zimet et al., 2011). Gaining a deeper understanding of how this unique risk 
factor, relationship status, operates will promote scientific advancement for HPV vaccination 
among young adult women. Targeting the informational needs, motivations, and behavioral skills 
required among women who are married or in long-term monogamous relationships through 
interventions will ultimately promote HPV vaccination among this historically un-vaccinated 
group. 
While it is not disputed that monogamy is a protective factor for many sexual and 
reproductive health outcomes (e.g., unintended pregnancy, HIV), risk for HPV still exists among 
this group, even among persons engaging in serial monogamy (Burchell et al., 2006). Women 
who have only one sexual partner of the opposite sex have an average lifetime risk of 85% for 
HPV infection (Chesson, Dunne, Hariri, & Markowitz, 2014). Moreover, according to the 
National Study of Family Growth, the average number of lifetime sexual partners for women is 
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approximately 3.6 (Chandra, Mosher, & Copen, 2011). The average number of sexual 
partnerships compounds the lifetime risk for HPV. These statistics regarding risk of HPV 
transmission and sexual partnerships for women underscore the importance of HPV vaccination 
regardless of sexual relationships; however, this may contradict common heuristic beliefs among 
women that monogamous sex is safe sex. Furthermore, the ACIP guidelines do not provide any 
conditions for vaccination based on relationship status or sexual activity for women (Centers for 
Disease Control and Prevention, 2010a, 2010b, 2011). Therefore, being in a long-term, 
monogamous relationship should not preclude HPV vaccination. 
Disentangling this complicated health message for dissemination and implementation 
into practice first requires a better understanding of the perspective of the target population to 
recognize how relationship status influences HPV vaccination decision-making. This must be 
considered within the context of other complex and evolving sexual and reproductive health 
guidelines (e.g., recommendations for Pap tests) that are also targeted at this population. 
Understanding why women may alter their risk perception for this particular health behavior will 
inform the type of shared decision-making and patient-provider communication that should 
occur surrounding this vaccine. Moreover, future interventions based on this research can tailor 
health information and messages specific to the unvaccinated sub-groups of interest (i.e., women 
in monogamous relationships) and reinforce messages to assist women in assessing risk for 
acquiring HPV infection (Williams et al., 2013). 
 
Public Health Significance 
Thus, the next step in the research trajectory for HPV vaccination uptake in young adult 
women is to understand how relationship status frames the HPV decision-making process. This 
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research is timely and innovative as it moves the current survey-based research forward to 
understand why this disparity in HPV vaccination exists among young adult women in long-term 
or monogamous relationships. This formative investigation will lay the groundwork for future 
research and interventions to improve HPV vaccination rates among young adult women.  
Furthermore, this research responds to a number of national research priorities. The 
National Institutes of Health, Office of Research on Women’s Health (ORWH) 2020 Strategic 
Plan recommended continued research to determine the best methods to improve adoption of 
prevention behaviors during adolescence and young adulthood, including HPV vaccine 
distribution (U.S. Department of Health and Human Services, Public Health Service, National 
Institutes of Health, & Office of Research on Women’s Health, 2010). Moreover, the Centers for 
Disease Control and Prevention (CDC) calls for additional research to increase HPV vaccine 
coverage by engaging patients and providers to eliminate missed clinical opportunities 
(Markowitz et al., 2014). Finally, the research’s long-term goals address multiple Healthy 
People 2020 objectives, including (1) reduce the proportion of females with HPV; (2) reduce 
invasive uterine cervical cancer cases; and (3) reduce the death rate from uterine cervical cancer 
(Healthy People 2020, 2015a, 2015d). Therefore, the significance of this proposed research is 
underscored by these national research goals. 
Finally, this research is relevant to emerging technologies (e.g., 9-valent vaccine; second-
generation HPV vaccines) and changing vaccine dosing schedules (i.e., changing from  two 
required doses rather than three required doses) (Markowitz et al., 2014). This evolution in HPV 
vaccination practices will expand protection against new HPV types and eliminate barriers to 
HPV vaccine completion (Joura et al., 2015). Therefore, it is critical to understand the sustained 
barriers to HPV vaccination among the unvaccinated young adult female population as health 
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messages surrounding the vaccine will become increasingly complicated with the evolving 
science. 
 
Specific Aims and Research Questions 
The long-term goal is to increase HPV vaccination rates among young adult women 18 to 
26 years of age, ultimately decreasing HPV-related disease (i.e., HPV-associated cancers, genital 
warts). The purpose of this study was to understand how young adult women’s relationship 
status influence informational needs, motivations, and behavioral skills related to HPV 
vaccination. This objective was achieved through the following specific aims and mixed-methods 
study design (Table 2). 
To effectively achieve these specific aims, a concurrent mixed-methods study design was 
conducted. In Phase I, a secondary data analysis using the 2010 National Health Interview 
Survey was conducted to determine if women in relationships were less likely to be interested in 
vaccination and identify the primary reasons (e.g., misinformation, motivations, behavioral 
skills) for non-vaccination among different relationship status groups. In Phase II, in-depth 
interviews were conducted with a sample (N=50) of 18 to 26 year old women at the University 
of South Florida, stratified by relationship status and vaccination status. A comparative thematic 
analysis was conducted to determine if there are differences in informational needs, motivations, 
behavioral skills, and HPV vaccine decision-making attributed to relationship status. 
 
Implications 
This study used the Information, Motivation, and Behavioral Skills (IMB) Model 
approach for study design by beginning with the elicitation phase, which is conducted prior to 
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Table 2: Specific Aims of Dissertation Research 
Specific Aims  Research Questions Phase 
1. Assess how relationship 
status affects primary 
reasons for non-
vaccination among 18 to 
26 year old women.  
1. Among unvaccinated 18 to 26 year old 
women, are married women less likely 
to be interested in the HPV vaccine 
compared to non-married women? 
2. Among 18 to 26 year old women who 
are not interested in the HPV vaccine, 
does relationship status impact the 
primary reason for non-vaccination? 
1. Secondary data 
analysis of 
NHIS 2010 
2. Understand how 
relationship status 
frames HPV vaccine 
informational needs, 
motivations, and 
behavioral skills among 
18 to 26 year old 
women. 
3. How do HPV vaccine informational 
needs, motivations, and behavioral skills 
differ among unvaccinated 18 to 26 year 
old women based on relationship 
status? 
4. How do HPV vaccine informational 
needs, motivations, and behavioral skills 
differ among vaccinated 18 to 26 year 
old women based on relationship 
status? 
 
5. How do HPV vaccine informational 
needs, motivations, and behavioral skills 
differ among women 18 to 26 years old 
and in relationships (i.e., married, living 
with a partner, or in a long-term 
monogamous relationship) based on 
vaccination status? 
6. How do HPV vaccine informational 
needs, motivations, and behavioral skills 
differ among women 18 to 26 years old 
and not in relationships (i.e., single or 
single and dating) based on vaccination 
status? 
2. In-depth 
interviews with 
college females 
18 to 26 years 
old (N=50) 
 
 
 
the intervention development and evaluation phases, to understand why young adult women are 
not getting vaccinated at the catch-up age range (Fisher & Fisher, 2002). Findings from this 
formative research will inform a quantitative survey utilizing the IMB Model to expand this 
research to a larger sample of women and increase the generalizability. Moreover, it will inform 
the types of health messages that should be tailored to different groups of young adult women 
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based on relationship status, ultimately improving patient-provider communication concerning 
actual risk for HPV and HPV vaccine shared decision-making. Future theory-based interventions 
developed from these findings will utilize the IMB Model approach for intervention design and 
intervention mapping methods (Bartholomew, Parcel, & Kok, 1998; Fisher & Fisher, 2002). 
 Moreover, future research should triangulate the findings from this study among young 
adult females with healthcare providers who administer the HPV vaccine to young adult women. 
While previous research indicates that these agents may have differential preferences for HPV 
vaccination based on relationship (Zimet et al., 2011), an understanding of how this bias 
operates, as well as the barriers that may need to be overcome is required. 
 This study has the potential to advance theoretical methodology and public health 
practice. Fisher (2012) has proposed the use of the IMB Model to understand HPV vaccination; 
however, no studies have used this theoretical model for HPV vaccination among young adult 
females and a limited number have used this model among other populations for the HPV 
vaccine (Fisher, 2012). Therefore, there is the potential to expand the utility and application of 
the IMB Model to new health behaviors and target populations. This study is the first step in the 
elicitation phase, while future research could expand upon these findings to develop and evaluate 
an intervention targeting HPV vaccination among young adult women. 
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Definition of Key Terms 
 
HPV – Human papillomavirus  
 
HPV4 – The quadrivalent HPV vaccine, which provides protection against HPV types 6, 
11, 16, and 18. It is otherwise known and licensed as Gardasil ®.  
 
HPV2 – The bivalent HPV vaccine, which provides protection against HPV types 16 and 
18. It is otherwise known and licensed as Cervarix ®.  
 
HPV9 – The 9-valent HPV vaccine, which provides protection against HPV types 6, 11, 
16, 18, 31, 33, 45, 52, and 58. It is otherwise known and licensed as Gardasil 9 ®. 
 
IMB Model – The Information, Motivation, and Behavioral Skills Model is a validated 
approach for predicting and promoting health behavior. 
 
NHIS – The National Health Interview Study is a nationally-representative annual cross-
sectional health survey in the United States.  
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CHAPTER 2: LITERATURE REVIEW 
 
Human Papillomavirus  
Human papillomavirus (HPV) is the most incident and prevalent sexually transmitted 
infection (STI) in the United States; it is estimated there are nearly 14 million incident cases and 
79 million prevalent cases a year (Satterwhite et al., 2013). There are two grades of HPV 
infections: high-risk and low-risk. High-risk HPV, such as types 16 and 18, are known to cause 
cancers, including cervical, vulvar, vaginal, penile, anal, and oropharyngeal (Munoz et al., 2003; 
zur Hausen, 2002). While low-risk HPV, such as types 6 and 11, are known to cause genital 
warts and recurrent respiratory papillomatosis (Lacey et al., 2006). HPV is transmitted primarily 
through genital sexual contact, but can also be transmitted via oral to genital contact and skin to 
skin genital contact. Other routes of transmission exist, including nonsexual routes, such as 
mother to child transmission and oral-digital infection, but are less common (Burchell et al., 
2006). 
 
HPV Epidemiology 
 HPV infection prevalence varies based on study sample (e.g., population-based vs. 
clinical sample). The National Health and Nutrition Examination Survey (NHANES) estimated 
the prevalence of cervico-vaginal HPV among women in 2003-2006 to be 42.5% (95% CI 40.4-
44.7%) and in 2007-2010 to be 39.8% (95% CI 37.7-42.0%). The prevalence was highest among 
women 20 to 24 years of age. Women in this age category had a prevalence of 19.9% (95% CI 
13 
15.5-25.2%) for vaccine-type HPV
1
 and 16.2% (95% CI 12.2-21.4%) for high-risk vaccine-type 
HPV
2
 (Markowitz et al., 2013). Among men, the prevalence of genital HPV was estimated to be 
50%; the incidence of genital HPV was not associated with age among men (Giuliano et al., 
2011). Moreover, it is estimated that the average lifetime probability of acquiring HPV among 
women with at least one male sexual partner is nearly 85% and among males with at least one 
female sexual partner is 91% (Chesson, Dunne, et al., 2014). 
 
Health Outcomes Associated with HPV  
Cancer. HPV is a causal agent for many cancers, including cervical, vulvar, vaginal, 
penile, anal, and oropharyngeal (Munoz et al., 2003; zur Hausen, 2002). Persistent HPV 
infections are primarily responsible for progressing to precancerous or cancerous conditions 
(Forman et al., 2012). According to the Centers for Disease Control and Prevention (CDC), an 
analysis of the National Program of Cancer Registries and the Surveillance, Epidemiology, and  
 
Table 3: HPV-Associated Cancer Rates per 100,000 
Anatomic Site Females Males 
Cervical 7.7 -- 
Vulvar 1.8 -- 
Vaginal 0.4 -- 
Penile -- 0.8 
Anal 1.8 1.2 
Oropharyngeal 1.4 6.2 
*Data source: NPCR, SEER 2004-2008 
                                                          
1
 Vaccine-type HPV refers to HPV types included in the vaccine; types 6, 11, 16 and 18 
2
 High risk vaccine-type refers to HPV types included in the vaccine and considered high-risk; types 16 
and 18 
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End Results program from 2004 to 2008 revealed an average of 33,369 HPV-associated cancer 
cases were diagnosed annually—this is a rate of 10.8 per 100,000 population. The rate was 
higher among females (13.2 per 100,000) compared to males (8.1 per 100,000) (Centers for 
Disease Control and Prevention, 2012). The rates of HPV-associated cancers depend upon 
anatomical site and sex (Table 3). HPV-associated cervical cancer has the highest rate (7.7 per 
100,000), followed by oropharyngeal cancer in males (6.2 per 100,000). Additionally, cancers at 
these sites are largely attributable to HPV, with nearly 96% of cervical cancer cases attributable 
to HPV (Table 4) (Gillison, Chaturvedi, & Lowy, 2008). This translates to approximately 11,500 
cervical cancer cases a year due to HPV (Centers for Disease Control and Prevention, 2012).  
 
Table 4: Percentage and Number of Cases Attributable to HPV Annually 
Anatomic Site % (Range) # (Range) 
Cervical 96 (95-97) 11,500 (11,400-11,600) 
Vulvar 51 (37-65) 1,600 (1,200-2,000) 
Vaginal 64 (43-82) 500 (300-600) 
Penile 36 (26-47) 400 (300-500) 
Anal 93 (86-97) 2,900 (2,700-3,000) Females 
1,600 (1,400-1,600) Males 
Oropharyngeal 63 (50-75) 1,500 (1,200-1,800) Females 
5,900 (4,700-7,000) Males 
*Data source: NPCR, SEER 2004-2008, Gillison et al. (2008). Cancer, 113 
 
 There is also substantial mortality associated with these cancers. While data were not 
available on the proportion of cancer deaths attributable to HPV, the overall mortality rates for 
the cancers at the anatomical sites associated with HPV were available. For women, the age-
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adjusted mortality rates annually using 2007-2011 data are as follows: cervical 2.3 per 100,000 
women, vulvar 0.5 per 100,000 women, anal 0.3 per 100,000 women, and oral cavity/pharynx 
1.4 per 100,000 women (vaginal cancer data are not available). For men, the age-adjusted 
mortality rates annually using 2007-2011 data are as follows: anal 0.2 per 100,000 men and oral 
cavity/pharynx 3.8 per 100,00 men (penile cancer data are not available) (National Cancer 
Institute, 2014).  
Genital warts. HPV is also a cause of genital warts; HPV types 6 and 11 are associated 
with over 90% of genital warts cases (Lacey et al., 2006). According to NHANES 1999-2004 
data, 5.6% of adults age 18 to 59 years report ever being diagnosed with genital warts. The 
proportion was higher for females (7.2%) compared to males (4.0%). Moreover, rates were 
highest among females 25 to 34 years of age and males 35 to 44 years of age (Dinh, Sternberg, 
Dunne, & Markowitz, 2008). 
Recurrent respiratory papillomatosis. Recurrent respiratory papillomatosis is a rare 
disease caused by HPV types 6 and 11. This condition produces benign warts in the upper 
respiratory tract that can cause airway obstruction. This disease typically has a juvenile onset 
prior to 18 years (Markowitz et al., 2014). 
 
HPV Vaccination 
Three vaccines have been developed and approved for use to prevent HPV and ultimately 
reduce the impact of HPV-related health outcomes (i.e., cancer and genital warts). The 
quadrivalent HPV vaccine (HPV4) was developed by Merck and Co, Inc. and prevents HPV 
types 6, 11, 16, and 18 (Food and Drug Administration, 2014b). It has an efficacy rate of 98.2% 
for HPV types 6, 11, 16, and 18 for clinical endpoints adenocarcinoma in situ and cervical 
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intraepithelial neoplasia 2/3; 100.0% for HPV types 6, 11, 16, and 18 for clinical endpoints 
vulvar intraepithelial neoplasia and vaginal intraepithelial neoplasia; and 98.9% for HPV types 6 
and 11 for genital warts as a clinical endpoint (Kjaer et al., 2009). The bivalent HPV vaccine 
(HPV2) was developed by GlaxoSmithKline and prevents HPV types 16 and 18 (Food and Drug 
Administration, 2014a). It has an efficacy rate of 94.9% for HPV types 16 and 18 for clinical 
endpoints adenocarcinoma in situ and cervical intraepithelial neoplasia 2/3 (Lehtinen et al., 
2012). The 9-valent HPV vaccine (HPV9) was developed by Merck and Co, Inc. and prevents 
HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. It has an efficacy rate of 96.7% for types HPV 
31, 33, 45, 52, and 58 for clinical endpoints cervical intraepithelial neoplasia 2/3, 
adenocarcinoma in situ, cervical cancer, vulvar intraepithelial neoplasia 2/3, vaginal 
intraepithelial neoplasia 2/3, vulvar cancer, and vaginal cancer (Food and Drug Administration, 
2015).   
HPV Vaccination Guidelines   
The Advisory Committee on Immunization Practices (ACIP) is responsible for setting 
guidelines for immunizations in the United States. Table 5 describes the nine year timeline for 
HPV vaccination recommendations from ACIP, starting with the first recommendation for HPV4 
among females (Markowitz et al., 2007). As of 2015, the current recommendations for HPV 
vaccination are: (1) HPV2, HPV4, and HPV9 for routine vaccination among females 11 to 12 
years of age; (2) HPV2, HPV4, and HPV9 for catch-up vaccination among females 13 to 26 
years of age; (3) HPV4 and HPV9 for routine vaccination among males 11 to 12 years of age; (4) 
HPV4 and HPV9 for catch-up vaccination among males 13 to 21 years of age; and (5) HPV4 and 
HPV9 for catch-up vaccination among male subpopulations until age 26, specifically men who 
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have sex with men (MSM) or men who are immunocompromised (Centers for Disease Control 
and Prevention, 2010a, 2010b, 2011; Petrosky et al., 2015). 
 HPV vaccination requires following a strict dosing schedule for vaccination completion. 
For all vaccines, three doses are required. The vaccine should be administered at 0, 1-2 months, 
and 6 months. Non-compliance with the schedule may offer limited immune response and 
protection (Widdice, Bernstein, Leonard, Marsolo, & Kahn, 2011). However, current research is 
dedicated to assessing the efficacy of only two doses of the vaccine in order to offer an 
alternative dosing schedule (Markowitz et al., 2014). 
 
Table 5: ACIP Recommendations for HPV Vaccination 
Time Target Group Recommendation 
2006 Females, 11-12 years Routine HPV4 vaccination 
 Females, 13-26 years Catch-up HPV4 vaccination 
2009 Females, 11-12 years Routine HPV2 vaccination 
 Females, 13-26 years Catch-up HPV2 vaccination 
 Males 9-26 years May receive HPV4 vaccination;  
not routine 
2011 Males, 11-12 years Routine HPV4 vaccination 
 Males, 13-21 years Catch-up HPV4 vaccination 
 Males, 21-26 years, MSM or 
Immunocompromised 
Catch-up HPV4 vaccination 
2015 Females, 11-12 years Routine HPV9 vaccination 
 Females, 13-26 years Catch-up HPV9 vaccination 
 Males, 11-12 years Routine HPV9 vaccination 
 Males, 13-21 years Catch-up HPV9 vaccination 
 Males, 21-26 years, MSM or 
Immunocompromised 
Catch-up HPV9 vaccination 
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Health Implications of the HPV Vaccine  
HPV vaccination has the potential to significantly reduce the morbidity and mortality 
associated with cancer. According to a population-based HPV model, HPV vaccination would 
prevent 45,500 cervical cancer cases and 14,600 cervical cancer deaths at 30% vaccine coverage 
among females 12 years and younger. These estimates increase dramatically for a 80% coverage 
level (98,900 cervical cancer cases and 31,700 cervical cancer deaths) (Chesson, Markowitz, & 
Dunne, 2014). While these models only incorporate cervical cancer, additional prevention can be 
inferred for other HPV-associated cancers with higher HPV vaccination coverage. Moreover, 
according to epidemiological cancer data of HPV-associated cancers, it is estimated that HPV 
vaccination could prevent nearly 26,000 cancer cases a year (Centers for Disease Control and 
Prevention, 2012). 
Additionally, ecological trends of genital warts in a public family planning clinic in 
California reveal decreases in genital warts rates among males and females since HPV vaccine 
approval (Bauer, Wright, & Chow, 2012). Similarly, evidence from Australia indicates as 
decrease in genital warts among young adult women attributable to the HPV vaccination 
program (Donovan et al., 2011). HPV vaccination has the potential to impact morbidity rates of 
genital warts; however, protection is only offered by the HPV4 and HPV9 vaccines that prevent 
low-risk HPV types 6 and 11 (Food and Drug Administration, 2014b). 
 
Economic Implications of the HPV Vaccine  
In addition to the potential morbidity and mortality implications associated with the HPV 
vaccine, economic evaluations are needed. The cost of the HPV vaccine series is estimated to be 
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$500 (American Cancer Society, 2014a). The cost-effectiveness of the vaccine series must be 
considered in relation to the potential economic costs associated with HPV-related outcomes. 
The majority of early studies examining the cost-effectiveness of the HPV vaccine 
examined female vaccination only. In these studies, HPV vaccination was considered cost-
effective compared to cervical cancer screening alone (Chesson, Ekwueme, Saraiya, Dunne, & 
Markowitz, 2011; Kim & Goldie, 2008). One study compared coverage rates for female 
vaccination at age 12 in the US. At 30% coverage, the cost of a quality-adjusted life year 
(QALY)
3
 gained was $2,000 compared to no vaccination. In a comparison of 45% coverage to 
the previously mentioned 30% coverage, the cost per QALY gained was $8,200. There is no 
consensus regarding a threshold for “good value” for a QALY gained; however, $50,000 per 
QALY is a commonly cited upper limit threshold (Eichler, Kong, Gerth, Mavros, & Jönsson, 
2004; Kim & Goldie, 2008). Including males into this model increases the costs substantially, 
especially when female vaccination coverage is higher. For example, compared to female 
vaccine coverage of 45%, a model of male and female vaccination coverage at 30% was 
estimated to cost $103,500 per QALY gained (Chesson et al., 2011). Furthermore, a systematic 
review of 29 studies examining HPV vaccine cost-effectiveness revealed that overall routine 
vaccination of females is cost-effective compared to traditional cervical cancer screening only; 
however, the value of adding males to vaccination programs is less clear (Seto, Marra, 
Raymakers, & Marra, 2012). This is likely due to the variability in estimate of female 
vaccination coverage; lower female vaccine coverage improves the estimated cost-effectiveness 
of including males in vaccine programs (Chesson & Markowitz, 2014). While the cost-
effectiveness of vaccinating the entire male population may not be optimal, one study has 
                                                          
3
 QALY refers to the incremental cost per quality-adjusted life year gained by HPV vaccination. The 
incremental cost per QALY is calculated as: (vaccination costs – medical costs averted from vaccination) 
/ (number of QALYs gained by vaccination) (Chesson et al., 2011). 
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evaluated the effectiveness of vaccinating the MSM population and found it to be a cost-effective 
prevention method for anal cancer and genital warts (Kim, 2010).  
 An additional consideration that has been explored is extending the age limit for 
vaccinating young women. Studies have consistently shown that HPV vaccination of young 
women is less cost-effective as age increases compared to only vaccinating adolescents.
4
 Yet, 
there is no consensus on a specific threshold where cost-effectiveness becomes futile (Chesson & 
Markowitz, 2014; Kim & Goldie, 2008; Markowitz et al., 2014).  
 While these models currently provide the best estimates available for the cost-
effectiveness of HPV vaccination, the majority studies typically focus on direct health effects 
and a limited range of cancer costs. This may significantly underestimate the cost-effectiveness 
of the HPV vaccine as it can affect a wider range of economic outcomes. Marsh et al. (2014) 
described the diversity of potential outcomes as extending beyond the individual, to family and 
caregivers, government (e.g., treatment costs), and societal costs (e.g., improved health equality). 
Moreover, the typically considered health-related costs exclude fertility impacts, out-of-pocket 
costs, loss of productivity, other sequelae, and a larger range of HPV-associated cancers (Marsh, 
Chapman, Baggaley, Largeron, & Bresse, 2014).  
 As HPV vaccination guidelines change (e.g., two doses) and other technologies evolve 
(e.g., 9-valent vaccine), the estimated economic impact of the HPV vaccine will need to be 
updated. Initial estimates of the cost-effectiveness for HPV9 indicate that the expanded vaccine 
is more cost-saving compared to HPV4, especially for females (Brisson, 2014). The key 
messages taken from the literature indicate that HPV vaccination is cost-effective for females and 
                                                          
4
 As the age range is extended in the cost-effectiveness vaccination models, the incremental cost per 
QALY gained increases to a level that may no longer be economically beneficial. For example, adding a 
catchup program to 26 years old increased the cost per QALY to $152,700 compared to routine 
vaccination at 12 years old (Kim & Goldie, 2008) 
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the effectiveness declines with increasing age; however, no upper threshold has been established. 
In addition, the cost-effectiveness of vaccinating males is less clear and further studies are 
required to fully understand the economic implications.  
 
HPV Vaccine Policies in the United States 
While ACIP provides national guidelines for HPV vaccination in the United States, the 
implementation of these guidelines vary by state. Given that there is a lack of standardization at 
the national level, each state’s policy must be evaluated as it may be the result of policy from 
state legislature or state executive branch (National Conference of State Legislatures, 2014). 
 Since 2006, 42 states and territories have introduced legislation to require the HPV 
vaccine, fund vaccination, or educate the public or parents of school children on HPV 
vaccination. Specifically, in the 2013-2014 legislative sessions, 10 states proposed legislation. 
Educational policies have been enacted in Iowa, Colorado, North Carolina, Texas, and North 
Dakota (Fernandez, Allen, Mistry, & Kahn, 2010). In 2007, Texas’ governor mandated the HPV 
vaccination for school-aged children; however, this was overridden by the Texas legislature. 
Only the District of Columbia and Virginia have enacted a legislative school vaccine 
requirement with an opt-out policy for girls entering the sixth grade; both of which occurred in 
2007 (Fernandez et al., 2010; National Conference of State Legislatures, 2014). As of 2014, 
Rhode Island has created executive legislation through the State Health Department to require 
the HPV vaccine for school entry for 7
th
 grade starting in the 2015 school year (Gaito & North, 
2014). No empirical evaluations have occurred to determine the effect of the Virginia and D.C. 
school vaccine mandates; however, National Immunization Survey-Teen (NIS-Teen) 2013 data 
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reveal that Virginia and D.C. are both below the national average for vaccine initiation and 
completion among females (National Center for Immunization and Respiratory Diseases, 2013). 
An examination of HPV vaccine related bills enacted in the US between 2006 and 2010 
indicated that only 23% were actually enacted. Among the 32 bills enacted, 44% involved 
policies, 25% provided education campaigns, 25% required insurance to cover vaccination, 13% 
included voluntary vaccination, and 9% mandated vaccination for school entry (Laugesen et al., 
2014). 
 Other developed countries (e.g., United Kingdom, Australia, and Canada) have national 
programs that publically fund HPV vaccination (Markowitz et al., 2012). In the United States, 
this is not the case. Financing of the HPV vaccine is mainly the result of private insurance. 
However, there are public financing options, such as the Vaccines for Children program, 
Medicaid, or Children’s Health Insurance Program (Kaiser Family Foundation, 2014). 
Alternatively, Merck and GlaxoSmithKline also offer assistance for vaccine payment (Kaiser 
Family Foundation, 2014). Since cost and insurance coverage are often cited as barriers to HPV 
vaccination in the United States by both target and catch-up age groups, consideration of 
alternative strategies for funding the vaccine is needed.  
 
HPV Vaccination Rates  
Despite the primary prevention benefits of HPV vaccination, the rates of uptake and 
completion remain low in the United States. As of 2013, using data from NIS-Teen, the rates of 
vaccination initiation was 57.3% for females and 34.6% for males ages 13-17 (Table 6) (Stokley 
et al., 2014). Fewer individuals received the second and third doses of the vaccine. In fact, the 
completion rates of the HPV 3-dose series among initiators is 70.4% for females and 48.3% for  
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Table 6: HPV Vaccination Rates Among 13-17 Year Olds 
# Doses Females Males 
≥1 57.3% ± 1.9% 34.6% ± 1.9% 
≥2 47.7% ± 2.0% 23.5% ± 1.7% 
≥3 37.6% ± 1.9% 13.9% ± 1.4% 
*Data source: NIS-Teen 2013 
 
males (Stokley et al., 2014). While these rates are increasing, the level of vaccination coverage is 
lower than other adolescent vaccines, such as Tdap (Tetanus, diphtheria, pertussis) and 
MenACWY (meningococcal). The Healthy People 2020 goals for teens 13 to 15 years in the US 
include coverage of 80% for at least one dose of Tdap, at least one dose of MenACWY, and 
three doses of HPV (males and females) (Healthy People 2020, 2015c). As of 2013, the goal was 
met for Tdap (87.5%) and close for MenACWY (78.1%) indicating these goals are achievable 
with current clinical encounters at this age range. However, HPV vaccination falls behind the 
current target (Stokley et al., 2014). If the HPV vaccine were administered during healthcare 
visits with other vaccine administration during this age range, then the rate of coverage for at 
least one HPV vaccine dose could be 92.6% (Centers for Disease Control and Prevention, 2013). 
 The NIS-Teen does not capture vaccination rates for persons 18 and older; therefore, 
other data sources are used for vaccination estimates. According to the National Health Interview 
Survey (NHIS), uptake
5
 of the HPV vaccine has increased among women 18 to 26 years of age 
from 11.6% (95% CI 9.7-13.6%) in 2008 to 34.1% (95% CI 31.6-36.7%) in 2012. Over the 
2008-2012 timespan, overall 23.3% of women received at least one dose, 18.0% of women 
received at least two doses, and 13.6% of women received at least three doses. Rates were 
                                                          
5
 Participants asked if they ever received the HPV vaccine; uptake defined as having received at least 1 
HPV vaccine dose. 
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significantly higher for women 18 to 21 years of age (31.8%) compared to women 22 to 26 years 
of age (16.9%) (Schmidt & Parsons, 2014). According to NHIS 2013 data, approximately 36.9% 
of women 19 to 26 years old received at least one dose of the HPV vaccine; among these women 
27.6% received the first dose during this age range (Williams et al., 2015). 
 Data regarding vaccination rates for young adult males are scarce. The latest data 
available are from the 2011-2012 NHANES dataset. The HPV vaccine uptake rate was only 
5.5% (95% CI 3.1-9.5%) and completion of the vaccine series was reported to be 59.1% (95% CI 
37.2-77.6%) (Pierre-Victor, Mukherjee, Bahelah, & Madhivanan, 2014). Alternatively, the 
National College Health Assessment (NCHA) data reported for the Fall 2013 survey, estimates 
the male, college student vaccination rate (at least one dose) to be 28.6% (American College 
Health Association, 2014). According to these data, the estimated proportion of college male 
HPV vaccination has ranged from 13.1% to 24.6% between 2008 and 2012. Despite these higher 
rates among college males, these rates are lower compared to college females (American College 
Health Association, 2010, 2011, 2012, 2013).  
 
Factors Influencing HPV Vaccination  
Macro level factors. Among the environmental factors at the organizational level, 
healthcare interaction and healthcare environment impact rates of vaccination (Tiro et al., 2012; 
Wei et al., 2013; Williams et al., 2013). Moreover, at the highest level of influence, health 
insurance, costs of vaccines, marketing of the vaccine, policies related to vaccination, and 
feminization of HPV have all influenced the ability to access and receive the HPV vaccine in the 
United States (Anhang Price et al., 2011; Daley, Buhi, Vamos, et al., 2012; Dempsey, Cohn, 
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Dalton, & Ruffin, 2011; Ford, 2011; Hodge et al., 2011; Jain et al., 2009; Laz et al., 2013; 
Lindley et al., 2013; Tiro et al., 2012; Wei et al., 2013; Zimet et al., 2010).  
 Provider recommendation. Key among all HPV vaccine target groups is the need for 
provider recommendation. Therefore, understanding the factors influencing a provider 
recommendation is necessary to consider. Characteristics of patients were a significant factor for 
provider recommendation, specifically, recommendation depended upon age (Vadaparampil, 
Murphy, Rodriguez, Malo, & Quinn, 2013), relationship status (Zimet et al., 2011), and gender 
(females more than males) (Vadaparampil et al., 2013). Additionally, perceived barriers included 
the anticipated parental response to the vaccine recommendation (Kahn et al., 2007), as well as 
logistical concerns (e.g., reimbursement, cost of vaccine) (Ko, Missmer, & Johnson, 2010). 
Practice environment also impacted providers; private practices and primary care practices were 
more likely to recommend the vaccine (Ko et al., 2010; Vadaparampil et al., 2014). Finally, 
practice guidelines are an external determinant to recommendation, especially given that the 
guidelines have changed multiple times since the vaccine has been introduced (Vadaparampil et 
al., 2013). 
 Factors among adolescents. Among adolescents, parents are the primary decision-
making agents with regard to vaccination. As a result, the bulk of the literature has focused on 
parents’ beliefs and attitudes toward HPV vaccination for their children (Fernandez et al., 2010). 
In a systematic review of parental factors influencing HPV vaccination of children, lack of 
knowledge or information, attitudes toward vaccination (e.g., vaccination in general, safety or 
side effects of vaccine), provider recommendation, risk perceptions, and outcome expectations 
with vaccination (e.g., belief child will engage in sexual activity) were reported as salient factors 
among parents (Trim, Nagji, Elit, & Roy, 2012). Additionally, perceived barriers are reported, 
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such as lack of insurance or funding for the vaccine (Donahue, Stupiansky, Alexander, & Zimet, 
2014). Parental spousal agreement was also a predictor of intention to vaccinate (Rickert et al., 
2014). 
 Factors among young adult males. As for young adult males, awareness, knowledge, 
perceived severity, perceived susceptibility, perceived barriers (e.g., cost, side effects), self-
efficacy and provider recommendation were associated with HPV vaccination (Daley et al., 
2011; Fontenot, Fantasia, Charyk, & Sutherland, 2014; Katz, Kam, Krieger, & Roberto, 2012; 
Newman et al., 2013). Additionally, rates of vaccination vary based on demographic 
characteristics, such as, poverty, race/ethnicity and education (Daley et al., 2011; Lu et al., 2013; 
Newman et al., 2013). 
 
Factors Influencing HPV Vaccination among Young Adult Females 
In order to assess the current state of HPV vaccination barriers and facilitators among 
young adult women in the United States, a systematic review of the literature was conducted. 
Articles were systematically selected from a search of PubMed and Web of Science databases, 
during a date range of June 1, 2006 to May 1, 2015. Search terms were organized into general 
categories of HPV (e.g., human papillomavirus, human papilloma virus, papillomavirus vaccines 
[MeSH], HPV, papillomavirus), immunization (e.g., immuniz*, vaccin*), female (e.g., female, 
women, woman, girl*), and young adult (e.g., college, catch-up, catch up, young adult). The 
search strategy in each database used the Boolean term of ‘AND’ for inclusion of each general 
category, and the Boolean term of ‘OR’ for inclusion of each search term within the category. 
Inclusion criteria applied were: (1) empirically-based; (2) published in a peer-reviewed journal; 
(3) reported stratified data for females 18 to 26 years of age; (4) referenced the HPV vaccine; (5) 
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conducted post-vaccine licensure; and (6) conducted in the United States. Studies were excluded 
if only a published abstract was available since not enough data would be available for 
abstraction. 
 
 
Figure 1: Search Results for Systematic Review 
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Figure 1 presents the search process for this systematic review. The primary search of the 
literature identified 1,892 records. After removing 181 duplicates, 1,711 articles remained. 
Articles were then screened based on titles and relevance to the research topic; this removed 
1,478 articles. Next, articles were assessed based on the abstract to determine the relevance to the 
research topic; this resulted in 112 articles remaining. These remaining articles had the full-text 
examined to determine eligibility based on the inclusion and exclusion criteria. The follow 
articles were removed: 17 for not providing age-stratified results, 7 for not providing gender-
stratified results, 3 for not referencing the HPV vaccine, 4 for being outside of the United States, 
2 for being before vaccine licensure, and 2 for only providing an abstract. As a result, 77 articles 
remained.  
The included observational studies had the following types of samples: 29 college (Allen 
et al., 2009; Bednarczyk et al., 2011; Bendik et al., 2011; Bennett et al., 2012; Bynum et al., 
2012; Bynum, Brandt, Friedman, Annang, & Tanner, 2011; Bynum, Brandt, Sharpe, et al., 2011; 
Cohen & Head, 2013; Daley, Vamos, et al., 2010; Dillard, 2011; Dillard & Spear, 2010; Gerend 
& Shepherd, 2011; Harper, Alexander, et al., 2014; Harper, Irons, et al., 2014; Hodge et al., 
2011; Hopfer & Clippard, 2011; Krakow et al., 2015; Krieger, Kam, Katz, & Roberto, 2011; 
Licht et al., 2010; Lindley et al., 2013; Marchand et al., 2012; Marchand, Glenn, & Bastani, 
2013; Patel et al., 2013; Patel et al., 2012; Ratanasiripong, 2014; Ratanasiripong et al., 2013; 
Roberts, Gerrard, Reimer, & Gibbons, 2010; Sandfort & Pleasant, 2009; Schaefer Ziemer & 
Hoffman, 2013), 17 large national surveys (Anhang Price et al., 2011; Caskey, Lindau, & 
Alexander, 2009; Ford, 2011; Gelman et al., 2013; Jain et al., 2009; Laz et al., 2013; Liddon, 
Hood, et al., 2012; Liddon, Leichliter, et al., 2012; Pourat & Jones, 2012; Rahman, Islam, & 
Berenson, 2015; Rahman et al., 2013; Schmidt & Parsons, 2014; Tiro et al., 2012; Vanderpool, 
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Williams, Klawitter, & Eddens, 2014; Wei et al., 2013; Williams et al., 2015; Williams et al., 
2013), 8 insurance records or electronic health records (Chao, Velicer, Slezak, & Jacobsen, 
2009, 2010; Cowburn et al., 2014; Hirth, Tan, Wilkinson, & Berenson, 2012; Kharbanda, Parker, 
Nordin, Hedblom, & Rolnick, 2013; Rosenthal et al., 2011; Verdenius et al., 2013; Zimet et al., 
2010), 5 clinics (Dempsey et al., 2011; Joseph et al., 2014; Kennedy, Osgood, Rosenbloom, 
Feinglass, & Simon, 2011; Klosky et al., 2015; Vanderpool, Casey, & Crosby, 2011), 3 minority 
population (e.g., American Indians) (Casey, Crosby, Vanderpool, Dignan, & Bates, 2013; Head 
& Cohen, 2012; Mills, Head, & Vanderpool, 2013), 2 combination of samples (e.g., clinic and 
community) (Crosby, Casey, Vanderpool, Collins, & Moore, 2011; Mills et al., 2011), 2 
community (Manhart et al., 2011; Vanderpool, Dressler, Stradtman, & Crosby, 2015) and 1 web-
based (Bernat et al., 2013). Of the 77 studies, 9 were interventions (Gerend & Shepherd, 2012; 
Gerend, Shepherd, & Lustria, 2013; Gerend, Shepherd, & Shepherd, 2013; Hopfer, 2012; 
Juraskova et al., 2012; Krieger & Sarge, 2013; Paiva, Lipschitz, Fernandez, Redding, & 
Prochaska, 2014; Patel et al., 2014; Vanderpool et al., 2013). Immunization rates, as well as, 
barriers and facilitators to HPV vaccination among females 18 to 26 years of age were abstracted 
from each article. These determinants were then stratified by levels of the Socioecological Model 
(i.e., intrapersonal, interpersonal, organizational, community, and policy) (McLeroy, Bibeau, 
Steckler, & Glanz, 1988). Pile sorting was used to assign a level and theme for each determinant 
identified in each paper (Bernard & Ryan, 2010c). 
 This review summarizes the current state of HPV vaccination and the barriers and 
facilitators of vaccination among women 18 to 26 years of age in the United States. It is evident 
from this review of the literature that the majority of the research available has focused on the 
intrapersonal level. Primarily, researchers have been interested in investigating the knowledge, 
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attitudes, and beliefs regarding HPV, HPV-related outcomes, and HPV vaccination among this 
age group.  
 
Intrapersonal Barriers and Facilitators 
 Demographic characteristics. Given the recommendation for routine vaccination of 
females 11 to 12 years of age, it is not surprising that HPV vaccination initiation and completion 
is more likely among younger women (i.e., 18 to 21 year olds) in the 18 to 26 year old category 
(Bendik et al., 2011; Bynum, Brandt, Sharpe, et al., 2011; Chao et al., 2010; Dempsey et al., 
2011; Hirth et al., 2012; Laz et al., 2013; Lindley et al., 2013; Rahman et al., 2015; Tiro et al., 
2012; Wei et al., 2013; Williams et al., 2015). Additionally, this age category is unique, in that 
one barrier to vaccination is pregnancy or attempting to conceive (Verdenius et al., 2013; Zimet 
et al., 2010). To date, the HPV vaccine is not recommended for use during pregnancy 
(Markowitz et al., 2014). 
 Additionally, disparities exist with regard to sub-populations receiving the vaccine. 
Racial and ethnic minorities tend to have lower uptake rates (Lindley et al., 2013; Williams et 
al., 2015). African Americans are consistently less likely to initiate and complete the HPV 
vaccine series compared to whites (Bednarczyk et al., 2011; Chao et al., 2010; Dempsey et al., 
2011; Ford, 2011; Kharbanda et al., 2013; Laz et al., 2013; Liddon, Leichliter, et al., 2012). 
Asians also have lower uptake rates (Kharbanda et al., 2013). According to NHIS 2010 data, 
Non-Hispanic whites were the most likely to be vaccinated (25.7%), followed by Non-Hispanic 
Asians (22.9%), Non-Hispanic blacks (21.5%), Other (19.0%) and Hispanics (16.7%) (Williams 
et al., 2013). In 2013, vaccination rates changed slightly for 19 to 26 year old women to whites 
(43.1%), followed by blacks (30.6%), Hispanics (30.3%), and Asians (19.8%) (Williams et al., 
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2015). Yet, rates for HPV vaccine uptake have increased across all racial/ethnic groups, 
according to NHIS 2008 to 2012 data (Schmidt & Parsons, 2014). 
 Having a low income or being below the federal poverty level was consistently associated 
with non-vaccination (Chao et al., 2010; Jain et al., 2009; Laz et al., 2013; Rahman et al., 2013; 
Wei et al., 2013). This is most likely connected to other social determinants of health (Healthy 
People 2020, 2014), such as access to health care, which will be explored at the organizational 
level. Additionally, a lower education level or not being in school was associated with non-
vaccination and lower awareness of the vaccine (Chao et al., 2010; Ford, 2011; Gerend & 
Shepherd, 2011; Manhart et al., 2011; Rahman et al., 2015; Rahman et al., 2013; Tiro et al., 
2012). 
 Knowledge. In the majority of behavioral health theories, it is recognized that a person 
must have awareness or knowledge of the health behavior in order to successfully engage in it 
(Brewer & Rimer, 2008). As a result, the bulk of the literature on HPV vaccination in females 18 
to 26 year olds has focused on knowledge levels related to HPV and the vaccine. Unfortunately, 
standard measures across studies do not exist; however, most studies conclude that limited 
knowledge is associated with lower vaccine uptake (Bynum, Brandt, Sharpe, et al., 2011; Daley, 
Vamos, et al., 2010; Hodge et al., 2011; Joseph et al., 2014). Many women cited needing more 
information about the vaccine as a primary barrier to vaccination (Joseph et al., 2014; 
Ratanasiripong et al., 2013; Zimet et al., 2010). Knowledge misperceptions include transmission 
of HPV (e.g., oral sex, genital skin to skin contact, genetics) and likelihood of cervical cancer 
(Cohen & Head, 2013; Sandfort & Pleasant, 2009). It must be noted that the majority of studies 
assessing knowledge do so among college samples of women, who may have higher levels of 
education. Therefore, this may overestimate HPV vaccine knowledge levels compared to the 
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general public. To support this notion, one study found that knowledge about the HPV vaccine 
was strongly associated with college educational attainment (Kennedy et al., 2011). Regardless, 
the NHIS indicates that awareness of the HPV vaccine has increased across years, and is less 
likely cited as a main reason for non-vaccination in 2010 compared to 2008 (Schmidt & Parsons, 
2014). 
 Attitudes and beliefs. In addition to knowledge scales, many measures exist to assess 
women’s attitudes toward the vaccine and beliefs about the vaccine. Given the novelty of the 
vaccine, many early studies reported perceived barriers such as concern that the vaccine is too 
new (Bednarczyk et al., 2011; Zimet et al., 2010), concern about side effects (Bednarczyk et al., 
2011; Hodge et al., 2011; Joseph et al., 2014; Ratanasiripong et al., 2013; Zimet et al., 2010), and 
concern about efficacy (Cohen & Head, 2013). Moreover, women also reported an overall dislike 
or fear toward needles, which was a primary barrier to uptake of the vaccine (Joseph et al., 2014; 
Ratanasiripong et al., 2013). However, these barriers may be overcome with perceived benefits 
of the vaccine. Women were more likely to be vaccinated or intend to be vaccinated with higher 
perceived benefits (e.g., vaccination is preventing an HPV infection), higher perceived 
importance of the vaccine, and a more positive attitude toward the vaccine (Bendik et al., 2011; 
Bennett et al., 2012; Dillard, 2011; Ratanasiripong et al., 2013; Rosenthal et al., 2011; Schaefer 
Ziemer & Hoffman, 2013). 
 Additionally, given that HPV is a sexually transmitted infection, stigma surrounding this 
characteristic is apparent. Women have reported that the vaccine may endorse sexual behavior or 
that they have heard of stigmatizing messages related to HPV (e.g., “people who have STDs are 
careless and dirty,” “only sluts get HPV,” or “if you got HPV it means you weren’t smart about 
who you were sleeping with”); and therefore are less inclined to be vaccinated (Hopfer & 
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Clippard, 2011, p. 269; Joseph et al., 2014). Interestingly, little research has focused on the 
concept that HPV is a sexually transmitted disease or associated with genital warts; rather the 
focus has been on framing the vaccine as a method of cancer prevention. In fact, women were 
more likely to be vaccinated when the vaccine was framed as cancer prevention (Hopfer & 
Clippard, 2011). This corroborates the finding that vaccine uptake is more likely if women have 
a higher perceived severity of cervical cancer, perceived likelihood of getting cervical cancer, or 
higher worry about cervical cancer (Bendik et al., 2011; Krakow et al., 2015). Yet, having 
fatalistic beliefs regarding cancer was associated with non-completion of the HPV vaccine series 
(Vanderpool et al., 2015). 
 Control. As in many health behavior theories, confidence in one’s ability to perform the 
behavior is integral to overcoming barriers to perform that behavior (Champion & Skinner, 2008; 
Montano & Kasprzyk, 2008). As would be expected, women with higher perceived behavioral 
control and self-efficacy were more likely to be vaccinated or intend to be vaccinated (Dillard, 
2011; Ratanasiripong et al., 2013; Schaefer Ziemer & Hoffman, 2013). These barriers that 
women overcome may not only be the barriers previously described at the intrapersonal level, 
but may exist at higher levels. 
 Risk perception and risk reality. One of the largest barriers to vaccination among 
females 18 to 26 years of age is a result of poor risk perception. Non-vaccinated women 
consistently report a low perceived HPV risk attributed to a number of reasons, including not 
being sexually active or using alternative HPV prevention methods (Anhang Price et al., 2011; 
Cohen & Head, 2013; Gelman et al., 2013; Hodge et al., 2011; Hopfer & Clippard, 2011; Joseph 
et al., 2014; Laz et al., 2013; Ratanasiripong et al., 2013; Schaefer Ziemer & Hoffman, 2013). 
However, national recommendations state that the HPV vaccine is the best prevention method 
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for HPV compared to condoms (e.g., inconsistent effectiveness) and monogamy or no current 
sexual activity (e.g., the possibility of future sexual partners) (Markowitz et al., 2014). 
 This concept of poor risk perception as a barrier is contrasted by the risk reality of many 
women who initiate the HPV vaccine. Interestingly, this is a health behavior that women who 
participate in high-risk behaviors are more likely to uptake. With regards to sexual activity, 
women who have a lower age of sexual debut, have more sexual partners, have vaginal sex, or 
engage in mutual masturbation are more likely to be vaccinated (Bednarczyk et al., 2011; Bendik 
et al., 2011; Bernat et al., 2013; Gerend & Shepherd, 2011; Lindley et al., 2013; Manhart et al., 
2011; Mills et al., 2011; Ratanasiripong, 2014; Tiro et al., 2012). Additionally, women who have 
already been diagnosed with HPV, have had an abnormal Pap test, and have had no Pap test were 
also more likely to initiate the HPV vaccination series (Anhang Price et al., 2011; Laz et al., 
2013; Ratanasiripong et al., 2013; Vanderpool et al., 2011). Finally, non-sexual risk behaviors 
are also associated with vaccine uptake; these include cigarette smoking, illegal drug use, and 
alcohol use (Manhart et al., 2011; Wei et al., 2013). As a result, it may be that these women who 
are engaging in high-risk behaviors have a more accurate perception of their risk profile, and are 
therefore more likely to be vaccinated. In contrast, other women may consider themselves 
“protected” from HPV given their sexual health profile; thus, these women have a lower 
perceived risk of HPV and are less likely to initiate the HPV vaccine series. This is especially 
important to recognize as this catch-up age category for HPV vaccination is the only age group 
where independent and autonomous decision-making can take place for the individual. 
 
Interpersonal Barriers and Facilitators 
 Healthcare providers. A healthcare provider recommendation or offer for the HPV  
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vaccination consistently increased initiation (Daley, Vamos, et al., 2010; Klosky et al., 2015; 
Licht et al., 2010; Marchand et al., 2012; Rosenthal et al., 2011; Zimet et al., 2010). Women 
cited not being offered the vaccine from their providers as a reason for not being vaccinated 
(Anhang Price et al., 2011). Additionally, women reported a high level of trust in their providers, 
as well as using the providers’ encouragement to overcome other barriers to vaccination (Dillard 
& Spear, 2010; Joseph et al., 2014). Rosenthal et al. (2011) identified physician recommendation 
as a moderating factor influencing HPV vaccination (OR=93.5, 95% CI 39.1-223.6), and as 
result stratified the analysis to understand the effect more fully. Women who received a 
physician recommendation were more likely to be vaccinated the stronger the recommendation 
(OR=1.4, 95% CI 1.1-1.9) (Rosenthal et al., 2011). Characteristics of the healthcare provider also 
influenced HPV vaccination; women with male providers were less likely to be vaccinated (Chao 
et al., 2010). Similar to this is the specialization of the practitioner; women were more likely to 
be vaccinated when visiting a family medicine or internal medicine physician (Chao et al., 2009, 
2010). It is therefore apparent that healthcare providers have an integral role as agents to HPV 
vaccination. 
 Subjective norms. Overall, when tested, subjective norms (i.e., perceived social pressure 
to perform a behavior) were a significant predictor to HPV vaccination and intention (Allen et 
al., 2009; Bennett et al., 2012; Ratanasiripong et al., 2013; Schaefer Ziemer & Hoffman, 2013). 
Subjective norms were strongest when considering “important people” as influential agents in 
decision-making (Bennett et al., 2012). Additionally, women reported higher uptake when 
encouraged by important others in their social network, such as sisters, sorority members, 
friends, mothers, and healthcare providers (Cohen & Head, 2013). Women who perceived higher 
social approval were also more likely to be vaccinated (Marchand et al., 2012). Thus, examining 
36 
the social network of women is necessary in order to elicit who are these “important people” that 
contribute to the decision-making process for the HPV vaccine. From the literature, three groups 
of people emerged: family members, peers, and partners. 
 Family members. Receiving supportive messages or hearing about the vaccine from 
family members increased the uptake of the vaccine (Hopfer & Clippard, 2011). Alternatively, 
women who reported that their parents advised them not to obtain the vaccine or were against the 
vaccine were less likely to be vaccinated (Ratanasiripong et al., 2013). Entangled in this issue is 
the reported barrier to vaccination of fear of parental disclosure, which may be emphasized 
among women who received negative messages about the vaccine from parents or family 
members (Hopfer & Clippard, 2011). This fear of disclosure may also be exacerbated among 
women who remain on family members’ insurance plans since evidence of HPV vaccination is 
provided on insurance billing forms.  
 Among family members, one key agent among young adult women was mothers. 
Mother-daughter communication and approval about the HPV vaccine positively impacted 
daughters’ vaccine behavior (Krieger et al., 2011; Roberts et al., 2010). One reason that mothers 
may appear to be influential agents compared to other family members is due to the design of 
studies to assess only maternal influence; however, one study did examine the role of fathers in 
HPV vaccination. In fact, among rural women, the perception that fathers wanted them to be 
vaccinated was a significant predictor of HPV vaccination (Casey et al., 2013).  
 Peers. Women reported that peer descriptive norms (e.g., friends being vaccinated), 
which reduced the stigma of HPV vaccination, were important to increasing the likelihood of 
vaccination (Hopfer & Clippard, 2011). Additionally, peer approval (i.e., injunctive norms) was 
reported as a facilitator for vaccine initiation (Manhart et al., 2011). Among a national survey of 
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college students, women who reported being vaccinated were more likely to be a member of a 
sorority, varsity athletics, or intramural/club sports (Lindley et al., 2013). Women in these groups 
may experience more support from their peer social networks when participating in these 
activities compared to women in non-formalized types of peer groups. 
 Partners. One of the most consistent findings in the literature was that married women 
or women in a relationship were less likely to be vaccinated or intend to be vaccinated (Anhang 
Price et al., 2011; Ford, 2011; Gelman et al., 2013; Jain et al., 2009; Joseph et al., 2014; Laz et 
al., 2013; Liddon, Hood, et al., 2012; Liddon, Leichliter, et al., 2012; Rahman et al., 2013; 
Schmidt & Parsons, 2014; Wei et al., 2013; Williams et al., 2013; Zimet et al., 2010). 
Furthermore, in a national survey among college students, women who were not in a relationship 
(OR=1.59, 95% CI 1.45-1.74) or in a relationship and not living with their partner (OR=1.31, 
95% CI 1.20-1.43) were more likely to be vaccinated compared to women in a relationship and 
living with their partner (Lindley et al., 2013). Hopfer and Clippard (2011) reported that women 
may frame their perception of HPV susceptibility based upon their relationship status (Hopfer & 
Clippard, 2011). Thus, partnership status, or rather monogamy, may be a key moderator to 
uptake of the HPV vaccine among this age group of women. Additionally, women were more 
likely to have a preference for male partners who were vaccinated, regardless of the woman’s 
vaccination status. This preference was stronger among women with a higher perceived 
vulnerability to HPV (Harper, Alexander, et al., 2014). Moreover, women were more likely to be 
vaccinated when they perceived the vaccine as being beneficial to their partner (Patel et al., 
2013). Among all key change agents influencing HPV vaccination status, it appears that partners 
are consistently reported in the quantitative, survey-based research, yet little examination has 
occurred as to how these key agents are influential.  
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Organizational Barriers and Facilitators 
 In this context, the organizational level includes the healthcare system organization, 
specifically, access to healthcare, insurance coverage, and healthcare interactions. 
 Insurance coverage and cost. Women who are uninsured or publically insured were 
consistently less likely to be vaccinated compared to women with private insurance (Anhang 
Price et al., 2011; Dempsey et al., 2011; Ford, 2011; Hodge et al., 2011; Jain et al., 2009; Laz et 
al., 2013; Lindley et al., 2013; Rahman et al., 2015; Tiro et al., 2012; Wei et al., 2013; Zimet et 
al., 2010). Additionally, women with insurance were more aware of the availability of the HPV 
vaccine compared to women without insurance (Ford, 2011; Pourat & Jones, 2012). Yet one 
study found that insurance continuity (i.e., having insurance over a three year period) was not a 
significant predictor of vaccine initiation (Cowburn et al., 2014). The issue of insurance coverage 
may represent a more global barrier related to the cost of the vaccination series. Women without 
insurance would need to pay out of pocket for the vaccine, which may cost approximately $140 
to $170 per dose (American Cancer Society, 2014b; Planned Parenthood, 2014). This is 
especially limiting since women (19 to 26 years) are no longer eligible for some programs that 
can circumvent the cost, such as Vaccines for Children (American Cancer Society, 2014b). Cost 
was repeatedly cited as a barrier to HPV vaccination among this target population (Head & 
Cohen, 2012; Joseph et al., 2014; Zimet et al., 2010). Moreover, among women who were not 
vaccinated and interested in obtaining the vaccine, one-third reported they would not receive the 
vaccine if they had to pay full cost (Williams et al., 2013). While insurance coverage and cost of 
the vaccine represent formidable barriers to vaccination, it must be recognized that these are not 
the only barriers that must be removed. Two studies offered the vaccine for free to women in 
rural areas of the United States. In these studies, despite the elimination of the main barrier, cost, 
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women still faced additional barriers to being vaccinated, such as distance to the clinic and fear 
of pain from the vaccine (Casey et al., 2013; Vanderpool et al., 2011). 
 Healthcare interaction. Women without a regular healthcare provider or without a visit 
to a healthcare provider in the last year were less likely to be vaccinated (Tiro et al., 2012; Wei et 
al., 2013; Williams et al., 2013). Given that women need to be seen by a medical provider in 
order to receive the vaccine, a lack of interaction with a healthcare provider is a key barrier. In 
order to assess this issue, many studies have used other types of health procedures or billing 
codes (e.g., Pap test in past three years
6
) as surrogate measures for healthcare interaction. 
Women who have not had a Pap test in the past three years or were not using hormonal birth 
control (which requires a prescription from a healthcare provider), were less likely to be 
vaccinated (Wei et al., 2013). Moreover, women who had sexually transmitted infection tests or 
Pap tests were more likely to be vaccinated compared to women who did not (Chao et al., 2010; 
Laz et al., 2013). Additionally, women who did not receive other types of vaccinations, such as 
influenza or Hepatitis B, were also less likely to be vaccinated (Anhang Price et al., 2011; Jain et 
al., 2009; Laz et al., 2013; Rahman et al., 2013; Schmidt & Parsons, 2014; Wei et al., 2013). 
However, there are some types of visits that reduce the likelihood of vaccination. Women with 
an obstetric history (e.g., birth, pregnancy or abortion in medical record) or having one or more 
pregnancies were less likely to be vaccinated (Chao et al., 2009, 2010; Verdenius et al., 2013). 
Similarly, women with more emergency department visits were less likely to complete 
vaccination; this may be the result of more serious health conditions that take priority to HPV 
vaccination or a proxy measure of lack of insurance (Chao et al., 2009). In order to help facilitate 
                                                          
6
 At the time of data collection (2010), Pap tests were recommended for women at the onset of sexual 
activity every three years. 
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HPV vaccination completion, utilization of immunization only appointments can increase rates 
of completion, especially for second and third doses (Dempsey et al., 2011). 
 
Community Barriers and Facilitators 
 Region. Women residing in the Northeast, West, or North Central/Midwest were more 
likely to uptake the HPV vaccine compared to other United States’ regions, while controlling for 
confounders, such as race and socioeconomic status (Lindley et al., 2013; Wei et al., 2013). 
Additionally, women in the South were the least likely to be vaccinated; however, these women 
reported the most interest in the vaccine (Rahman et al., 2013; Schmidt & Parsons, 2014). Thus, 
women in the South may face barriers to receiving the vaccine despite an interest in uptake. 
 Accessibility. Not only is region of the United States a factor impacting HPV vaccination 
among young adult females, but also level of urbanization. Women living in rural areas may 
face more difficulties physically accessing the HPV vaccine and thus have lower rates of uptake 
(Crosby et al., 2011; Hodge et al., 2011). Rural women reported wanting more accessible 
community locations where they could receive the vaccine (Mills et al., 2013). Additionally, 
accessibility may be impacted by a number of factors, including not knowing where to get the 
vaccine, transportation barriers, and other responsibilities (e.g., childcare, work, or school) (Mills 
et al., 2013). Confounding the issue of accessibility is the necessity for the three-dose vaccine, 
meaning three separate visits, which serve as additional barriers (Head & Cohen, 2012). 
 
Policy Barriers and Facilitators 
 No studies reported policy-related barriers or facilitators to HPV vaccination among this 
specific age and gender group. However, this does not indicate there are none present. 
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Interventions 
 There is a dearth of interventions implemented among this population in order to increase 
HPV vaccination rates. Included in this review are nine studies that attempted to improve HPV 
vaccination intention, uptake, or completion. The majority of these interventions implemented 
educational techniques (e.g., tailored binder of information, education video, narrative message, 
fact sheet, online information, or DVD) (Gerend & Shepherd, 2012; Gerend, Shepherd, & 
Lustria, 2013; Hopfer, 2012; Juraskova et al., 2012; Krieger & Sarge, 2013; Paiva et al., 2014; 
Vanderpool et al., 2013).  
Among these studies, a tailored educational binder to perceived barriers improved HPV 
vaccination intentions compared to a non-tailored message among unvaccinated college women. 
One of these barriers was “I’m in a monogamous/committed relationship.” While overall the 
intervention improved intention for vaccination, it is unknown the effect of each specific 
message (Gerend, Shepherd, & Lustria, 2013). Additionally, a DVD intervention improved 
completion of the HPV vaccination series compared to standard of care among a community 
sample of women (Vanderpool et al., 2013). One randomized control trial compared the effect of 
disease framing of HPV (either cervical cancer or genital warts) in a fact sheet among female 
university students; there was no significant effect (Juraskova et al., 2012). Similar results were 
found for a video that used loss-framing (i.e., emphasizing the costs of not getting vaccinated) or 
gain-framing (i.e., emphasizing the benefits of getting vaccinated) for vaccination among 
unvaccinated college women; there was no significant difference in vaccination between groups 
(Gerend & Shepherd, 2012). In comparison, another study assessed disease message framing and 
found framing HPV within the context of genital warts impacted intentions to talk to a healthcare 
provider about the HPV vaccine among college-age females (Krieger & Sarge, 2013). One other 
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study found a computer-based, tailored, education intervention to be feasible and acceptable 
among a sample of college women (Paiva et al., 2014). A potential bias of the majority of these 
educational interventions is that these were conducted among college/university students, who 
may have higher knowledge levels than community-based samples of 18 to 26 year old women 
(Kennedy et al., 2011), thus diminishing the effects of these interventions. 
Patel et al. (2014) aimed to improve completion of the HPV vaccine series among women 
in a community reproductive health center. The intervention used cues to action, specifically 
automated reminder messages. These were delivered from the reproductive health center via 
patient’s preferred method of communication. The reminder system did not successfully increase 
completion rates (Patel et al., 2014). 
Only one study emphasized the role of healthcare providers and peers in vaccination at a 
university health center. In this randomized control trial, health messages included HPV 
susceptibility, self-efficacy and safety. These messages were delivered by four types of agents: 
peer only, medical expert only, combination or peer and medical expert, or neither. At the two 
month follow-up, the peer-expert combination had the strongest effect (OR=2.01, 95% CI 1.05-
4.10), while the other modes of delivery did not significantly impact HPV vaccination (Hopfer, 
2012). 
 
Application of Theory in Interventions 
The majority of these studies utilized a theoretical framework to develop or evaluate the 
intervention implemented. These theoretical frameworks included: the Health Belief Model 
using only the  perceived barriers construct for the study (Gerend, Shepherd, & Lustria, 2013; 
Gerend, Shepherd, & Shepherd, 2013), the Culture-Centric Narrative Theory (Hopfer, 2012), the 
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Theory of Planned Behavior (Juraskova et al., 2012; Vanderpool et al., 2013), the Extended 
Parallel Process Model (Krieger & Sarge, 2013), the Transtheoretical Model (Paiva et al., 2014), 
and a combination of the Theory of Planned Behavior and the Health Belief Model (Gerend & 
Shepherd, 2012). Only one study did not use a theoretical framework in the intervention (Patel et 
al., 2014).  
 
Limitations of Current Research 
 The review of the literature revealed as plethora of barriers and facilitators to HPV 
vaccination among young adult women. Despite the large amount of evidence describing these 
multi-level factors, there are a limited number of interventions among women 18 to 26 years of 
age. Among the nine interventions included in this review, only two included tailoring to specific 
sub-sets of women (e.g., tailored to perceived barriers or stage of change) (Gerend, Shepherd, & 
Lustria, 2013; Paiva et al., 2014). Yet, evidence supports the use of tailoring for health messages 
(Kreuter & Wray, 2003), more specifically with HPV vaccine messages (Allen et al., 2009; 
Gerend, Shepherd, & Lustria, 2013; Reiter, Brewer, Gottlieb, McRee, & Smith, 2009b). 
Therefore, it is necessary to identify the types of characteristics among the target population that 
require segmentation and tailored message framing in order to improve HPV vaccination. 
 
Relationship Status and HPV Vaccination among Young Adult Women 
 According to the literature review, one of the most consistent predictors of HPV 
vaccination is relationship status among young adult women. Specifically, women in long-term 
or monogamous relationships are less likely to be vaccinated. The bulk of the available research 
has focused on epidemiological risk factor associations regarding relationship status and HPV 
vaccination using cross-sectional designs and large datasets or surveys. None of these studies 
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have investigated how relationship status operates as a risk factor and how to intervene to 
improve vaccination rates among young adult women. 
 
Relationship Status is a Predictor of Vaccination – Quantitative Data 
Among studies conducted within the 18 to 26 year old female target population, there are 
14 studies supporting the association between relationship status and HPV vaccination (Anhang 
Price et al., 2011; Bernat et al., 2013; Ford, 2011; Joseph et al., 2014; Laz et al., 2013; Liddon, 
Hood, et al., 2012; Liddon, Leichliter, et al., 2012; Lindley et al., 2013; Rahman et al., 2013; 
Schmidt & Parsons, 2014; Wei et al., 2013; Williams et al., 2013; Zimet et al., 2010). The 
majority of these studies utilized nationally-representative surveys, including the National Health 
Interview Survey (NHIS)
7
, the National Survey of Family Growth (NSFG)
8
, the Behavioral Risk 
Factor Surveillance System (BRFSS)
9
 and the National College Health Assessment (NCHA)
10
 
(Table 7).  
Using data from NHIS surveys between 2008 and 2010, adjusted odds ratios reporting the 
association between relationship status (reference group = married/in relationship) and HPV 
vaccination uptake ranged between 2.4 to 4.1, all statistically significant (Anhang Price et al., 
2011; Laz et al., 2013; Wei et al., 2013; Williams et al., 2013). Similar findings were reported for 
NHIS data examining interest in the HPV vaccine (Schmidt & Parsons, 2014). Analyses using 
NSFG utilized different parameters for their populations and examined initiation of vaccination 
and intention for vaccination; all analyses found statistically significant associations between 
  
                                                          
7
 NHIS is used to monitor the health status of the U.S. population on a range of health topics. 
8
 NSFG is used to describe pregnancy, fertility, and contraception rates among U.S. men and women. 
9
 BRFSS is used to monitor prevalence of major behavioral risk factors among the U.S. population. 
10
 NCHA is used to monitor the health status and risk factors for participating U.S. universities. 
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Table 7: Quantitative Studies Reporting Effect of Relationship Status on HPV Vaccine Uptake 
Publication Years Dataset, 
 Sample Age 
OR, 95% CI Comparison 
Group 
Referent  
Group 
Ford, 2011 2007-08 NSFG, 18-24 7.7, 1.8-33.3
†
 Single Married 
Liddon, et 
al., 2012 
2007-08 NSFG, 20-24 2.7, 1.4-5.4 Never 
Married 
Other 
Rahman, et 
al., 2013 
2008-10 BRFSS, 18-26 1.4, 129-1.6
†
 Never 
Married 
Other + Married 
Anhang, et 
al., 2011 
2008 NHIS, 18-26 4.1, 1.9-8.6 Other Married 
Lindley, et 
al., 2013 
2009 NCHA, 18-24 1.6, 1.5-1.7 Not in a 
relationship 
In a relationship/ 
living together 
Laz, et al., 
2013 
2010 NHIS, 18-26 3.1, 1.7-5.6 Single Married 
Wei, et al., 
2013 
2010 NHIS, 18-26 2.4, 1.4-4.2 Never 
Married 
Married or living 
together 
Williams, et 
al., 2013 
2010 NHIS, 18-26 2.4, 1.4-4.2 Other Married 
†
Inverse of the odds ratio calculated for consistency of referent group  
 
these outcomes and relationship status (Ford, 2011; Liddon, Hood, et al., 2012; Liddon, 
Leichliter, et al., 2012). One study used the BRFSS dataset for 2008 to 2010 and found that 
women who were married, divorced, widowed, or separated were less likely to be vaccinated 
than single, never married women (Rahman et al., 2013). 
Overall, the survey-based, quantitative research supports the finding that young adult 
women in relationships are less likely to receive or have interest in the HPV vaccine compared to 
young adult women who are single. This consistent epidemiological support warrants further 
investigation to how this risk factor may be moderating HPV vaccination uptake among the 18 to 
26 year old female population. 
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A Women’s Health Issue 
While males (18 to 21 years old, and 21 to 26 years old for high risk populations) may 
also make autonomous decisions regarding HPV vaccination in young adulthood, relationship 
status does not appear to be a significant risk factor among this group. In a systematic review 
examining HPV vaccine acceptability among males, relationship status was not a significant 
demographic factor identified in the 29 included studies (Newman et al., 2013). Moreover, in a 
web-based survey among young adult males and females, there were differences in factors 
associated with vaccine uptake; in particular marital status was a predictor among females and 
not a predictor among males (Bernat et al., 2013). This indicates the possibility of differences in 
risk profile among males and females in this age category for HPV vaccination. 
 
Hypothesized Mechanism  
While the epidemiological data support the connection between relationship status and 
HPV vaccination, these studies have not attempted to understand the mechanism for this 
association. However, other quantitative findings investigating perceived risk or susceptibility 
may connect this risk factor to HPV vaccination. Specifically, women who have lower HPV risk 
perceptions are less likely to be vaccinated (Anhang Price et al., 2011; Cohen & Head, 2013; 
Gelman et al., 2013; Hodge et al., 2011; Hopfer & Clippard, 2011; Joseph et al., 2014; Laz et al., 
2013; Ratanasiripong et al., 2013; Schaefer Ziemer & Hoffman, 2013). Schaefer Ziemer and 
Hoffman (2013) examined how Health Belief Model constructs differed between vaccinated and 
unvaccinated women. Many unvaccinated women reported that they did not need the vaccine 
since they did not perceive themselves as at risk, especially with monogamous partners. Thus, 
these women were evaluating their proximal risk for HPV based on their current relationship or 
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sexual partnership rather than considering their future risk for HPV. A similar evaluation of risk 
occurs among women who report never having had sex and do not intend to be vaccinated; these 
women are also altering their risk perceptions for HPV based on proximal factors, but based on 
current sexual behavior (Liddon, Hood, et al., 2012). Schaefer Ziemer and Hoffman (2013) 
suggest that future behavioral HPV vaccination research and interventions should emphasize that 
future behavior and partner behavior affect HPV risk among women. 
Similarly, Cohen and Head (2013) found that unvaccinated women reported an attitude of 
low perceived risk for HPV, which was supported by the beliefs that HPV can be prevented 
through monogamy and knowledge of their partners’ sexual history. To date, only one qualitative 
study has investigated the narratives of HPV vaccinated and unvaccinated women as it relates to 
sexual behavior (i.e., sexually active, not sexually active). Hopfer and Clippard (2011) reported 
an emerging finding from this study that women framed their risk perceptions for HPV based on 
relationship status. Again, false beliefs regarding risk for HPV were prominent among these 
young adult women, including “I don’t feel personally vulnerable [to HPV] because I am in a 
committed relationship where we are only seeing each other” (Hopfer & Clippard, 2011, p. 272). 
Moreover, this discordance between risk perception and risk reality among women in this 
age category is evident among traditionally sexually high-risk groups (e.g., multiple sexual 
partners, previously diagnosed with HPV). In this case, many of the high-risk groups are getting 
vaccinated compared to the perceived low risk counterparts (Anhang Price et al., 2011; 
Bednarczyk et al., 2011; Bendik et al., 2011; Bernat et al., 2013; Gerend & Shepherd, 2011; Laz 
et al., 2013; Lindley et al., 2013; Manhart et al., 2011; Mills et al., 2011; Ratanasiripong et al., 
2013; Tiro et al., 2012; Vanderpool et al., 2011). Overall, this concept is counterintuitive to 
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typical health-related research, which focuses on high-risk groups not accessing healthcare 
services. 
Young adult women are not the only group with false beliefs regarding risk for HPV. 
Healthcare providers may also be contributing to the low HPV vaccine uptake among women in 
relationships. Zimet et al., (2011) reported physicians giving a lower priority to vaccinating 
female patients who were married or in a monogamous relationship compared to women who 
were single or dating. In contrast, these physicians surveyed did not alter priority perceptions 
based on women’s sexual history (e.g., HPV infection, abnormal Pap test) (Zimet et al., 2011). 
Thus, healthcare providers may suffer from the same risk perception bias as young adult women 
regarding relationship status and HPV vaccination. This finding is concerning since 
recommendation for vaccination from a healthcare provider was significantly associated with 
HPV vaccine uptake among this population. Rosenthal et al. (2011) found that the strength of 
physician recommendation was the strongest predictor of HPV vaccine uptake, and in fact 
marital status was no longer a significant predictor. The authors suggested that despite married 
women being less inclined to be vaccinated, a strong physician recommendation may increase 
that likelihood (Rosenthal et al., 2011). 
 
But isn’t, “Monogamous Sex, Safe Sex”?  
While monogamy is considered a protective factor for many sexual and reproductive 
health outcomes, it is not necessarily a guarantee to be protected from HPV throughout the 
lifespan. In the United States, monogamy is often conflated with serial monogamy. Most people 
are not lifetime monogamists with only one sexual partner (Conley, Ziegler, Moors, Matsick, & 
Valentine, 2013). The average number of lifetime partners among women in the U.S. is 3.6, 
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according to the National Survey of Family Growth 2006-2008 (Chandra et al., 2011). Evidence 
supports that serial monogamy is considered a risk factor for acquiring HPV. Even if a woman’s 
current sexual partner is monogamous, that does not circumvent the issue of that partner’s 
previous sexual network, which is critical for HPV transmission (Burchell et al., 2006). 
Additionally, recent research has evaluated the prevalence of HPV in recently formed 
partnerships. The study found that heterosexual dyads in their “first relationship” with vaginal 
sex had a prevalence of HPV that was approximately 17% (Burchell et al., 2014).  
Moreover, if a woman has one sexual partner at the time for her vaccination decision, that 
does not preclude her from exposure to HPV at the time of vaccination or in the future. The 
prevalence of HPV is highest among females age 20 to 24 (59.8%, 95% CI 54.0-65.3%) 
(Markowitz et al., 2013). Furthermore, it is estimated that the average lifetime probability of 
acquiring HPV among women with at least one male partner is approximately 85% (Chesson, 
Dunne, et al., 2014). In a study examining the incidence of HPV among heterosexual couples, 
women in a heterosexual relationship had a 28% (95% CI 14%-40%) cumulative incidence of 
any HPV type and 17% (95% CI 8%-26%) cumulative incidence of oncogenic HPV over a 12 
month period. The 24 month prevalence of HPV among women in a heterosexual couple was 
67.7% for any type of HPV and 46.5% for oncogenic HPV types (Nyitray et al., 2013). This 
demonstrates that the risk for HPV among women in relationships or with lower sexual risk 
profiles is not as low as perceived. 
Despite this evidence supporting the risk for HPV with serial monogamy, heuristic 
beliefs regarding the safety of monogamy overshadow the actual risk. Monogamy is perceived as 
being “safe sex” and protecting individuals from STIs. However, serial monogamy without 
additional protective behaviors (e.g., STI testing, waiting an amount of time for sexual behavior) 
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does not necessarily protect against STIs. In fact, serial monogamy may produce added risk for 
an individual who proceeds with sexual interaction with a partner without added precautions, 
such as condom use (Conley et al., 2013).  
 
 Impact of Relationship Status on Other Health Behaviors 
Other sexual and reproductive health behaviors are influenced by relationship status, 
specifically condom use. A similar discrepancy occurs where persons in regular, long-term 
relationships have less condom use compared to more transient or new relationships (Macaluso, 
Demand, Artz, & Hook, 2000; Santelli et al., 1996). However, the differences between how 
condom use and HPV vaccination relates to relationship status may be attributed to the proximity 
of the behavior and outcome. Condom (non-)use and its associated outcomes, such as pregnancy 
and STIs, is a proximal connection between behavior and outcome. In contrast, HPV vaccination 
and its associated outcomes, such as future HPV infection or HPV-associated cancers, is a more 
distal association between behavior and outcome. Thus, the connection of relationship status to 
perceived risk of an outcome may be operating similarly among condom use and HPV 
vaccination; however, it may differ based on the proximity of the outcome (e.g., short term STI 
vs. long-term cervical cancer). 
 
Theoretical Framework 
 The theoretical framework utilized for this study was the Information, Motivation, and 
Behavioral Skills (IMB) Model to understand and promote HPV vaccination among young adult 
women (Fisher & Fisher, 2002; Fisher, 2012). This study was supplemented with  two constructs 
from the Health Belief Model, perceived severity and perceived susceptibility, which were 
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included within the Risk Perception sub-construct of the Motivation construct of IMB 
(Champion & Skinner, 2008). 
 
 IMB Model Overview 
 The IMB Model was developed as a way to understand HIV risk and prevention in the 
context of social-psychological conceptualizations (Fisher & Fisher, 2002). Not only does the 
IMB Model provide a theoretical framework that can be applied to a range of preventive 
behaviors, including condom use (Misovich, Fisher, & Fisher, 1997), but it also has a 
methodological approach for designing theory-based interventions. Specifically, the approach 
involves three steps: elicitation, intervention design and implementation, and evaluation of the 
intervention (Fisher & Fisher, 1992). The IMB Model includes three overall determinants to 
behavior: information, motivation, and behavioral skills (see Table 8 for the description of each 
construct and an example application to HPV vaccination). There are sub-categories within the 
motivation and behavioral skills constructs, which further delineate the determinants for 
behavior. In addition to these constructs, the IMB Model also recognizes macro-level factors that 
may work directly or indirectly to influence a behavior (Fisher, 2012). 
 
IMB Model Application to Condom Use and Relationship Status 
 As previously stated, the IMB Model was initially developed as a behavioral framework 
for preventing HIV. As such, one of the health behaviors of interest was condom use. 
Interestingly, previous research has been conducted to evaluate the impact of relationship status 
on condom use utilizing the IMB Model, and the finding may have some application to this 
current research (Misovich et al., 1997). 
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Table 8: IMB Model Constructs and Application to HPV Vaccination Examples 
Construct Definition Application 
Information Information regarding preventive behavior Information about risk for HPV and 
potential protection from HPV 
vaccination 
Motivation 
   Personal 
   Social 
   Perceived  
   vulnerability 
Attitudes toward practicing preventive acts 
Perceptions of social support for 
performing acts 
Perceived vulnerability to the 
disease/outcome 
Distrust of vaccines 
Physician recommendation 
Perceived vulnerability to HPV 
Behavioral Skills 
   Objective ability 
   Perceived self-   
        efficacy 
Ability to perform behavior 
Confidence in ability to perform behavior 
Schedule appointment 
Confidence to discuss vaccine with 
partner 
Macro Factors Factors that directly or indirectly impact 
behavior 
Insurance coverage and vaccine cost 
 
 
 Within this model, Misovich, Fisher & Fisher (1997) posit that distinctive Information, 
Motivation, and Behavioral Skills exist among persons in a relationship and the use of condoms. 
Regarding Information, people in relationships are more likely to rely on heuristic beliefs that 
“monogamous sex is safe sex” and “known-partners-are-safe-partners.” These beliefs may 
impede the individual from appropriately evaluating the risk of unprotected sex and the risk for 
HIV. Moreover, there appear to be beliefs that limit the individual from evaluating their partner’s 
risk for HIV, further elevating risk. For Motivation, personal motivation for condom use is 
largely associated with trust in the relationship and of the partner. Especially if the individual 
does not receive social support for condom use from their partner, they are less likely to engage 
in the behavior. The most important motivating factor, which aligns with the issues described in 
the information construct, is the low perceived vulnerability for HIV for themselves and partners. 
These are largely formed by the false heuristic beliefs that inform the risk evaluation. Finally, the 
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Behavioral Skills described are unique to the self-efficacy and ability to perform behaviors 
related to condom use, specifically negotiating use with a partner and maintaining proper use 
(Misovich et al., 1997).  
The authors of this review emphasized the unique composition of the IMB Model 
constructs for persons in relationships as it relates to condom use. The deficits in each of these 
constructs should be targeted for prevention interventions in order to improve condom use 
(Misovich et al., 1997). Moreover, the findings from this review have implications for this 
research. Specifically, the Information and Motivation constructs report heuristic beliefs, partner-
specific influences, and perceived risk that translate for HPV vaccination among women in 
relationships. Thus, these findings were applied in the in-depth interview guide instrument 
development to recognize the potential issues that women may face for HPV vaccination 
decisions in the context of the IMB Model. 
 
 IMB Model Application to Current Study 
The IMB Model was used as the theoretical framework for guiding the study of 
informational needs, motivations, and behavioral skills framed by relationship status impacting 
HPV vaccination among young adult females (Figure 2). The study involved an assessment of 
the four constructs (i.e., information, motivation, behavioral skills, and macro-level factors), 
which may influence HPV vaccination behavior among four groups of women: (1) married or 
living with a partner; (2) single, but in a long-term monogamous relationship; (3) single and 
dating; and (4) single, but not in a relationship or dating (Zimet et al., 2011).  These constructs 
were also assessed across two groups of women based on vaccination status: (1) recently HPV 
vaccinated; and (2) HPV unvaccinated.  
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 The first construct considered is Information. Traditionally, the IMB Model has described 
this construct as cognitive processes that influence a behavior. However, given that women are 
receiving information from a range of health information sources (e.g., Internet, peers, family, 
partners, healthcare providers) (Daley, Vamos, et al., 2010; Sandfort & Pleasant, 2009), it is 
necessary to include a measure of trustworthiness or value regarding these information sources. 
The more valued the information source, the more likely the woman may be to prioritize that 
information (Redmond, Baer, Clark, Lipsitz, & Hicks, 2010; Worsley, 1989). Additionally, 
information about HPV and the HPV vaccine can influence motivation, behavioral skills, and  
 
 
Figure 2: Application of IMB Model to HPV Vaccination in Young Women 
 
vaccination. Many women cited needing more knowledge about the vaccine as a primary barrier 
to vaccination, indicating how lack of information may impact motivations or behavioral skills to 
vaccination (Joseph et al., 2014; Ratanasiripong et al., 2013; Zimet et al., 2010). Moreover, from 
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the literature, there appear to be heuristic beliefs that monogamous sex is safe sex or that 
condoms alone can prevent the transmission of HPV (Anhang Price et al., 2011; Cohen & Head, 
2013; Gelman et al., 2013; Hodge et al., 2011; Hopfer & Clippard, 2011; Joseph et al., 2014; Laz 
et al., 2013; Ratanasiripong et al., 2013; Schaefer Ziemer & Hoffman, 2013). These 
informational beliefs may inform how women align their current sexual health behaviors and 
relationships with the need for the HPV vaccine. Therefore, Phase II of the study included a 
measure of women’s basic knowledge of HPV and the HPV vaccine, as well as assess the 
information’s source trustworthiness, which may impact how likely that person is to act on that 
information.  Additionally, in Phase I of the study, some of the NHIS reasons for non-
vaccination align with these false beliefs reported in the literature (e.g., don’t know enough about 
the vaccine; not sexually active). How these differ based on relationship status is reported.  
The second construct is HPV vaccine motivation. Fisher & Fisher have conceptualized 
this construct to include three primary components: personal motivation, social motivation, and 
perceptions of personal vulnerability to the disease (Fisher & Fisher, 2002). In this study, 
personal motivation encompassed factors such as attitudes about vaccination and perceived 
benefits and barriers to vaccination. Additionally, social motivation included perceived support 
and social norms from significant others. From the review of the literature, important others 
include: healthcare providers, partners, parents/family, and peers. Therefore, this study elicited 
the injunctive norms of approval/disapproval from important others for HPV vaccination. 
Perceptions of personal vulnerability to HPV will also be evaluated to determine if risk 
perceptions regarding acquiring HPV differ based on relationship status and motivate the need 
for HPV vaccination. The concept of personal vulnerability to HPV was operationalized utilizing 
the Health Belief Model constructs of perceived susceptibility and perceived severity, which 
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together operate as perceived threat. Perceived susceptibility is one’s belief regarding the chance 
of getting a condition, in this case HPV and HPV-related outcomes. Perceived severity is one’s 
belief of the seriousness of the health condition (Champion & Skinner, 2008). The combination 
of the Health Belief Model perceived threat construct with the IMB Model has been used and 
evaluated previously (DeBate et al., 2013). 
Behavioral skills is the third construct of the IMB Model. This concept is typically 
ignored in other health behavior theories, which only emphasize perceived ability or control, 
rather than actual skill or competence to perform the behavior. The skills considered integral to 
HPV vaccination include: communication with important others (e.g., healthcare provider, 
partner), funding the vaccine, accessing the vaccine, and complying with the three dose series 
(Fisher, 2012). To help understand the skills required for vaccination, participants were asked to 
describe how they would go about obtaining the HPV vaccine (unvaccinated) or how they went 
about getting the vaccine (vaccinated) in order to elicit the procedural knowledge to obtain the 
vaccine.  
The final construct included the macro-level factors, which are higher-level determinants 
that may directly or indirectly impact behavior. From the review of the literature, it was clear that 
HPV vaccination is not only situated at an intrapersonal level; rather, higher levels of influence 
impact this behavior. The review of the literature revealed barriers that extend beyond a 
woman’s control, including cost of the vaccine, insurance coverage, and healthcare interaction 
(Anhang Price et al., 2011; Dempsey et al., 2011; Ford, 2011; Head & Cohen, 2012; Hodge et 
al., 2011; Jain et al., 2009; Joseph et al., 2014; Laz et al., 2013; Lindley et al., 2013; Tiro et al., 
2012; Wei et al., 2013; Williams et al., 2013; Zimet et al., 2010). It was important to take into 
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consideration these potentially significant macro-level barriers that can impact a woman’s HPV 
vaccination behavior.  
This study has the potential to move the IMB Model field forward by demonstrating 
application of the model to the HPV vaccination topic among young adult females. Fisher (2012) 
emphasized the need for research using the IMB Model for this specific behavior, HPV 
vaccination. Empirical evidence to support the framework in the elicitation phase will support 
the justification that this robust theory has the ability to explain vaccination behavior in this 
population. Moreover, the research findings from this study can inform the development of 
validated instruments for using the IMB Model for HPV vaccination in quantitative research 
studies. This can eventually assist in the development and evaluation of theory-based 
interventions using the IMB Model. 
In summary, the IMB Model is the most appropriate theoretical framework for guiding 
the research to understand why and how informational needs, motivations, and behavioral skills 
may be framed by relationship status for HPV vaccination among young adult females. This 
robust framework comprises information, motivation, behavioral skills, and macro-level factors 
constructs that can be applied to this focused area of research. 
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CHAPTER 3: METHODS 
 
Overview 
The long-term goal of this research is to increase HPV vaccination rates among young 
adult women 18 to 26 years of age, ultimately decreasing HPV-related disease (i.e., HPV-
associated cancers, genital warts). The purpose of this study was to understand how young adult 
women’s relationship status influences informational needs, motivations, and behavioral skills 
related to HPV vaccination. This objective was achieved through the following specific aims and 
mixed-methods study design: 
 
1. Assess how relationship status affects primary reasons for non-vaccination 
among 18 to 26 years old women.  
A secondary data analysis using the 2010 National Health Interview Survey was 
conducted to determine if women in relationships were less likely to be interested in 
vaccination and identify the primary reasons (e.g., misinformation, motivations, 
behavioral skills) for non-vaccination among different relationship status groups. 
 
2. Understand how relationship status frames HPV vaccine informational needs, 
motivations, and behavioral skills among 18 to 26 year old women.  
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In-depth interviews were completed with a sample (N=50) of 18 to 26 year old 
women at the University of South Florida, stratified by relationship status and HPV 
vaccine status. A comparative thematic analysis was conducted to determine if there 
were differences in informational needs, motivations, behavioral skills, and HPV 
decision-making. 
 
Timeline 
Table 9: Timeline for Dissertation Research Study 
Activity Feb Mar Apr May Jun Jul Aug Sept Oct 
Dissertation proposal X         
Phase I 
IRB approval  X        
Data cleaning  X        
Data analysis  X X       
Report findings   X X X X X X X 
Phase II 
Develop instruments X         
Pilot interview guide 
and recruiting materials 
X         
Finalize instruments  X        
IRB approval  X        
Recruitment  X X       
Data collection  X X       
Data analysis   X X X     
Report findings      X X X X 
Dissertation defense         X 
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Population 
 HPV vaccination is approved for use among adolescent females 11 to 12 years of age, but 
also as catch-up vaccination until the age of 26 (Centers for Disease Control and Prevention, 
2010a; Markowitz et al., 2007). The target population for this research study was women in the 
18 to 26 year old age range. Two separate samples were used in this concurrent mixed-methods 
study that included this target population. The first sample for Phase I was derived from a 
nationally-representative cross-sectional survey and restricted to 18 to 26 year old females who 
were HPV unvaccinated. The second sample for Phase II was recruited from the University of 
South Florida and included 18 to 26 year old females based on relationship status and HPV 
vaccination status. 
 
Approach 
This mixed-methods study design included two separate phases that both aligned with the 
study objective to understand how young adult women’s relationship status influences 
informational needs, motivations, and behavioral skills related to HPV vaccination. Phase I was a 
quantitative analysis of a nationally-representative health survey and Phase II was a qualitative 
analysis of in-depth interviews from a smaller sample of women. 
 
Phase I: Quantitative, Secondary Data Analysis 
 
Overview  
The purpose of this research phase was to assess how relationship status affects the 
primary reasons for non-vaccination among women 18 to 26 years old. To achieve this goal, a 
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secondary data analysis was conducted using the National Health Interview Survey (NHIS) 2010 
with supplemental cancer questions related to HPV vaccination. Previous studies using this 
dataset have reported marital status as a significant factor for HPV vaccine uptake among this 
population and reported the overall primary reasons for non-vaccination; however, there has not 
been a specific investigation regarding the different categories of marital status (e.g., single, 
married, divorced, separated, widowed) and vaccination interest, combined with reasons for non-
vaccination among young adult women (Laz et al., 2013; Schmidt & Parsons, 2014; Wei et al., 
2013; Williams et al., 2013). 
 
 Subjects and Setting  
The purpose of the NHIS is to monitor the health status of the United States’ population 
among civilian noninstitutionalized persons. The survey has been conducted since 1957 and the 
content of the survey is continuously updated. The NHIS is a cross-sectional household interview 
survey with a multistage area probability design sampling plan that is representative of 
households in the United States. The sampling plan is updated following each decennial census. 
Moreover, the sampling procedure oversamples for Black, Asian and Hispanic persons. For the 
2010 survey, within each household sampled, one civilian adult was randomly selected to 
complete the Sample Adult questionnaire. Survey participation was completely voluntary. 
Details regarding the complex sampling design for the NHIS can be found in Parsons et al. 
(2014). The 2010 survey data were collected through a household interview by trained 
interviewers from the U.S. Bureau of the Census. The questionnaire was completed using a 
computer assisted personal interviewing device, where interviewers can directly impute the 
participants’ responses. 
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 The 2010 survey included a final sample size of 27,157 for persons 18 years of age or 
older that completed the Sample Adult component of the interview. The conditional response 
rate for this component among eligible sample adults was 77.3%. However, the final response 
rate for the Sample Adult was 60.8% considering the refusal household response rate (Division 
of Health Interview Statistics & National Center for Health Statistics, 2011a) 
 
Phase I: Research Question I 
 Research question. Among unvaccinated 18 to 26 year old women, were married 
women less likely to be interested in HPV vaccination compared to non-married women? It was 
hypothesized that women who were married (in a relationship) were less likely to be interested in 
the HPV vaccine compared to non-married women. 
Sample. The sample was restricted to NHIS Sample Adults (N=27,157) who were female 
and between the ages of 18 to 26 years (N=2,011). The sample was further restricted to women 
who responded to the HPV vaccine questions (N=1,892) and were not vaccinated with the HPV 
vaccine (N=1,461) as these participants responded to the interest in the HPV vaccine questions. 
Finally, cases were removed that had missing data for the primary analysis variables, including 
HPV interest (N=1) and unknown marital status (N=3). This resulted in a final sample size of 
1,457 women for Analysis 1 (Figure 3). 
Data collection procedures. The datasets, formats, and codebooks were downloaded 
from the NHIS website. These included information from the Person, Sample Adult, Cancer 
Supplement, and Income Imputation datasets. The datasets were sorted by household and persons 
ID numbers (HHX and FPX) and merged together in SAS 9.4. Only variables required for this 
analysis were kept in the final dataset. 
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Figure 3: NHIS Sampling Strategy 
 
Instrumentation. The variables considered for this analysis were based on previous HPV 
vaccine research among young adult women (Laz et al., 2013; Schmidt & Parsons, 2014; Wei et 
al., 2013; Williams et al., 2013). Univariate analysis procedures, such as Proc Survey Freq and 
Proc Survey Means, were used to examine the distribution of each variable. Additionally, NHIS 
codebooks were consulted to identify any skip patterns in the dataset. Based on this review, the 
variables for consideration in the final model were re-coded (Table 10).  
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Table 10: Recoding of Variables for Phase 1 Research Question 1 Analysis 
Description Variable  Question Response Categories 
Primary Variables 
Interest in 
Vaccine 
HPVINT Would you be interested in 
getting the HPV vaccine? 
1 Yes 
2 No or Don’t Know 
 
Relationship 
Status 
R_MARITL Are you now married, 
widowed, divorced, 
separated, never married, 
or living with a partner? 
0 Married 
1 Widowed, Divorced, or Separated 
2 Living with Partner 
3 Never married 
Health-Related Variables 
Had HPV HPVHAD Have you ever been told 
by a doctor or other 
healthcare professional 
that you had HPV? 
0 Yes 
1 No or Don’t Know 
 
Heard HPV 
Vaccine 
SHHPVHRD Two vaccines, or shots, to 
prevent HPV infection are 
available in the United 
States. Both vaccines 
prevent cervical cancer 
and one also prevent 
genital warts. The two 
HPV vaccines are 
sometimes called 
CERVARIX ® or 
GARDASIL ®. Before 
this survey, have you ever 
heard of HPV vaccines or 
shots? 
0 Yes 
1 No 
 
Abnormal 
Pap Test 
PAPABN3 Have you had a Pap test in 
the LAST 3 years where 
the results were NOT 
normal? 
0 Yes 
1 No (includes women who did not have 
a Pap in the last 3 years) 
 
Regular 
Healthcare 
Provider 
AMDLONG About how long has it 
been since you saw or 
talked to a doctor or other 
healthcare professional 
about your own health?  
0 In the last year 
1 More than a year 
 
OB/GYN AHCSYR7 During the past 12 months, 
have you seen or talk to 
any of the following 
healthcare providers about 
your own health? A doctor 
who specializes in 
women’s health? 
0 In the last year 
1 More than a year 
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Table 10 (Continued)  
General 
Physician 
AHSCY8_9 During the past 12 months, 
have you seen or talk to 
any of the following 
healthcare providers about 
your own health? A doctor 
who treats a variety of 
illnesses (a doctor in 
general practice, family 
medicine, or internal 
medicine)? 
0 In the last year 
1 More than a year 
 
Flu Shot SHTFLUYR During the past 12 months, 
have you had a seasonal 
flu shot? 
0 Yes 
1 No 
 
Hepatitis B 
Shot 
SHTHEPB Have you EVER received 
the hepatitis B vaccine? 
0 Yes 
1 No 
 
Demographic Variables 
Region REGION NHIS – Recode 0 Northeast 
1 Midwest 
2 South 
3 West 
Hispanic ORIGIN_I Does person consider self 
Hispanic/Latino? 
0 Yes 
1 No 
Race RACERPI2 NHIS – Recode 0 White only 
1 Black/African American only 
2 Other (AIAN, Asian, Other, Multiple 
Race) 
 
Age AGE NHIS – Recode  0 18-21 years 
1 22-26 years 
Education EDUC What is the HIGHEST 
level of education you 
completed or the highest 
degree you have received? 
0 Less than High School Diploma 
1 GED or High School Diploma 
2 More than High School 
Health 
Insurance  
NOTCOV NHIS – Recode 0 Not covered or Don’t know 
1 Covered 
 
Family 
Income 
POVRATI3 NHIS – Recode and 
Multiple Imputation 
 
Ratio of family income to 
the federal poverty level 
0 200% + 
1 100% < 200% 
2 < 100% 
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The initial research plan intended to utilize personal reported income in the last year as a 
measure of income for this analysis. However, upon examining the frequencies for this variable, 
440 participants had missing data (due to skip pattern of being an unemployed adult), 106 did not 
know, and 43 refused to answer. Due to the amount of missing data for the income variables in 
the NHIS dataset, multiple imputation was utilized as an analysis tool to account for the missing 
data. Five separate datasets were developed by the NHIS with the imputed values for family 
income. These imputations were based upon a variety of demographic and health-related 
variables. The imputed family income variable was transformed using the U.S. Census Bureau’s 
poverty threshold to calculate the poverty ratio value (Division of Health Interview Statistics & 
National Center for Health Statistics, 2011b). 
For this analysis, the Income Imputation file was downloaded from the NHIS website and 
the SAS code for multiple imputation was used to generate the 5 separate imputed datasets. Each 
of these datasets was merged with the primary study dataset including the variables listed above. 
Family poverty ratio was the only variable in this analysis that included imputed values. This 
continuous variable was then transformed into a 3-level categorical variable (<100%, 100% < 
200%, and 200% + of the federal poverty level).  
Data analysis. All analysis procedures utilized survey-weighted SAS 9.4 procedures, 
unless otherwise specified. These survey-weight procedures were weighted using primary 
sampling units, strata and clustering variables (STRAT_P, PSU_P, and WFTA, respectively). 
Univariate descriptive statistics were computed for each variable after re-categorization using 
frequencies. Due to limitations in multiple imputation analysis using Proc Survey Freq, only the 
first multiple imputation dataset was used to report poverty level frequencies. Bivariate 
frequencies and Rao-Scott chi-square tests were then calculated to compare each independent 
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variable to the outcome variable, interest in HPV vaccine. The Rao-Scott chi-squared test was 
used since it is the default chi-square test for survey-weighted data. It uses a simple correction to 
the Pearson chi-square test, which accounts for the complex sampling design of the survey that 
limits the assumption of independent and identically distributed observations. This correction 
considers the generalized design effect of the data (Rao & Scott, 1981). 
Model building. Survey logistic regression was used to estimate the crude odds ratios and 
95% confidence intervals between the outcome variable and each independent variable. This 
provided the unadjusted effect for each variable on interest in the HPV vaccine. Interaction was 
then assessed prior to evaluating potential confounding (Kleinbaum, Kupper, Nizam, & 
Rosenberg, 2014). Since the primary purpose of this analysis was to describe the impact of 
relationship status on HPV vaccine interest, the approach for assessing effect modification 
examined only the primary predictor variable of interest (i.e., relationship status) with all other 
independent variables. These models were hierarchically well-formulated, meaning it included 
the interaction term (relationship status and the independent variable tested) and the two main 
effects for these variables. None of the interaction models produced a significant interaction term 
(p>0.10); therefore, it was determined that effect modification of the relationship status and HPV 
vaccine interest association was not present.  
Next, models were fitted to estimate the odds of interest in the HPV vaccine with 
relationship status and each remaining predictor variable. The purpose of this exercise was to 
screen for confounders to include in the final analysis model. Confounders were screened for 
inclusion in the model if addition of that variable resulted in a change of the adjusted odds ratios 
of more than 10% (Greenland & Rothman, 2008). However, no variables produced a 10% 
change. Therefore, in order to develop the final model for analysis, crude odds ratios were 
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examined for significance with the outcome variable and the literature was consulted for the 
most salient confounding variables. This selection process produced the final model for 
consideration to include the following variables: relationship status, Hispanic, race, region, age, 
insurance coverage, poverty ratio, abnormal Pap test, heard of the HPV vaccine, flu shot in last 
12 months and receipt of the hepatitis B vaccine. 
Model diagnostics. Model assumptions for logistic regression were assessed; these 
include: detecting outlying or influential points (Pearson residuals and DFBETAs), a test of 
linearity for continuous predictors (not applicable), and model fit assessment (Hosmer-
Lemeshow Goodness of Fit Test) (Vittinghoff, Glidden, Shiboski, & McCulloch, 2005). Note 
that the diagnostic procedures for the model did not utilize survey weights as SAS 9.4 does not 
support these procedure options in survey-weighted models. The plots for the Pearson residuals 
and DFBETAS did not identify any observations that would be considered outliers or influential. 
The Hosmer-Lemeshow Goodness of Fit Test produced a chi-square value of 3.1330 and a p-
value of 0.9257. This non-significant value indicated no gross lack of fit with the model. 
Additionally, the c-statistic for the model was 0.668.  
The model was also assessed for multicollinearity. While the logistic regression function 
in SAS 9.4 does not support the ability to assess multicollinearity, linear regression functions can 
be used since these assessments do not rely on the outcome variable (IBM, 2014). A linear 
regression model was fitted with the binary outcome variable and predictors. All categorical 
predictors were re-coded as dummy variables for this analysis. This model produced the 
tolerance and variance inflation factors used to assess multicollinearity. None of the predictor 
variables had a tolerance level less than 0.2 or a variance inflation factor greater than 5, 
indicating multicollinearity was not present in the model (Logan, 2011). 
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This study was adequately powered to investigate the research question in Analysis 1, 
which used logistic regression. According to a preliminary sample size analysis using G*Power, 
the sample size of 1,457 was more than the minimum 849 required for 95% power (Faul, 
Erdfelder, Lang, & Buchner, 2007). This power analysis was based on the following criteria: two 
tailed test, odds ratio of 1.30, proportion of women interested in the vaccine who are in a 
relationship 35%, alpha level 5%, and power level 95%. The parameter for the prevalence in the 
unexposed is based on previous research: 35% proportion of women interested in the vaccine 
who are in a relationship (Schmidt & Parsons, 2014). The hypothesized odds ratio represents a 
small effect size (Chen, Cohen, & Chen, 2010). 
 Final model. Survey weighted logistic regression was used to produce crude and adjusted 
odds ratios and 95% confidence intervals for the odds of interest in the HPV vaccine with the 
following independent variables: relationship status, Hispanic, race, region, age, insurance 
coverage, poverty ratio, abnormal Pap test, heard of the HPV vaccine, flu shot in last 12 months 
and receipt of the hepatitis B vaccine. This model included the domain function to account for 
the 5 imputed datasets for the poverty ratio variable. SAS multiple imputation analysis 
procedures (PROC MIANALYZE) was used to estimate the model effects of the log odds ratios 
and log odds 95% confidence interval for each variable. These were then exponentiated to 
produce odds ratios and 95% confidence intervals, while accounting for the imputed data. 
Prevalence ratios. The odds ratios and 95% confidence intervals produced by the logistic 
regression models (crude and adjusted) were converted to prevalence ratios due to the high 
prevalence of the outcome in this analysis (Zhang & Yu, 1998). The equation for conversion is: 
RR = OR / (1 – PO) + (PO x OR). The prevalence of the outcome in each reference category was 
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used to estimate the prevalence ratio. The prevalence ratios and 95% confidence interval were 
reported. 
 Sensitivity analysis. Due to the small frequency of the Widowed, Separated, and 
Divorced relationship status category (<5%), a sensitivity analysis was conducted to determine if 
removing this group from the final model affected the measures of effect significantly. The same 
procedures for multiple imputation, logistic regression, and prevalence ratio conversions were 
used on a subset of the data excluding women in the “Widowed, Separated, and Divorced” 
category (N=1,392). A threshold of 10% was used for each measure of effect to determine if 
significant change had occurred between the final model and the sensitivity analysis model.  
 
Phase I: Research Question II 
 Research question. Among unvaccinated 18 to 26 year old women, who are not 
interested in the vaccine, is there an association between relationship status and the primary 
reasons for non-vaccination? It was hypothesized that there were differences in primary reasons 
for non-vaccination among relationship status group categories. 
Sample. The sample was restricted to NHIS Sample Adults (N=27,157) who were female 
and between the ages of 18 to 26 years (N=2,011). The sample was further restricted to women 
who responded to the HPV vaccine questions (N=1,892), were not vaccinated with the HPV 
vaccine or refused this question (N=1,479), and reported being not being interested in the HPV 
vaccine or don’t know if interested in the HPV vaccine (N=988) as these participants responded 
to the reasons for not interested in the HPV vaccine questions. Finally, cases were removed that 
had missing data for the primary analysis variables, including unknown marital status (N=3) and 
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refusing the primary reason for non-vaccination question (N=1). This resulted in a final sample 
size of 984 women for Analysis 2. 
Data collection procedures. The datasets, formats, and codebooks were downloaded 
from the NHIS website. These included information from the Person, and Sample Adult, Cancer 
Supplement datasets. The datasets were sorted by household and persons ID numbers (HHX and 
FPX) and merged together in SAS 9.4. Only variables required for this analysis and descriptive 
sample variables were kept in the final dataset. 
Instrumentation. Two variables were of interest for this research question, specifically 
primary reason for non-vaccination and relationship status. Univariate frequency analysis 
procedures were used to examine the distribution of each variable. Based on this review, the 
relationship status variable was re-coded (Table 11).  
 
Table 11: Recoding of Variables for Phase 1 Research Question 2 Analysis 
Description Variable  Question Response Categories 
Primary Variables 
Relationship 
Status 
R_MARITL Are you now married, 
widowed, divorced, 
separated, never 
married, or living with a 
partner? 
0 Married 
1 Widowed, Divorced, or Separated 
2 Living with Partner 
3 Never married 
Primary 
Reason 
HPVNOT 
 
What is the MAIN 
reason you would NOT 
want to get the vaccine? 
01 Does not need vaccine 
02 Not sexually active 
03 Too expensive 
04 Too old for vaccine 
05 Doctor didn't recommend it 
06 Worried about safety of vaccine 
07 Don't know where to get vaccine 
08 My spouse/family member is against it 
09 Don't know enough about vaccine 
10 Already have HPV 
11 Other 
99 Don't know 
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 Data analysis. Univariate survey-weighted frequencies were computed for the reasons 
for non-vaccination variable and the relationship status variable. Next, a bivariate cross-
tabulation was calculated for these two variables, which revealed multiple cells with less than 5 
observations. Due to the survey-weighting of these data and lack of exact tests available for these 
survey procedures in SAS (SAS Institute Inc., 2015), data were transformed for the survey-
weighted chi square test to determine if there was an association between relationship status and 
reasons for non-vaccination. The cross-tabulations indicated the majority of the missing data was 
in the Widowed, Separated, and Divorced relationship status category, therefore this was 
removed from the final analysis (N=940). Additionally, the top four reasons for non-vaccination 
were identified and the remaining reasons were combined into an “other” category to allow for 
the chi-square test to be operational with the survey-weighted procedures.  The top four reasons 
were selected because remaining survey responses had cells with small numbers, which SAS 
survey procedures are not equipped to handle (i.e., Fishers Exact test is not available with survey 
procedures in SAS) (SAS Institute Inc., 2015). 
 
Phase II: Qualitative Interviews, Young Adult Women 
  
Overview 
The purpose of Phase II was to understand how relationship status frames HPV vaccine 
informational needs, motivations, and behavioral skills among 18 to 26 year old women. In-
depth interviews with college women were conducted. Qualitative methods were preferred in this 
instance since the research question aimed to understand and explain people’s views and 
behaviors, ultimately using an interpretivist approach (Hennink, Hutter, & Bailey, 2011b). 
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Additionally, this methodology was consistent with the IMB Model approach to study design 
(Fisher & Fisher, 2002). The first step is the elicitation process to identify the existing 
information, motivation, and behavioral skills for the health promotion behavior (Fisher & 
Fisher, 2002). 
 
Subjects and Setting 
Phase II recruitment and data collection was conducted between March 2015 and April 
2015. The target population for this research question was women between the ages 18 to 26 
years at the University of South Florida. Women were recruited for participation through 
multiple modalities in order to increase participation, which included: (1) course announcements 
in multiple disciplines across campus (e.g., public health, anthropology, nursing), (2) on-campus 
flyers at different locations (e.g., Education Building, Interdisciplinary Sciences Building, 
College of Medicine, Morsani Center, Library, and Gym), (3) various USF 
department/organization listserv announcements (e.g., Department of Civil and Environmental 
Engineering, Department of Anthropology, USF Sororities), (4) handouts distributed through 
Student Health Services healthcare providers at USF, and (5) a mass-informational email to all 
USF-Tampa female students between the ages of 18 and 26 years. The combination of these 
recruitment methods resulted in 1,113 people taking the recruitment eligibility survey (Appendix 
A). Women who completed the survey and in-depth interview were provided an electronic $10 
gift card to either Amazon or Starbucks. 
Moreover, the study used quota sampling strategy (Bernard & Ryan, 2010e). There were 
eight stratified sub-groups for which adequate sample sizes were aimed to reach. Participants 
were stratified by relationship status (married or living with a partner; single but in a long-term 
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monogamous relationship; single and dating; single but not in a relationship or dating) and HPV 
vaccination status (vaccinated in the last six months or non-vaccinated). The categorization for  
relationship status was based on previous research conducted by Zimet et al. (2011) regarding 
healthcare providers’ preferences for HPV vaccination based on relationship status and sexual 
history. This provided built in variability to the data to assess the impact of relationship status on 
information, motivation, and behavioral skills related to the vaccine. According to Guest et al. 
(2006) major themes and saturation can be achieved at a minimum of six interviews (Guest, 
Bunce, & Johnson, 2006). The minimum number of women that were recruited for each stratum 
was six with the option of adding additional participants to reach data saturation. This resulted in 
a total of 50 participants; six per stratum, except for the long term monogamous relationship 
status categories, which each had 7 participants in attempt to reach data saturation (Table 12).  
 
Table 12: Phase II Samling Strategy 
  Unvaccinated Vaccinated 
Married or living with a 
partner N=6  N=6 
Single, but in a long-term 
monogamous relationship  N=7  N=7 
Single and dating  N=6   N=6 
Single, but not in a 
relationship or dating  N=6   N=6 
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Women were eligible for the study if they met the following criteria: (1) student at the 
University of South Florida, (2) between 18 and 26 years of age, (3) has not received any doses 
of the HPV vaccine OR has received the first dose of the HPV vaccination series in the last 6 
months; (4) speaks English, and (5) provides informed consent. Women were screened to 
determine which stratified category for sampling they qualify. The only exclusion criterion was 
if sampling was completed for a category.  
 
Recruitment Challenges 
 The recruitment process for seven out of the eight strata was achieved in a two week 
period in March and April 2015. However, only two women started the eligibility survey and fell 
in the married/living with a partner and recently vaccinated category; one was interviewed and 
one did not provide contact information. To help assist in the recruitment process for this group 
of women, the recruitment handouts and announcements were revised to specify these specific 
relationship status and vaccination criteria. These were then distributed through USF’s 
organizations listserv. Through this second round of recruitment, an additional five women were 
recruited and participated in the study. 
 
Data Collection Procedures 
The recruitment and sampling plan included multiple steps (Figure 4). Recruitment 
announcements were distributed through the modalities previous described. Within these 
recruitment materials was a link and/or QR code to a web-based survey to screen for eligibility 
through Qualtrics (Qualtrics, 2013). Persons who were eligible to participate then completed an  
76 
 
Figure 4: Phase II Procedures 
 
informed consent document, demographic questions, knowledge questions and provided contact 
information to schedule the in-depth interview (i.e., name, email, phone number). Among 
persons who completed the baseline eligibility survey, selected participants scheduled a 20 to 25 
minute in-depth interview via telephone or Skype (based on participant’s preference). Due to the 
high volume of women responding to the eligibility survey and providing contact information in 
some of the quota sampling strata, eligible participants were contacted on a first-come first-serve 
basis, as well as with consideration for scheduling preferences. The eligibility survey was 
initiated by 1,331 persons; 60% received the HPV vaccine, 31% never received the HPV 
vaccine. Among the sample initiating the survey, 7% received the HPV vaccine in the last 6 
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months. Among those persons, 388 were eligible, 375 consented, and 352 completed the entire 
survey with contact information. Therefore the response rate among those considered eligible for 
the study was 90.7%. The women selected for an in-depth interview were contacted via email 
with multiple dates and times to schedule an interview based on the participant’s preferences.  
All interviews were conducted over the telephone, which was the preference of all 
participants rather than using video conferencing. During the interview administration, field 
notes were written to allow the interviewer to reflect on important details of the interview, which 
may not have been captured by reading transcripts in data analyses. All interviews were audio-
recorded with two devices (one for back-up). Audio-recordings were then be transcribed 
verbatim (11 were transcribed by the researcher and 39 were transcribed using professional 
services – Verbalink). Transcriptions did not include participants’ names or any other type of 
identifying information. Once transcriptions were completed, the audio files were destroyed to 
protect participants’ confidentiality. A unique participant identifying number was used to link the 
survey content to the interview transcript/audio file. Data from the surveys were downloaded 
from USF Qualtrics (Qualtrics, 2013). The names and contact information from the participants 
were only used for scheduling the interview. Once the interview was completed the names and 
contact information were destroyed.  
 
Instrumentation 
Four sets of instruments were developed for Phase II data collection: (1) eligibility 
questionnaire; (2) demographic questions; (3) knowledge questions; and (4) semi-structured 
interview guide (Appendix B). These instruments were pre-tested with three individuals who 
were similar to the target population of this study and who were not included in the final sample. 
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This assisted in the quality of the instruments prior to implementation for data collection. The 
primary purpose of the pilot tests was to assess content validity, feasibility, and acceptability of 
the interview guide. The norm for qualitative interviews is to pilot test with a few interviews 
among people with similar characteristics to the target population (Hennink, Hutter, & Bailey, 
2011a). 
Eligibility questionnaire. The eligibility questionnaire asked participants screening 
questions based on inclusion criteria. These included sex (female), age (18 to 26), HPV 
vaccination status (not-vaccinated or vaccinated within the last 6 months), and relationship 
status. Persons who met the criteria continued with the demographic and knowledge questions. 
Those persons who did not meet the criteria ended the survey. 
Demographic questions. The participant demographic questions described the 
respondent’s socio-demographics (e.g., race/ethnicity, insurance status, sexual orientation). 
Knowledge questions. The knowledge questions were a true/false format and content 
related to HPV transmission and the HPV vaccine. The knowledge test was the validated HPV 
vaccine knowledge scale, previously administered to college females (Daley, Vamos, et al., 
2010). These close-ended questions objectively assessed the HPV and HPV vaccine knowledge 
level among participants. Additionally, the respondents were asked to report information sources 
for the HPV vaccine.  
Interview guide. The interview was conducted using a semi-structured interview guide. 
The interview guide was developed using the constructs from the IMB Model (i.e., Information, 
Motivation, Behavioral Skills, and Macro Factors) and preliminary research related to condom 
use and relationship status using the IMB Model (Fisher & Fisher, 2002; Fisher, 2012; Misovich 
et al., 1997). Questions regarding perceived vulnerability/threat to HPV were developed based 
79 
on constructs of perceived severity and perceived susceptibility in the Health Belief Model 
(Champion & Skinner, 2008). All questions were open-ended with probing questions to allow for 
more detail (Bernard & Ryan, 2010a). Moreover, the content validity of the interview guide was 
examined by the IMB Model co-creator, William A. Fisher PhD, Distinguished Professor in the 
Department of Psychology and the Department of Obstetrics and Gynecology at the University 
of Western Ontario. 
During the data collection process, an additional question was added to the information 
section of the interview guide. Women reported on who they have heard about the HPV vaccine 
from and who they trusted the most. However, to add detail on where they wished to receive 
more information from, a question on information source preferences for the future was asked. 
These modifications were added after pilot testing of the interview guide. 
 
Pilot Testing 
Pilot testing was conducted on March 12, 2015 with three subjects. Two were 
unvaccinated, but one was “living with a partner” and the other was “single, but not dating.” One 
was vaccinated and “living with a partner.” The length of the interviews was between 15 to 25 
minutes. The pilot test entailed completing the online survey and the telephone interview. After 
the survey and interview was completed, the pilot participants were asked their feedback on the 
instruments and the process.  
 The primary area that required revisions was the beginning portion of the interview – the 
information section and transition to the remaining part of the interview. Prior to conducting the 
interview, the scores from the knowledge survey for each participant were reviewed to identify 
three to four questions that the participants were unsure about or were incorrect. These were used 
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to fill the stem, “People mention ________. What do you think about this statement? Why?” 
Participants had a difficult time describing how they felt about the statement. Their responses 
were either, “I don’t know” or “I don’t know a lot about HPV.” This important feedback 
informed revisions of the interview instrument. Moreover, the revisions assisted in standardizing 
this section of the interview guide. First, any similarities between the three pilot participants on 
questions that were frequently missed on the knowledge scale were examined. Next, the survey 
results from Daley et al. (2010), which was conducted among female college students, was 
evaluated to determine the most frequently missed questions. These two processes elucidated 
general categories of information that were frequently missed to HPV and the HPV vaccine. The 
information questions were revised as follows: 
1. What are some of the things you know about HPV? 
a. Probe: Transmission  
b. Probe: Outcomes – cancer, genital warts, herpes, HIV 
c. Probe: Curability and length of infection 
2. What are some of the things you know about the HPV vaccine? 
a. Probe: Who can get it? 
b. Probe: When should you get it? 
c. Probe: Any negative effects associated with it? 
 The next area identified that required modifications was transitions. First, after the 
participant was asked if the conversation can be audio-recorded, they were then ask, “So to start, 
what do you think about the HPV vaccine?” This overlapped with some of the information 
elicited in the information section. Therefore, this question was removed. Second, the interview 
guide contained a script describing the HPV vaccine so that all participants move forward in the 
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interview with basic knowledge about the vaccine. One of the pilot participants mentioned that 
because she had low knowledge about the vaccine, she thought this was only being read to her 
due to her low knowledge. She was reassured that this was not the case, and she recommended 
including a statement prior to reading this script that this is read to all participants and is part of 
the standard procedures for the interview. As a result, prior to reading the HPV vaccine 
description, the interview guide included:  
“I am going to read you a quick description of the HPV vaccine. I read this to all 
participants in the interview that way we are all on the same page moving forward 
with our conversation. Is that okay?” 
Finally, I reflected as the interviewer on how the three pilot interviews went. I needed to be 
cognizant of my affirmations and include a larger variety other than “okay.” I realized that I used 
this throughout the interviews due to the fact that it is being conducted on the telephone. I want 
the interviewee to know that I am paying attention to what they are saying by verbally 
acknowledging it, since they cannot see my body cues. Additionally, I needed to be comfortable 
with the interview guide in order to be flexible with the order of questions. Overall, the pilot 
testing was a needed exercise to revise the instruments and practice the interviewing process. 
 
Data Analysis  
Qualitative data analysis is a cyclical and iterative process. First, a codebook was 
developed with the a priori deductive codes based on the IMB Model. Each code contained a 
code name, description, and examples. Open coding was conducted to apply these initial 
deductive codes to the data. Additionally, during this process, emergent codes were identified 
and added to the codebook (Bernard & Ryan, 2010d; Vamos, n.d.). These emergent codes 
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included anti-vaccine movement and personal decision. The constant comparative method was 
used to assist in categorizing codes (Bernard & Ryan, 2010c). Once all the codes were applied to 
the transcripts, themes and relationships among codes were identified through axial coding. 
Summaries of major themes were written, and representative quotes were selected. A final read 
through of the data was conducted using selective coding to validate the relationships between 
categories (Bernard & Ryan, 2010d; Vamos, n.d.). Throughout the coding process, memos were 
written to document emerging ideas, insights, or thoughts related to the data analysis. Data 
analysis was conducted using Atlas.ti 7 data management software (Atlas.ti Scientific Software 
Development, 2012). 
Because stratified groups of women were sampled for this study, a comparative thematic 
analysis was used to compare and contrast information, motivation, behavioral skills, and macro 
factors among the groups (Bernard & Ryan, 2010c; Guest, MacQueen, & Namey, 2012). 
Specifically, matrices were developed to quantitatively and qualitatively compare the content of 
the codes across interviews within stratified groups. Four group comparisons occurred during 
data analysis (Figure 5). These included: (1) comparing the IMB themes across the four different 
relationship status categories among unvaccinated women; (2) comparing the IMB themes across 
the four different relationship status categories among vaccinated women; (3) comparing the 
IMB themes across vaccination status among women single and single and dating; and (4) 
comparing the IMB themes across vaccination status among women in married or living with a 
partner and single, but in a long-term monogamous relationship.  
Within each of these groups, data saturation was assessed. Saturation is reached once 
information is no longer being added with each additional interview (Glaser & Strauss, 2009). 
The study design of including at least six participants per group was based on empirical evidence 
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that data saturation can be reached at this level (Guest et al., 2006). While composing summary 
statements for each group among major themes for this analysis, saturation was assessed by  
 
Figure 5: Phase II Analysis Strategy 
 
reviewing the homogeneity of the participant responses. The two groups for long-term 
monogamous relationship status required additional interviews to reach data saturation due to 
outlier cases in the sample. As a result, one interview was added to each of these two groups. 
 One method to improve the objectivity of results was to assess the reliability of the data 
analysis process. Inter-rater reliability is a methodology used to compare the coding process 
between one or more individuals (Bernard & Ryan, 2010b). The purpose was to confirm that the 
coding process was systematic and reproducible. To determine the reliability of the coding 
process and codebook, an additional researcher coded 10% of the transcripts to produce an inter-
rater reliability measure. Once the primary researcher (Thompson) coded all of the transcripts 
(N=50), a second researcher then coded 10% sample of the transcripts (N=5) independently 
using the developed codebook. Any discrepancies in the codes were discussed between coders 
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and a final decision on the appropriate approach to proceed was determined. A threshold of a 
Cohen’s kappa of 80% was used to indicate “almost perfect agreement” among coders (Bernard 
& Ryan, 2010b; Landis & Koch, 1977). The inter-rater reliability coding process for this study 
produced a Cohen’s kappa of 88% indicating almost perfect agreement. 
 
Triangulation 
 The findings from Phases I and II meaningfully informed the interpretation of the overall 
results. Phase I quantitatively reported the differences in the primary reason for non-vaccination 
by relationship status among young adult women using a nationally representative sample. Phase 
II elicited the knowledge and perceptions of young adult women to explain why these reasons 
may exist. Together this provided an overall picture of the disparities for HPV vaccination as it 
relates to relationship status among young adult women with generalizability and depth. 
 
Protection of Human Subjects  
This project aimed to protect the human subjects involved. The project received two 
separate Institutional Review Board (IRB) approvals prior to commencement of each phase of 
the research study. This project was non-invasive and presented minimal risk to human subjects. 
Subjects were women between the ages of 18 and 26 years old. There were two aims, each of 
which had different human subjects, risks and benefits, and data monitoring plans. 
  
Phase I 
 To achieve the specific aim of Phase I, a secondary data analysis of NHIS 2010 was 
conducted. This is a publically available dataset distributed by the National Center for Health 
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Statistics. The data are de-identified, thus protecting the anonymity and confidentiality of 
participants. Therefore, this phase was categorized as Exempt Review of Human Subjects 
Research, Category Four according the University of South Florida IRB. Data were downloaded 
from the CDC website and stored on a personal hard drive. All results were reported in aggregate 
numbers and cells less than five were not reported.  
  
Phase II 
 Human subjects. To achieve the specific aim of Phase II, in-depth interviews were 
conducted with young adult 18 to 26 year old women attending the University of South Florida. 
Women were recruited through announcement, handouts, and flyers at the University of South 
Florida. Fifty were recruited and invited to participate in a scheduled interview. Women were 
eligible for the study if they meet the following criteria: (1) student at the University of South 
Florida, (2) between 18 and 26 years of age, (3) has not received any doses of the HPV vaccine 
OR received the first HPV vaccine within the last 6 months; (4) speaks English, and (5) provides 
informed consent. Women were provided an informed consent form electronically during the 
eligibility screening questionnaire, which required a check box to consent prior to proceeding 
with the survey. Women who consented were asked to provide contact information to schedule 
an in-depth interview that would last approximately 30 to 45 minutes. The interview was 
conducted via telephone. An in-depth interview guide was used to lead the interview and was 
based on the IMB Model constructs. The interview was audio-record and transcribed. All 
identifiers were removed and the data de-identified. Additionally, participants completed the 
eligibility questionnaire, as well as a knowledge survey scale. These were collected using 
Qualtrics. All data were de-identified and only linked to using a unique participant code. The 
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unique participant code was only linked to a participant’s name and contact information (phone 
and email) to schedule and contact for the follow-up interview. Once a contact and interview was 
conducted, the identifying information was destroyed. No identifiers were included in any report 
or dissemination product following this research. All electronic files were stored on a password 
protected computer. 
 This study followed all guidelines designated by the USF IRB, including informed 
consent and voluntary participation/withdrawal from the study.  
 Risks and benefits. The following risks were reasonable in relation to the benefits of this 
study. This research was considered to be minimal risk. There were no known additional risks 
for participating in this study. While name and contact information data were collected, these 
were not linked to any participant data from the surveys or interviews. No personally identifying 
information was used in any dissemination products.  
 There were limited benefits to participating in this study. All participants contributed to 
formative research for future HPV vaccination interventions that will benefit the larger public. 
Moreover, participants were offered $10 for their time and participation.  
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CHAPTER 4: RESULTS 
 
Overview 
 The goal of this study was to understand the information, motivation, and behavioral 
skills related to HPV vaccination among young adult women. The results of this dissertation are 
presented in two sections. First, the quantitative analysis of the National Health Interview Survey 
2010 is presented, which examined the association between relationship status and interest in 
HPV vaccination among unvaccinated women. Second, the results of the qualitative analysis of 
information, motivation, and behavioral skill decision-making factors for HPV vaccination 
among a sample of college women interviewed are presented. 
 
Phase I: Quantitative Analysis 
 The quantitative analysis for Phase I comprised two separate research questions used to 
examine the National Health Interview Survey 2010.  
 
Phase I Research Question I – Interest in HPV Vaccination 
 Description of sample. The final analytic sample from the NHIS 2010 dataset comprised 
1,457 women (Table 13). The majority of women had no interest in receiving the HPV vaccine 
(69%). With regard to relationship status, over half were never married (59%), and the remaining 
were married (22%), living with a partner (14%), or widowed, divorced, or separated (4%). 
Demographic characteristics revealed the majority of the sample was non-Hispanic, White, from 
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the South, between the ages of 22 and 26, had insurance coverage, and 200% above the poverty 
ratio. Nearly 70% of women had heard of the HPV vaccine in the past. Within the sample, only 
11% had a previous abnormal Pap test and 11% had a flu shot in the past 12 months. Over half of 
participants received the Hepatitis B vaccine previously. 
 Bivariate analyses. Each predictor variable was examined with the outcome variable, 
interest in the HPV vaccine. Significant associations were found for all variables, except for race, 
age, and insurance coverage (Table 13). Crude prevalence ratios estimated the effect size for the 
association between the predictor variable and outcome variable. Women who were living with a 
partner (PR=1.50, 95%CI 1.13-1.92) or never married (PR=1.41, 95%CI 1.14-1.71) were 
significantly more likely to be interested in the HPV vaccine compared to married women. There 
were no significant differences between women who were married and women who were 
widowed, divorced, or separated. Additionally, women who were Hispanic, <100% below the 
poverty ratio, had a history of an abnormal Pap test, heard of the HPV vaccine, had a flu shot in 
the last 12 months, and received the Hepatitis B vaccine were more likely to be interested in the 
HPV vaccine. Women living in the Midwest were less likely to be interested than women living 
in the South.  
 Final model. The final regression model examining the effect of relationship status on 
interest in HPV vaccination adjusted for Hispanic ethnicity, race, region, age, insurance 
coverage, family poverty ratio, abnormal Pap history, heard of the HPV vaccine, flu shot in the 
last 12 months, and ever received the Hepatitis B vaccine (Table 14). Compared to crude effects, 
the adjusted model had attenuated effects for living with a partner (PR=1.50; aPR=1.44), region 
(Midwest: PR=0.73, aPR=0.71), abnormal Pap (PR=1.79, aPR=1.75), and Hepatitis B vaccine 
(PR=1.37, aPR=1.30), while having an augmented effect for Hispanic (PR=1.25, aPR=1.39), 
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<100% of the poverty level (PR=1.24, aPR=1.27), heard of the HPV vaccine (PR=1.53, 
aPR=1.58), and had a flu shot (PR=1.41, aPR=1.49).  
Women who were living with a partner (PR=1.44, 95% CI 1.07-1.87) or never married 
(PR=1.41, 95% CI 1.12-1.73) were more likely than married women to be interested in the HPV 
vaccine. There were no significant differences between women who were married or widowed, 
divorced, or separated. Hispanic women were more likely to be interested in the vaccine 
compared to non-Hispanic women (PR=1.39, 95% CI 1.15-1.64). Other significant demographic 
factors include women living in the Midwest being less likely to be interested in the vaccine 
compared to women living in the South. Additionally, women below 100% of the poverty level 
compared to women 200% or more above the poverty level were more likely to be interested. 
Other health indicators also significantly increased likelihood of interest in the HPV vaccine, 
including having an abnormal Pap test, having a flu shot, and having the Hepatitis B vaccine. 
Finally, women who have heard of the HPV vaccine were 58% more likely to be interested in the 
vaccine compared to women who had not heard of the vaccine. 
 Sensitivity analysis. Among the sample of 1,457 women for this analysis, 0.3% were 
widowed, 1.8% were divorced, and 2.3% were separated. Due to the low frequencies of these 
groups, and as a combined group, a sensitivity analysis was conducted, which examined the full 
model while excluding these records (N=1,392). Comparing the adjusted prevalence ratios of the 
full model with the adjusted prevalence ratios of the sensitivity analysis did not identify any 
changes greater than 10% in the measures of effect (Table 15). Therefore, this group did not 
significantly alter the prior analysis. 
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Table 13. Frequencies of Demographic and Health Characteristics by Interest in the HPV 
Vaccine among the NHIS 2010 Sample of Women 18-26 Years (N=1,457) 
Variable N Total % Total N Yes % Yes P-value 
HPV Interest      
    Yes 483 31.5%    
    No 974 68.5%    
Relationship Status     <0.01 
    Married 313 22.1% 85 23.7%  
    Widowed, Div, Sep 65 4.3% 21 30.9%  
    Living with  Partner 211 14.2% 77 35.6%  
    Never Married 868 59.4% 300 33.4%  
Hispanic     <0.01 
    Yes 366 14.6% 138 38.0%  
    No 1091 85.4% 345 30.4%  
Race     0.28 
    White 998 74.4% 320 30.6%  
    Black 296 17.0% 107 35.4%  
    Other 163 8.6% 56 31.6%  
Region     <0.01 
    South 563 39.3% 209 34.6%  
    Northeast 188 14.2% 56 28.7%  
    Midwest 325 25.7% 84 25.1%  
    West 381 20.8% 134 35.5%  
Age     0.85 
    18-21 years 463 31.6% 150 31.1%  
     22-26 years 994 68.4% 333 31.6%  
Insurance Coverage     0.90 
    Yes 1043 73.3% 342 31.6%  
    No 414 26.7% 141 31.2%  
Poverty Ratio     0.03 
    200% + 566 41.9% 172 27.9%  
    100 < 200% 363 24.2% 120 32.8%  
    < 100% 528 33.9% 191 35.0%  
Abnormal Pap Test      
    Yes 161 11.1% 84 51.8% <0.01 
    No 1296 88.9% 399 28.9%  
Heard of the Vaccine     <0.01 
    Yes 954 70.4% 358 35.1%  
    No 503 29.6% 125 22.9%  
Flu Shot last 12 mo     <0.01 
    Yes 159 11.3% 68 42.3%  
    No 1298 88.7% 415 30.0%  
Hepatitis B Vaccine     <0.01 
    Yes 805 57.4% 315 35.5%  
    No 652 42.6% 168 26.0%  
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Table 14. Crude and Adjusted Converted Prevalence Ratios for Interest in the HPV Vaccine 
among the NHIS 2010 Sample of Women 18-26 Years (N=1,457) 
Variable %Interest Crude OR
† 
 
 (95% CI) 
††
 
Crude PR
†††
 
(95% CI) 
Adjusted OR 
(95% CI) 
Adjusted PR 
(95% CI) 
Relationship Status      
    Married 23.7% Referent Referent Referent Referent 
    Widowed, Div, Sep 30.9% 1.44(0.78, 2.66) 1.30(0.82, 1.91) 1.36(0.73, 2.54) 1.26(0.78, 1.86) 
    Living with Partner 35.6% 1.78(1.18, 2.69) 1.50(1.13, 1.92) 1.67(1.09, 2.56) 1.44(1.07, 1.87) 
    Never Married 33.4% 1.62(1.19, 2.19) 1.41(1.14, 1.71) 1.62(1.17, 2.24) 1.41(1.12, 1.73) 
Hispanic      
    Yes 38.0% 1.41(1.09, 1.82) 1.25(1.06, 1.46) 1.68(1.24, 2.27) 1.39(1.15, 1.64) 
    No 30.4% Referent Referent Referent Referent 
Race      
    White 30.6% Referent Referent Referent Referent 
    Black 35.4% 1.24(0.95, 1.63) 1.16(0.96, 1.37) 1.23(0.90, 1.69) 1.15(0.93, 1.40) 
    Other 31.6% 1.05(0.73, 1.51) 1.03(0.79, 1.31) 1.19(0.81, 1.74) 1.12(0.86, 1.42) 
Region      
    South 34.6% Referent Referent Referent Referent 
    Northeast 28.7% 0.76(0.57, 1.02) 0.83(0.67, 1.01) 0.75(0.53, 1.05) 0.82(0.64, 1.03) 
    Midwest 25.1% 0.63(0.48, 0.84) 0.73(0.58, 0.89) 0.61(0.45, 0.82) 0.71(0.56, 0.88) 
    West 35.5% 1.04(0.79, 1.37) 1.03(0.85, 1.21) 1.05(0.78, 1.42) 1.03(0.84, 1.24) 
Age      
    18-21 years 31.1% Referent Referent Referent Referent 
     22-26 years 31.6% 1.02(0.80, 1.31) 1.02(0.85, 1.20) 1.02(0.78, 1.35) 1.02(0.84, 1.22) 
Insurance Coverage      
    Yes 31.6% Referent Referent Referent Referent 
    No 31.2% 0.99(0.76, 1.27) 0.99(0.83, 1.17) 0.97(0.74, 1.27) 0.98(0.81, 1.17) 
Poverty Ratio      
    200% + 27.9% Referent Referent Referent Referent 
    100 < 200% 32.8% 1.27(0.96, 1.68) 1.18(0.97, 1.41) 1.26(0.91, 1.73) 1.17(0.94, 1.44) 
    < 100% 35.0% 1.37(1.07, 1.77) 1.24(1.05, 1.46) 1.42(1.06, 1.89) 1.27(1.04, 1.52) 
Abnormal Pap Test      
    Yes 51.8% 2.65(1.91, 3.67) 1.79(1.51, 2.07) 2.53(1.79, 3.57) 1.75(1.46, 2.05) 
    No 28.9% Referent Referent Referent Referent 
Heard of the Vaccine      
    Yes 35.1% 1.81(1.44, 2.28) 1.53(1.31, 1.76) 1.91(1.48, 2.46) 1.58(1.34, 1.84) 
    No 22.9% Referent Referent Referent Referent 
Flu Shot last 12 mo      
    Yes 42.3% 1.70(1.21, 2.40) 1.41(1.14, 1.69) 1.88(1.28, 2.75) 1.49(1.18, 1.8) 
    No 30.0% Referent Referent Referent Referent 
Hepatitis B Vaccine      
    Yes 35.5% 1.57(1.27, 1.94) 1.37(1.18, 1.56) 1.44(1.15, 1.81) 1.30(1.11, 1.49) 
    No 26.0% Referent Referent Referent Referent 
†OR = odds ratio 
†† 95%CI = 95% confidence interval 
†††PR = prevalence ratio 
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Table 15. Sensitivity Analysis for Adjusted Converted Prevalence Ratios for Interest in the HPV 
Vaccine among the NHIS 2010 Sample of Women 18-26 Years (N=1,392) 
Variable %Interest Adjusted PR 
(95% CI) † 
% Change  
Relationship Status    
    Married 23.5% Referent  
    Living with Partner  1.44(1.07, 1.87) 0% 
    Never Married  1.40(1.11, 1.71) 0% 
Hispanic    
    Yes  1.40(1.16, 1.65) 1% 
    No 30.4% Referent  
Race    
    White 30.3% Referent  
    Black  1.20(0.97, 1.45) 4% 
    Other  1.17(0.90, 1.46) 4% 
Region    
    South 34.2% Referent  
    Northeast  0.84(0.65, 1.07) 2% 
    Midwest  0.73(0.59, 0.90) 3% 
    West  1.05(0.85, 1.28) 2% 
Age    
    18-21 years 31.3% Referent  
     22-26 years  1.01(0.83, 1.21) 1% 
Insurance Coverage    
    Yes 31.6% Referent  
    No  0.99(0.80, 1.19) 1% 
Poverty Ratio    
    200% + 27.6% Referent  
    100 < 200%  1.21(0.97, 1.46) 3% 
    < 100%  1.29(1.07, 1.53) 2% 
Abnormal Pap Test    
    Yes  1.74(1.44, 2.05) 1% 
    No 28.9% Referent  
Heard of the Vaccine    
    Yes  1.65(1.38, 1.93) 4% 
    No 22.5% Referent  
Flu Shot last 12 mo    
    Yes  1.36(1.13, 1.58) 9% 
    No 41.4% Referent  
Hepatitis B Vaccine    
    Yes  1.27(1.08, 1.47) 2% 
    No 26.3% Referent  
†Prevalence ratio and 95% confidence interval 
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Phase I Research Question II – Reason for Non-Interest in HPV Vaccine 
 Description of sample. The second sample from the NHIS 2010 dataset comprised 984 
women who provided a reason for non-interest in the HPV vaccine (Table 16). Due to skip 
patterns in the dataset, this sample contained a different subset of women compared to the 
analytic sample one in Table 13. The majority of women were never married (58%), followed by 
married (25%), living with a partner (13%) and widowed, divorced or separated (4%). Most 
women were non-Hispanic, White, from the South, between the ages 22 and 26 years, and had 
insurance coverage. Additionally, most women had not had an abnormal Pap test and had heard 
of the HPV vaccine. Approximately half of participants received the Hepatitis B vaccine and less 
than 10% received the flu shot in the last 12 months. 
 Primary reasons for non-vaccination. The percentage of each primary reason among 
each relationship status category is reported since the percentages are adjusted for survey 
weighting (Tables 17 and Figure 6). Within each relationship status category, the most common 
reason for non-vaccination and non-interest was reported as “does not need vaccine” (40% 
overall). The second most common reason for women who were married (14%); widowed, 
divorced, or separated (18%); and never married (13%) was “doesn’t know enough about 
vaccine,” while women who were living with a partner had “worried about safety of the vaccine” 
(15%). Overall, more than 70% of responses among all relationship status categories were “does 
not need vaccine,” “doesn’t know enough about vaccine,” “worried about vaccine safety,” and 
“doctor didn’t recommend.” Very few participants reported the remaining available factors as 
reasons for non-vaccination. The only exception being that women who were never married were 
more likely to list “not sexually active” compared to other relationship status categories (11%).   
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Table 16. Description of NHIS 2010 Sample of Women 18 to 26 Years who were Not Interested 
in the HPV Vaccine (N=984) 
Variable N Total % Total 
Relationship Status   
    Married 231 24.7% 
    Widowed, Div, Sep 44 4.3% 
    Living with Partner 135 13.2% 
    Never Married 574 57.8% 
Hispanic   
    Yes 231 13.2% 
    No 753 86.8% 
Race   
    White 683 75.3% 
    Black 192 16.1% 
    Other 109 8.6% 
Region   
    South 357 37.5% 
    Northeast 132 14.7% 
    Midwest 244 28.1% 
    West 251 19.8% 
Age   
    18-21 years 317 31.8% 
     22-26 years 667 68.2% 
Insurance Coverage   
    Yes 707 73.1% 
    No 277 26.9% 
Abnormal Pap Test   
    Yes 79 8.0% 
    No 905 92.0% 
Heard of the Vaccine   
    Yes 601 66.4% 
    No 381 33.3% 
Flu Shot last 12 mo   
    Yes 92 9.6% 
    No 892 90.4% 
Hepatitis B Vaccine   
    Yes 498 54.2% 
    No 483 45.8% 
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Table 17. Primary Reason for Non-Interest and Non-Vaccination by Relationship Status among 
NHIS 2010 Women 18 to 26 Years (N=984) 
 Married Widowed, 
Divorced, 
Separated 
Living 
with 
Partner 
Never 
Married 
Total 
Does Not Need Vaccine 47.6% 51.8% 40.9% 34.7% 39.5% 
Doesn’t Know Enough About Vaccine 14.4% 18.4% 8.3% 12.7% 12.8% 
Worried About Safety of the Vaccine 3.9% 10.0% 15.2% 14.9% 12.0% 
Doctor Didn’t Recommend 10.4% <2% 7.8% 6.3% 7.3% 
Not Sexually Active <2% <2% <2% 11.1% 6.8% 
Too Expensive 2.2% 3.8% 2.1% 2.8% 2.6% 
Too Old for Vaccine 2.1% 2.2% 4.8% 3.1% 3.1% 
Don’t Know Where to Get Vaccine <2% 0 <2% <2% <2% 
My Spouse/Family Member is Against It <2% 0 0 <2% <2% 
Already Have HPV 3.3% 3.6% 5.4% 2.2% 2.9% 
Other 13.0% 5.1% 13.2% 9.4% 10.6% 
Don’t Know <2% 3.3% <2% 2.0% <2% 
 
 
 
Figure 6. Percentages of Main Reason for Non-Vaccination by Relationship Status 
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Due to the limited number of responses in many categories, these were combined to 
reflect an “other” reason for non-vaccination and non-interest. Additionally, the widowed, 
divorced, and separated group was removed from the analysis due to low frequencies (N=44). 
The resulting 940 participants’ primary reason for non-vaccination is provided in Table 18. 
Using a Wald chi-square test, an association between relationship status and primary reason for 
non-vaccination was present (χ2 = 63.77, p-value < 0.0001). Women who were married were 
more likely than other relationship status categories to believe that they did not need the vaccine, 
while women living with a partner were more concerned about the safety of the vaccine. In 
contrast, never married women were the most likely to report an “other” reason for non-
vaccination, which may be attributed to the large percentage indicating not being sexually active.  
 
Table 18. Primary Reason (condensed) Non-Interest and Non-Vaccination by Relationship 
Status among NHIS 2010 Women 18 to 26 Years (N=940) 
 Married Living with 
Partner 
Never 
Married 
Total 
Does Not Need Vaccine 47.6% 40.9% 34.7% 38.9% 
Doesn’t Know Enough About Vaccine 14.4% 8.3% 12.7% 12.5% 
Worried About Safety of the Vaccine 3.9% 15.2% 14.9% 12.1% 
Doctor Didn’t Recommend 10.4% 7.8% 6.3% 7.6% 
Other 23.6% 27.9% 31.6% 28.9% 
 
 This research study involved two phases, a quantitative and qualitative phase. To assist in 
the comparison of the quantitative results in this phase to the interview results in Phase II, the 
two relationship status categories Married and Living with a Partner were combined in order to 
compare these to the Never Married group (Table 19). Similar sampling stratifications were used 
in Phase II. Using a Wald chi-square test, an association between relationship status and primary 
reason for non-vaccination was present (χ2 = 25.57, p-value < 0.0001). More women in the 
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relationship groups believed they did not need the vaccine compared to the never married group. 
In contrast, more women in the relationship status group did not receive a doctor 
recommendation for the vaccine compared to the never married group.  More women in the 
never married group cited safety concerns as a reason for non-interest in the HPV vaccine.  
 
Table 19. Primary Reason (condensed) Non-Interest and Non-Vaccination by Combined 
Relationship Status among NHIS 2010 Women 18 to 26 Years (N=940) 
 Married or 
Living with 
Partner 
Never 
Married 
Total 
Does Not Need Vaccine 45.3% 34.7% 38.9% 
Doesn’t Know Enough About Vaccine 12.3% 12.7% 12.5% 
Worried About Safety of the Vaccine 7.9% 14.9% 12.1% 
Doctor Didn’t Recommend 9.5% 6.3% 7.6% 
Other 25.1% 31.6% 28.9% 
 
 
Phase II: Qualitative Analysis 
 Descriptive characteristics of the eligible sample and interviewed sample are reviewed. 
Additionally, key themes from the in-depth interviews by IMB construct are described.  
 
Descriptive Characteristics of Sample 
 Description of eligible sample. A total of 352 women completed the eligibility 
questionnaire, informed consent, and provided contact information for the in-depth interviews. 
The majority of women who were eligible for the study did not receive the HPV vaccine (85%) 
(Table 20). Approximately a third of the sample were either single or in a long term 
monogamous relationship, respectively. The smallest category was women who were married or 
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living with a partner (13%). The average age of respondents was 21 years (range 18-26). 
Regarding race and ethnicity, 19% were Hispanic, 9% were international students, and 52% were 
White. The majority of women self-identified as heterosexual (87%). The primary mode of 
insurance was through private insurance (63%), while 9% reported being uninsured. Most 
women had heard of the HPV vaccine from a healthcare provider (68%) and the average 
knowledge scale score was 15.3 out of a possible 23 (higher score indicating higher knowledge). 
 Description of interview sample. The final interview sample comprised 50 women from 
the eligible 352. The relationship status and vaccination status frequencies reflect the quota 
sampling technique employed for conducting interviews. All groups had 6 participants, with the 
exception of women in the long term monogamous relationship categories, each of which had 7 
participants. Descriptive characteristics were relatively similar when comparing the eligible 
sample to the interview sample (Table 20).  
Moreover, characteristics were similar across the eight quota categories (Table 21). The 
knowledge scale score was the highest for women who were vaccinated and married or living 
with a partner, and lowest for women who were unvaccinated and single and dating (this is 
attributed to one participant listing unsure for every knowledge item resulting in a zero score). 
This study’s sampling design was stratified by relationship status: married/living with a 
partner; long-term monogamous relationship; single and dating; and single. Women were asked 
to self-identify their relationship status on the eligibility questionnaire and then described their 
relationship status in more detail during the interview. Women who were unvaccinated described 
their relationship at the present time and women who were vaccinated were asked to recall their 
relationship at the time of vaccination. Descriptions of these relationship status groups are 
presented in Table 22. 
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Table 20. Descriptive Demographic Characteristics of Eligible Sample and Interviewed Sample 
 Eligible Sample (N=352) Interview Sample (N=50) 
HPV Vaccination 
   Never 
   Last 6 months 
 
299 (84.9%) 
53 (15.1%) 
 
25 (50.0%) 
25 (50.0%) 
Relationship Status 
   Married or Living with Partner 
   Long Term Monogamous 
   Single and Dating 
   Single 
 
46 (13.1%) 
116 (33.0%) 
79 (22.4%) 
111 (31.5%) 
 
12 (24.0%) 
14 (28.0%) 
12 (24.0%) 
12 (24.0%) 
Age  21.1 (2.0) years 21.3 (2.1) years 
Hispanic 68 (19.3%) 12 (24.0%) 
International Student 32 (9.1%) 2 (4.0%) 
Race 
   American Indian/Alaskan Native 
   Asian 
   Native Hawaiian/Pacific Islander 
   Black 
   White 
   Other 
   Multiracial 
 
3 (0.9%) 
50 (14.2%) 
1 (0.3%) 
67 (19.0%) 
188 (53.4%) 
23 (6.5%) 
20 (5.7%) 
 
1 (2.0%) 
8 (16.0%) 
0 (0%) 
8 (16.0%) 
24 (48.0%) 
4 (8.0%) 
5 (10.0%) 
Sexual Orientation 
   Bisexual 
   Homosexual 
   Heterosexual 
   Unsure 
   Other 
 
23 (6.5%) 
12 (3.4%) 
305 (86.7%) 
7 (2.0%) 
5 (1.4%) 
 
4 (8.0%) 
0 (0%) 
45 (90.0%) 
1 (2.0%) 
0 (0%) 
Insurance Status 
   Private 
   School 
   Medicaid 
   Other 
   Uninsured 
   Not Sure 
 
220 (62.5%) 
23 (6.5%) 
24 (6.8%) 
44 (12.5%) 
32 (9.1%) 
9 (2.6%) 
 
29 (58.0%) 
4 (8.0%) 
8 (16.0%) 
3 (6.0%) 
6 (12.0%) 
0 (0%) 
Knowledge Scale Score 15.3 (4.1) 15.3 (3.9) 
Heard of HPV From…. 
   Healthcare Provider 
   Family 
   Partner 
   Friends 
   Radio 
   TV 
   Internet 
   Other 
   Never 
 
238 (67.6%) 
112 (31.8%) 
9 (2.6%) 
128 (36.4%) 
25 (7.1%) 
147 (41.8%) 
109 (31.0%) 
34 (9.7%) 
29 (8.2%) 
 
38 (76.0%) 
17 (34.0%) 
2 (4.0%) 
21 (42.0%) 
5 (10.0%) 
17 (34.0%) 
18 (36.0%) 
3 (6.0%) 
0 (0%) 
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Table 21. Descriptive Demographic Characteristics of Interviewed Sample by Stratifications 
(N=50) 
Vaccination Status Unvaccinated Vaccinated 
Relationship Status M/LP LTM SD S M/LP LTM SD S 
N 6 7 6 6 6 7 6 6 
Age  22.8 
(1.5) 
21.9 
(2.7) 
21.3 
(2.4) 
21.5 
(1.9) 
22.0 
(1.1) 
20.1 
(2.0) 
19.5 
(1.6) 
21.5 
(1.9) 
Hispanic 1 2 2 1 1 3 1 1 
International Student 0 0 0 1 1 0 0 0 
Race 
   American Indian/Alask. Native 
   Asian 
   Native Hawaiian/Pacific Island. 
   Black 
   White 
   Other 
   Multiracial 
 
0 
0 
0 
0 
5 
0 
1 
 
0 
2 
0 
0 
3 
2 
0 
 
0 
1 
0 
1 
3 
1 
0 
 
0 
2 
0 
2 
1 
1 
0 
 
1 
1 
0 
0 
4 
0 
0 
 
0 
0 
0 
3 
3 
0 
1 
 
0 
0 
0 
1 
3 
0 
2 
 
0 
2 
0 
1 
2 
0 
1 
Sexual Orientation 
   Bisexual 
   Homosexual 
   Heterosexual 
   Unsure 
   Other 
 
1 
0 
5 
0 
0 
 
1 
0 
6 
0 
0 
 
0 
0 
6 
0 
0 
 
0 
0 
6 
0 
0 
 
0 
0 
6 
0 
0 
 
1 
0 
5 
1 
0 
 
1 
0 
5 
0 
0 
 
0 
0 
6 
0 
0 
Insurance Status 
   Private 
   School 
   Medicaid 
   Other 
   Uninsured 
   Not Sure 
 
3 
1 
0 
0 
2 
0 
 
5 
1 
0 
1 
0 
0 
 
4 
1 
0 
0 
1 
0 
 
2 
0 
3 
0 
1 
0 
 
5 
1 
0 
0 
0 
0 
 
3 
0 
3 
0 
1 
0 
 
2 
0 
1 
2 
1 
0 
 
5 
0 
1 
0 
0 
0 
Knowledge Scale Score 15.0 
(3.8) 
15.3 
(3.9) 
13.5 
(7.0) 
14.0 
(3.2) 
18.2 
(2.8) 
15.6 
(3.4) 
16.0 
(2.5) 
14.5 
(4.0) 
Heard of HPV From…. 
   Healthcare Provider 
   Family 
   Partner 
   Friends 
   Radio 
   TV 
   Internet 
   Other 
 
3 
2 
0 
1 
1 
5 
2 
1 
 
5 
3 
0 
5 
1 
3 
3 
0 
 
6 
3 
0 
4 
1 
2 
3 
0 
 
3 
1 
0 
2 
1 
2 
2 
0 
 
6 
2 
2 
1 
0 
0 
1 
0 
 
6 
3 
0 
3 
0 
2 
1 
1 
 
3 
1 
0 
3 
0 
2 
3 
1 
 
6 
2 
0 
2 
1 
1 
3 
0 
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Table 22. Description of Relationship Status by Sampling Group 
Vaccination Relationship Description 
Unvaccinated Married/Living 
with Partner 
All women mutually monogamous with current partner. 
All women stated they saw a future with this partner. 
One married, the rest living with a partner. 
Length of relationship range 1 year – 7 years 
Long-Term 
Monogamous 
Five women mutually monogamous with current partner and 
two women not sexually active with current partner. 
All women stated they saw a future with this partner. 
Length of relationship range 1 year – 6 years 
Single and 
Dating  
Four women mutually monogamous with current partner; 
length of relationship range 2 months – less than a year. 
Two women dating; one was not sexually active at the time and 
the other was sexually active with her partner. 
Single All women were not sexually active or in any type of 
partnership at the time of interview.  
Vaccinated Married/Living 
with Partner 
All women mutually monogamous with partner at the time of 
vaccination. 
All women stated they saw a future with this partner. 
One married, the rest living with a partner at the time of 
vaccination. One woman was no longer living with her partner, 
but they were still in a relationship at the time of interview. 
Length of relationship range 2 years – 4 years. 
Long-Term 
Monogamous 
Six women were mutually monogamous with partner at the 
time of vaccination; one woman was not sexually active at the 
time. 
All women stated they saw a future with this partner at the 
time; one of the women is no longer in that relationship.  
Length of relationship range 5 months – 3 years. 
Single and 
Dating 
All but one woman had been sexually active at the time of the 
vaccination or prior to vaccination.  
Two women described their relationships as “on-and-off 
again.” 
Two women said they were currently sexually active and 
monogamous in the partnership. 
Single Only one woman was never sexually active.  
The remaining five women were currently single, but had 
sexual partners in the past or currently (not monogamous). 
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IMB Model Factors Influencing HPV Vaccination 
Information – HPV and HPV vaccine. Women’s knowledge about HPV and the HPV 
vaccine were assessed through two modalities, the closed-ended survey and the open-ended 
interview. The percent correct for each knowledge survey question was compared to findings 
from the qualitative interviews (Table 23).  
Overall, there were no major differences in knowledge about HPV or the vaccine by 
vaccination status or relationship status. When asked generally about HPV in the interviews, 
some women stated that it is the human papillomavirus and described differences in HPV 
presentation/transmission between sexes. However, the majority of women needed to be probed 
on the topic. In the survey, the majority of women correctly knew that there were many types of 
HPV (78%), men and women would get HPV (96% and 78%), and you can have HPV without 
knowing it for you and your partner (96%). Less than half of the sample knew that HPV was not 
a bacterial infection, while over 90% reported that HPV is a virus.  
With regard to the curability of HPV, most women in the interview reported that people 
have HPV for life and that it cannot go away (N=20). However, the majority of these statements 
included the context of uncertainty by qualifying the statement with “I don’t know” or “I’m 
unsure.” This limited knowledge on the curability of HPV in the interviews agrees with the lower 
frequencies of similar questions correct on the knowledge scale. This was especially true for only 
12% getting the statement correct for “Most HPV infections clear up within a short time.” 
The survey only focused on two prevention methods for HPV: condoms (78%) and the 
vaccine (98%). The majority of participants answered these questions correctly. Similar answers 
were reported in the interviews; however, additional prevention methods were cited, including 
abstinence and sex with known partners. 
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Table 23. Comparison of Quantitative and Qualitative Assessment of Knowledge about HPV 
 
Quantitative Knowledge Survey (% correct) Themes from Qualitative Knowledge 
Interview 
G
en
er
al
 I
n
fo
 
There are many types of HPV (78%) 
Only men can get HPV (96%)*  
You can have HPV without knowing it (96%) 
You can always tell when someone else has 
HPV (96%) 
HPV is a virus (92%) 
Only women can get HPV (78%)* 
HPV is a bacterial infection (44%)* 
 
HPV stands for human papillomavirus  
Awareness that females and males could 
get HPV, but uncertainty regarding if males 
are affected or just carriers 
Limited knowledge regarding types of 
HPV  
 
C
u
re
 
Antibiotics can cure HPV (58%)* 
HPV can be cured (40%)* 
Most HPV infections clear up within a short 
time (12%) 
 
Most women stated you have HPV for life 
or that it does not go away (N=20); others 
were uncertain 
Uncertainty regarding curability of HPV 
P
re
v
en
t 
Using a condom decreases the chance of HPV 
transmission (78%) 
There is a vaccine for women that prevents 
certain types of HPV (98%) 
 
Women reported varies prevention 
modalities: vaccine (N=21), condoms or 
barrier methods (N=18), abstinence (N=8), 
sex with known partners (N=2) 
T
ra
n
sm
is
si
o
n
 
HPV is spread on toilet seats (56%)* 
Transmission of HPV can occur through sexual 
contact with another person (88%) 
HPV is a sexually transmitted infection (68%) 
HPV can be passed to a newborn at birth (52%) 
Even if you do not see a wart, you can transmit 
HPV (76%) 
 
Most women knew that HPV was sexually 
transmitted (N=38); however there was 
uncertainty regarding exact routes of 
transmission (e.g., skin to skin, oral, 
vaginal-penile, bodily fluids, kissing) 
 
O
u
tc
o
m
es
 
Some types of HPV cause cervical cancer 
(94%) 
HPV can cause HIV/AIDS (56%)* 
HPV can cause abnormal Pap smears in women 
(74%) 
HPV can cause herpes (30%)* 
HPV can cause genital warts (60%) 
HPV can affect a woman’s ability to get 
pregnant (6%)* 
The most frequently reported outcome 
associated with HPV was cervical cancer 
(N=24) 
Other outcomes included: genital warts 
(N=13), cancer unspecified (N=5), 
reproductive cancers (N=2), vaginal cancer 
(N=1), uterine cancer (N=1), ovarian 
cancer (N=4), penile cancer (N=1), rectal 
cancer (N=1), anal cancer (N=2), 
orolaryngeal cancer (N=1), infertility 
(N=2) 
 
*False statement; % reflects the proportion of participants who were correct 
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Most women in the interview knew that HPV was transmitted sexually (N=38); however, 
some were uncertain when stating this. Similarly 68% and 88%, respectively, of the interviewed 
sample correctly reported on the knowledge scale that “HPV is a sexually transmitted infection” 
and that “transmission of HPV can occur through sexual contact with another person.” 
Moreover, while women knew the sexually transmitted nature of the virus, they were unsure of 
specific routes, such as penile-vaginal sex, oral sex, or skin to skin contact.  
 Women were more likely to know that HPV causes cervical cancer in both the survey and 
interview. Fewer women were aware that HPV could cause genital warts, abnormal pap smears, 
and other types of cancers (e.g., anal, vaginal, oral). Additionally, women often conflated genital 
warts with herpes in their description of the outcomes related to HPV. Of particular concern is 
that approximately half of the participants believed that HPV causes HIV/AIDS and the majority 
of women believe HPV affects fertility. 
 During the interview, women were asked to share everything that they knew about the 
HPV vaccine. There was confusion as to whether males could also receive the HPV vaccine. Yet 
more than half of the women were aware that both sexes could receive the HPV vaccine (N=28). 
Moreover, there were a variety of age ranges reported for when people should receive the HPV 
vaccine. For the most part, the ranges were between teens and twenties; however, some women 
reported that people should get the vaccine after becoming sexually active (N=7). Some of the 
participants mentioned that there are side effects associated with the HPV vaccine; however, this 
was usually a nebulous statement. Only four women, who had received the HPV vaccine, were 
able to accurately describe what these side effects entailed (e.g., pain, fainting). 
Information – Trusted and preferred sources. The majority of women in the interview 
sample reported they had heard of HPV from a healthcare provider (76%). During the interview, 
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the interviewer listed the information sources each woman had marked on the survey and then 
asked her to describe which source she trusted the most. The majority of women said that they 
trusted a healthcare provider the most as the source for HPV information (N=31 out of 38 who 
listed it). This was attributed to them knowing the individual’s medical history, having training 
in the field, and having their best interests in mind.   
 
“I feel like I trusted them a lot. They reassured me about the vaccine, told me not 
a lot about it. But I mean enough that I felt safe enough to take it. And they gave 
me a packet explaining what it was. I didn't actually read a lot of it. In all of my 
honesty, but yeah.” (P9, Vaccinated, Long-term Monogamous).   
 
“Because they are medical professionals and you know they take the oath so I 
assume that they have my best interests at heart.” (P10, Unvaccinated, 
Married/Living with Partner) 
 
“Because, um, they're like, my doctor, and I feel like they would be like – I guess, 
more objective view, versus like, your friends and stuff.  Um, I don't know, 'cause 
they're a doctor, I guess.  They're paid to know what they're talking about.” (P36, 
Vaccinated, Single) 
 
“Normally they [doctors] are very informative and they had more experience 
dealing with certain fields than I have so I would trust them to give me the right 
advice when it comes to certain things like vaccines, what you should have done, 
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um the types of care that would be best for you, stuff like that. I know this isn't 
always going to be the case but you just you kind of have to have faith in your 
doctor and hope that they will.” (P45, Vaccinated, Married/Living with Partner) 
 
Other trusted sources of information included: parents, friends, or Internet. Women were 
asked where they would prefer to receive additional information about the HPV vaccine during 
the interview. The two primary modes of information were a healthcare provider or the Internet. 
When the Internet was mentioned, women said they would prefer reputable sources, such as 
WebMD or scientific reports. 
Motivation – Attitudes about vaccines in general. Similar to the information theme, 
there were no major group differences in attitudes about vaccines generally. Most women had 
favorable opinions about vaccines (N=44) stating that they were valuable for personal and 
population health since these could prevent diseases.  
  
“I think – well, because they protect a lot of people from, you know, it’s kind of 
like a tier one preventative measure that can be taken so that like widespread, you 
know, diseases and stuff or to prevent the disease from becoming really 
widespread.” (P8, Unvaccinated, Single and Dating) 
 
A few women even mentioned the benefit of herd immunity, and the importance of 
getting vaccinated since certain groups cannot get vaccinated (N=4).  
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And, I think vaccines are important because you're not just protecting, like, 
yourself; you're protecting others who may not necessarily be able to get the 
vaccine, or people who have like, weaker immune systems and are more 
susceptible to it.” (P36, Vaccinated, Single) 
 
“I think there's more benefits than risk and I'm a strong advocate of herd 
immunity as well for those who can't get vaccinated. And a lot of people think that 
because certain diseases aren’t prevalent in America anymore they are still 
prevalent in other countries and because of all the international travel there is it's 
important that everyone remains - continues to get vaccinated.” (P50, 
Vaccinated, Married/Living with Partner) 
 
However, there were women across all subgroups who were more weary of vaccines 
(N=10). Reasons for concern included: too many vaccines, needing different dosing schedules, 
favored natural medicine, unsure of efficacy, distrust in the FDA and clinical trials, wanting to be 
aware of what is in the body, wanting to be more informed, fear of bad reactions, and that their 
attitude depends on the vaccine.  
 
“I'm not a proponent.  Um, I never get a flu shot.  I don’t really believe in 
vaccines.  I think it just puts a lot of unnecessary stuff in your body and, you 
know, with the flu shot they only – like they pick the seven most common strains 
they're predicting for that year and give it to you, so you could still end up with 
the flu. I think it's not a guaranteed thing.  So I wouldn't say that I'm pro-vaccine. 
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Um, I mean I think – I mean I'm not one of those people that believes that like 
vaccines cause autism.  I think we should all get vaccinated for chicken pox and 
measles and what-have-you, but I don’t really believe in taking anything 
additionally.” (P15, Vaccinated, Married/Living with Partner) 
 
One emergent theme during the discussion of vaccines was the polarization of this topic. 
A few women reported being “pro-vaccine” when asked how they feel about vaccines in general 
(N=3). Women then elaborated on the anti-vaccine movement resulting in people not vaccinating 
their children, which has invaded the culture in the United States. General attitudes about the 
anti-vaccine movement were that it was not evidence-based, it was causing more harm than 
good, and influenced by celebrity figures. 
Motivation – Attitudes about HPV vaccine. Women were then asked to describe their 
attitudes specifically about the HPV vaccine. There were significant group differences, with the 
unvaccinated groups having more mixed feelings about the HPV vaccine and the vaccinated 
group having more favorable attitudes about the HPV vaccine.  
Most unvaccinated women had favorable opinions about the HPV vaccine (N=13), which 
was attributed to disease prevention. A couple even questioned why they had not received the 
vaccine yet given the positive attributes (N=2). However, negative attitudes about the HPV 
vaccine were apparent, including: negative side effects (N=3), unsure of the intended audience 
(e.g., sexually active only) (N=2), newness (N=2), is for people more at risk of HPV (e.g., more 
sexual partners) (N=2), and promotes sexual activity (N=1). Others were generally unware about 
the HPV vaccine (N=6). In contrast, vaccinated women had more favorable opinions (N=23), 
similar to the unvaccinated women citing that it was important due to its potential for disease 
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prevention. A few women even stated that they believed everyone should get the HPV vaccine 
(N=3). 
Overall there was a sentiment that the HPV vaccine was a different type of vaccine 
compared to required (e.g., MMR) or optional vaccines (e.g., flu) currently available. As one 
participant summarized, 
 
Interviewer: “Do you see the HPV vaccine as being an important vaccine?” 
Interviewee: “Um, yeah.  I would see that as more important than, like, a flu 
shot.” 
Interviewer: “Okay, but maybe how about compared to the vaccines that are 
required?” 
Interviewee: “Hmm.  Um, probably not as important.”(P13, Unvaccinated, Long-
term Monogamous) 
 
In contrast, some participants echoed this concept of the HPV vaccine being in its own 
class of vaccines. Women had a difficult time placing it as either a required or optional 
vaccine for the public. 
 
Interviewer: “In terms of comparing it to other vaccines, do you think it should be 
a required vaccine, or is it something that's more optional?” 
Interviewee: “I think it's definitely more optional.  Um, I'm not sure if it should be 
required 'cause I feel like everybody should have that type of choice. But I know 
the HPV vaccine when they were like trying to give it to younger girls, there was 
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like an issue about like basically, ‘Is that promoting younger girls to have sex?’ 
which it's not.  It's just preventing if I ever do decide to have sex, you know, that 
they'll have that protection.  Um, but, yeah, I think it should be optional, and I 
think, you know, people should decide like the steps or the choices you should 
make on that.” (P25, Vaccinated, Long-term Monogamous) 
 
Despite the differences in attitudes about the HPV vaccine between vaccinated and 
unvaccinated women, there were generally four key messages about the good things about the 
HPV vaccine across all groups. These themes included: (1) prevents diseases (e.g., HPV, genital 
warts, cervical cancer, cancer) (N=43); (2) keeps you safe and protected (N=8); (3) reduces 
spread of HPV and/or protects partners (N=8); and (4) not having to worry about HPV or some 
of its outcomes (N=7).  
 
“Good things, um, well one thing, even if you are not sure about your partner you 
know that even if that person he or she has something, if you got HPV vaccinated, 
you will be safe. You will not have to worry about it. And most importantly it can 
lead to cervical cancer and I think you are protected against that.” (P5, 
Unvaccinated, Single) 
 
“It will make me safer in the future ‘cause I won’t, you know, spread – if I don’t 
already have it, HPV, which I don’t, then if I, you know, I have intercourse with 
more people then I won’t spread it to them if I am protected against it.” (P35, 
Unvaccinated, Single and Dating) 
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Similarly there were no major differences in bad attributes of the HPV vaccine. These 
included (1) side effects (N=20); (2) the fact that it was a shot or a vaccine (N=8); and (3) the 
cost (N=5). There were a quarter of participants who could not list any negative attributes about 
the vaccine—seven vaccinated and six unvaccinated. Cost was mentioned in the context of it is 
an expensive vaccine for women who do not have insurance, but not necessarily a personal 
barrier.  
 
“…maybe cost? For some people. I'm not sure. Uh, I mean I don't know if HPV 
[vaccine] is covered under all people's insurance or sometimes if the vaccine is 
not required, it's not necessarily covered for people.” (P1, Unvaccinated, 
Married/Living with Partner) 
 
Additionally, women had fear of shots or needles, which translated in the vaccine being less 
favorable due to the administration method.  
 
“For me, I just don't like shots, so for me it'd be like having to go get a shot that 
would probably the worst to me.” (P21, Unvaccinated, Single and Dating) 
 
Side effects were again cited as a bad feature of the vaccine; however, participants continued to 
have difficulties describing these side effects. Six vaccinated women and three unvaccinated 
were able to describe the side effects, which were primarily pain, nausea, and rash. One woman 
described weighing the costs and benefits, essentially her risk for HPV against the potential side 
effects. 
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“So I think the bad thing would be if there was any side effects, whatever that 
would come along with. You know, if it goes cause like some sort of – maybe like 
some discomfort, like uncomfortable sex or something like that.  And if I’m not 
sexually active or if my partner later on is not – doesn’t have HPV, then why 
would I get the vaccine if I know I’m not gonna get it?” (P6, Unvaccinated, 
Single) 
 
Motivation – Social influences. Women were asked who in their life influenced their 
decision for vaccination or non-vaccination. For unvaccinated women, these influential agents 
impacted their decision not to get the vaccine or would be influential if they decided to get the 
vaccine. All were probed for key groups identified in the literature, which include healthcare 
providers, parents, peers, and partners. Again, there were no major differences observed by 
sampling group. More than half of participants reported that their healthcare provider’s 
recommendation influenced or would influence (for unvaccinated women) their decision to get 
the HPV vaccine (N=33). This was attributed to providers being familiar with their health 
history, being able to explain their risk for HPV, and reassuring the participant that it was a good 
vaccine to get.  
 
“Like my doctor probably. But only 'cause she's pretty like trustworthy.  I feel 
like, um, if she is really, um – uh, what's the word I'm looking for – like 
sympathetic. Like I don't feel like she's like the kind of – like not try to get this 
over, and over and get in, get out, "Tell me what your complaints are."  So if she 
recommended something, I would feel like it was because she's trying to do 
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something good rather than just like trying to make money.” (P23, Unvaccinated, 
Long-term Monogamous) 
 
“It made me worry a little less, so I, like I said, I trust my doctor.  He’s been my 
doctor since – you know, my pediatrician since birth.  So, he wouldn’t do 
anything – he wouldn’t make me do anything stupid.” (P27, Vaccinated, Single 
and Dating) 
 
The second key agent to HPV vaccine decision-making was a parental figure, specifically the 
mother (N=23). Some mothers’ negative opinions about the HPV vaccine or medicine in general 
influenced women’s decisions about the vaccine. However, mothers were seen as important 
because they ensured health and healthcare throughout childhood.  
 
“Um, well, 'cause she's always been very like adamant about like making sure 
that my health needs are provided for, and making sure that, um, I have the 
proper vaccinations…”(P23, Unvaccinated, Long-term Monogamous) 
 
Additionally, some women reported that mothers’ personal experiences with HPV or cervical 
cancer were also influential (N=2). Other family members were mentioned as being important 
figures, but not as frequently as mothers. These were fathers, sisters, and grandparents. 
Less influential figures were peers and partners. Friends were seen as important figures in 
the HPV vaccine decision-making process when they could share their experience with the 
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vaccine (N=18). These narratives of getting the vaccine reassured women that the vaccine was 
safe and a good option for them.  
 
“Um, I guess friends, too, like a couple other friends have had it, like I haven't, 
like, gone into detailed conversations with them about it, but just seeing, like, like 
the majority of my friends, like, have it or get it done, I guess that would persuade 
me more to get it, like I feel like, "Okay," like, "This is safe.  If this person did it, 
then I'll be fine."” (P11, Unvaccinated, Single and Dating) 
  
Across all relationship status groups, partners were rarely mentioned as influential for 
getting the HPV vaccine (N=11). Women reported they discussed the vaccine with their partner 
and that it was dismissed or the partner had no opinion. This was illustrated by this participant’s 
description of her boyfriend,  
 
“Him [boyfriend] personally, he didn't really have an opinion on it [HPV 
vaccine] which was weird because I wanted to talk to him, I wanted to get his 
opinion. He's not really opinionated on stuff like that so, he didn't really give me 
it.” (P48, Vaccinated, Married/Living with Partner) 
 
Others mentioned they thought their partner should look into the vaccine too. However, only a 
few of these comments reported that the partner had a major influence on the individual’s 
decision-making. 
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One emergent theme during this interview process was the idea that HPV vaccine 
decision-making was a personal decision, rather than dependent upon others. Approximately a 
quarter of the women reported that getting the HPV vaccine was a personal decision (N=12).  
However, most of these women also mentioned influential others described above. Therefore, for 
this group of women while others in the social environment may influence HPV vaccine 
decision-making, the ultimate decision rested with the individual to decide if the vaccine is right 
for her. 
Motivation – Reasons for (non-)vaccination. To gain context to the HPV vaccine 
decision-making process, participants were asked the primary reason they did not receive the 
HPV vaccine when they were an adolescent. Three primary reasons emerged across all sampling 
groups. The first was that the vaccine was never brought up by a healthcare provider or any other 
agent (N=21). In other words, the participant never heard of the HPV vaccine during 
adolescence. The second reason for non-vaccination was a maternal figure deciding that the 
adolescent female did not need the HPV vaccine (N=14). This is similar to the comment from the 
social motivation that mothers were the primary caretakers for health-related needs during 
childhood and adolescence. Mothers did not want the female adolescent to get the vaccine out of 
fear of increased sexual activity, the newness of the vaccine, the side effects, or not seeing their 
daughter at risk.  
 
“My mom said it wasn't important, and this was in high school, because my 
doctor offered it to me, and I was 16 – I think I was 16 or 17, and my mom was 
just like, "Oh, you don't need that," and especially since, I mean, I don't know why 
she said that.  Probably because I wasn't having sex then, but that's really why I 
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never got the vaccine, and I wasn't offered it again, you know, like out of sight, 
out of mind.” (P12, Unvaccinated, Long-term Monogamous) 
 
Finally, many women mentioned that they did not receive the HPV vaccine as an adolescent 
because they were not sexually active at the time (N=11). This corroborates the misperception 
that the HPV vaccine is only for persons who have initiated sexual activity and at higher risk of 
HPV. As one participant stated, “I wasn’t having sex so I didn’t see a need for it.” (P49, 
Vaccinated, Long-term Monogamous). It was not only the individual participant who believed 
that they did not need the vaccine due to sexual inactivity, but it was also perceived that parents 
and healthcare providers agreed with this belief. 
While there was consistency across groups regarding the reasoning for not getting a 
vaccine at a younger age, there was more variability for HPV vaccine decisions in young 
adulthood. Unvaccinated women in relationships (long-term monogamous or married/living with 
a partner) described four primary reasons: (1) monogamy or perceived low risk (N=5); (2) not 
offered or recommended by a healthcare provider (N=4); (3) time and/or money (N=2); and (4) 
use of other preventive measures (e.g., Pap test) or belief in natural medicine (N=2). 
Unvaccinated women who were single and dating were more unsure of the reasons why they 
have not received the HPV vaccine as a young adult (N=3). Women who were unvaccinated and 
single only also stated two primary reasons for non-vaccination. The first was a lack of 
awareness about the vaccine (N=2), and the second was they perceived themselves not at risk for 
HPV due to sexual inactivity (N=3). Cost was also a reason for two participants in the single and 
dating, and single groups. Overall in the unvaccinated groups, it was clear that lack of awareness 
117 
of the HPV vaccine served as a primary obstacle to vaccination, as well as perceptions of low 
risk of HPV. 
 In contrast, there were many more factors that contributed to the decision-making process 
among women in the vaccinated groups. Women who were vaccinated and in relationships had a 
variety of cues that influenced their decision to get the vaccine. These included a family history 
of cancer (N=3), a history of HPV or an abnormal Pap (N=2), becoming sexually activity (N=2), 
needed follow-up shots (N=2), getting insurance (N=1), vaccine was free until age 19 (N=1), 
living with a partner (N=1), became aware of the vaccine recently (N=1), belief that the vaccine 
was required for college (N=1) and parents recommending (N=1). Women who were vaccinated 
and single and dating or single only stated that they received the vaccine now because a 
doctor/friend/mother recommended the vaccine (N=7), they just became aware of the vaccine 
and wanted the added protection (N=2), belief it was required for school (N=2) or it was 
convenient (N=1). While doctor recommendation was a factor for women not in relationships, it 
was not listed as a reason for women in relationships.  
Motivation – Relationship status and HPV vaccine decision-making.  Participants 
were asked how they thought their relationship status impacted their decision to get the HPV 
vaccine. The summaries are presented by relationship status category in Table 24. Note that 
women in married/living with a partner and long-term monogamous categories were 
consolidated into one group due to similar findings. It was the original intention to consolidate 
single and dating and single only into one category as well; however, these groups had distinct 
responses that are presented individually. 
There was variability observed for how relationship status impacted HPV vaccine 
decision-making. Unvaccinated women who were either in a relationship or single only stated 
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that their current relationship status was reasoning for not getting the vaccine now, this was 
attributed to monogamy or number of partners and sexual inactivity. Women in both of these 
groups said they would be more likely to get the vaccine if their relationship were to change. In 
contrast, women who were single and dating reported that their relationship status did not impact 
their decision not to get the HPV vaccine. If their relationship changed to a long-term 
relationship, they reported they would be less inclined to get vaccinated. Across all groups of 
vaccinated women, relationship status was less influential on their decision to get the vaccine; 
rather the women reported wanting the security of protection. 
Motivation – Risk perceptions – Perceived susceptibility. Participants’ perceived 
susceptibility to HPV was evaluated by asking what they thought their risk of HPV was with and 
without the vaccine. The summaries are presented by relationship status category in Table 25.  
Risk perceptions for HPV differed primarily across relationship statuses, rather than 
vaccination status. This is likely attributed to the questioning of the perceptions of risk qualified 
by with or without the vaccine. Women in relationships stated that their perceived risk of HPV 
was low, which was attributed to monogamy and number of sexual partners. These women said 
their risk would minimally decline with the vaccine. The perception of risk was more variable for 
single and dating women, who attributed their risk to similar factors, but also unprotected sex, 
annual exams, distance to partner, and sexual activity. All women in these groups said their risk 
would decrease with the vaccine. Finally, women who were single said that their risk for HPV 
was low and that their risk would decline or remain the same with the vaccine. A larger 
proportion of unvaccinated women who were single were sexually inactive compared to women 
who were vaccinated.  
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Table 24. Comparison of Relationship Status’ Impact on HPV Vaccine Decision-Making by 
Sampling Group 
 Unvaccinated Vaccinated 
In a 
Relationship 
 
(Includes 
Married/Living 
with Partner 
and Long-term 
Monogamous) 
Because they were in monogamous 
relationship and/or had few partners 
they did not need the HPV vaccine. 
 
“Because, I know that it is a sexually 
transmitted infection and I believe 
that if I'm in a monogamous 
relationship that the likelihood that I 
get it is less than. I know that people 
aren't perfect, things happen. But I 
genuinely believe that we are going 
to be mutually exclusive, long-term.” 
(P10) 
 
If relationship status changed, they 
would consider getting the vaccine 
because they need protection from 
the uncertain risk. 
 
“So if he had had more sexual 
partners or if I was interested in 
having more sexual partners, I 
would definitely go out and get the 
vaccine just because I don't know 
where like his partners would have 
been coming from, or wouldn't have 
known where my future partners are 
coming from.” (P23) 
Some women (N=5) said they 
wanted the vaccine for the protection 
in their relationship at that time. 
 
“Yes, it’s – it’s really wanting 
protection as well, just not myself 
but also him, I didn’t want him to 
accidently get it from me if I 
somehow got it.” (P41) 
 
The majority of women (N=8) said 
that it was a personal decision only 
to get the vaccine and their 
relationship had no influence. 
 
“…it was more for my own personal 
health.” (P9) 
 
If relationship status changed to 
single, it would be even more 
important to get the vaccine. 
 
“So I feel like if I wasn't in a 
monogamous relationship I probably 
would've been more concerned, 
'cause I would've felt like there's 
more chance of contracting it.” 
(P15) 
Single & 
Dating 
Relationship did not have a major 
influence on decision, but there was 
a concern of needing it for future 
partners. 
 
“Right now, since I’m not sleeping 
with anyone, I’m like, ugh, I don’t 
need to get it yet, but then at the 
same time I’m like, well, I might 
sometime soon so I probably should 
be protected and that’s where I’m at 
with that.”  (P35) 
 
Half women said they wanted to get 
the vaccine because of the 
uncertainty of their current/future 
sexual partners’ history. 
 
“Yes, only because like we were 
sexually active, and I was like any 
kind of like extra protection I was 
game for. He – he had been with 
other people before, and I'm like you 
can't really tell when somebody has 
HPV; he might not even know.” 
(P19) 
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Table 24 (Continued) 
Single & 
Dating 
Women said they would be less 
inclined to get the vaccine if they 
became monogamous or entered a 
long-term relationship. 
 
“I feel like if I, like, was with this 
person, like long-term and that's it, 
like I probably wouldn't be as 
inclined to do it.” (P11) 
Half women said it was a personal 
decision only to get the vaccine and 
their relationship had no influence. 
 
“I don’t remember thinking about 
the relationship when I got the 
vaccine.  I thought more, um, I guess 
in the future.  I thought about, like, 
um, more up, like, later on in life, 
you know, as you would want to be, 
you know, protected against 
that….Like, I didn’t want to 
eventually be married and have that, 
you know, worry in my mind about 
HPV.” (P27) 
Single Only 
 
Women said they did not need the 
vaccine due to lack of sexual 
activity. 
 
“Yeah, in – in a sense it does ‘cause 
as I mentioned before, I – my 
lifestyle is to be abstinent ‘til 
marriage so the fact that I’m not 
married just means that I’m not 
going to – I’m not going to need the 
vaccine.  So in a sense, like if I got 
marriage and my partner ended up 
being – ended up having HPV or 
something, then I would get the 
vaccine.” (P6) 
 
If relationship status changed to a 
serious relationship or if they were 
to get married, they would consider 
getting vaccinated. 
 
“Interviewer: Let's say 
hypothetically if your relationship 
status changed in the future, maybe 
you found a partner, would this 
change your decision about the 
vaccine? 
Interviewee: Yes it would. I would 
go and get the vaccine.” (P5) 
Women in this group said that their 
relationship status did not impact 
their decision to get the HPV 
vaccine. 
 
“I don't think it [relationship status 
– single] really impacted it.  Like, I 
think even if I hadn't been seeing 
anyone I probably would've gotten it 
anyway because my doctor 
recommended it.  So, I don't think it 
really had a major impact on my 
decision.” (P36) 
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Table 25. Comparison of Perceived Risk of HPV With and Without the Vaccine by Sampling 
Group 
 Unvaccinated Vaccinated 
In a 
Relationship 
 
(Includes 
Married/Living 
with Partner 
and Long-term 
Monogamous) 
Without Vaccine: Low risk for HPV 
attributed to monogamy and number of 
sexual partners. 
 
“I have this thing – like this – this, uh, 
association, "Oh, we've been together.  
We don’t have it.  We're fine," though I 
know that's not always the case that, 
you know.” (P16) 
 
With Vaccine: Risk would decline 
slightly or stay the same because it is 
already low. 
 
“I feel like if I were in – I don't know 
like single or perhaps in like a non-
exclusive relationship, it’s something 
that I would think about a little bit 
more.  But as – yeah, I’m just like – it – 
it hasn’t really felt as relevant for me, 
but I definitely think that there’s like a 
lot of benefits to it.” (P7) 
Without Vaccine: Low risk for HPV 
attributed to monogamy and number of 
sexual partners; however, some (N=5) 
women stated it was high because of 
uncertainty or “you never know.” 
 
“I'd probably say it is low… Um, just 
that I'm only with one person at one 
time. So it's like I don't have multiple 
partners.” (P49) 
 
“I feel like it's high, but I'm also the 
same person that, like, you know, when 
you hear like 1 in 4 people have an 
STD, I find that to be extremely high.  
In my mind it feels high.” (P15) 
 
With Vaccine: Risk would decrease 
minimally because already low. 
 
“Um, of course, now it's [risk for 
HPV] definitely much, much lower.  
There's still a risk because the vaccine 
doesn't work 100 percent.” (P46) 
Single & 
Dating 
 
Without Vaccine: Varied risk among 
women, ranging from low, medium, 
high, and unsure. Risk for HPV was 
attributed to monogamy, unprotected 
sex, and annual checkups. 
 
“I don't know.  I don’t think it’s – I 
don’t think it’s very high.  But you 
don’t know.  I mean I – ‘cause it’s not 
my choice.  Like I don’t – you know, I 
don’t have a lot of sexual partners and 
I haven’t in the past and I only have 
one ever.  So like - but still, it only 
takes one person to get it so I don't 
know.  I don't think in the high risk 
group, but maybe I am.” (P35) 
  
Without Vaccine: Varied risk among 
women, ranging from low, medium, to 
high. Risk was attributed to current 
sexual activity (e.g., distance partner, 
not sexually active, on-and-off again 
partner). 
 
“Um, honestly, I know that the, like, 
amount of people that have this [HPV] 
is high.  So, um, I honestly don’t date a 
lot.  I haven’t had, like, a lot of 
boyfriends and stuff that are sexual 
relationships with people, so my 
chances are fairly low, but I know 
there are a lot of people out there.  So I 
would say, you know, still the risk is, is 
high.” (P27) 
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Table 25 (Continued) 
Single & 
Dating 
 
With Vaccine: All women said risk 
would decline with the vaccine. 
 
“Yeah, whatever risk I may have had, 
yes, it will definitely decline with the 
vaccine.” (P37) 
With Vaccine: All women said risk 
would decline with the vaccine. 
 
“Yes, I think that – I mean I’m not a 
100 percent protected from it but a lot 
less prone to the infection or the virus 
I mean.” (P40) 
Single Only 
 
Without Vaccine: Zero risk because 
not sexually active. 
 
“Personally, I think it’s probably like a 
.01 percent. Again, because of the 
abstinence policy that I abide by and 
again, if I had a marriage – when – 
when I get married I – it’s – it’s sort of 
like a trust thing, you know?  You 
should know if your –if your partner 
has HPV.” (P6) 
 
With Vaccine: Half of women said 
there would be no change in risk 
because they are not at risk to begin 
with, while the other half said the risk 
could decrease. 
 
“No, my risk wouldn’t change ‘cause 
although like I would understand 
getting the vaccine would change my 
mindset, it still wouldn’t change my 
lifestyle, like just because – just 
because I wear a seatbelt in the car 
doesn’t mean that I’m gonna drive 
faster.” (P6) 
Without Vaccine: Four said low risk 
attributed to sexual history and two 
said high because of either their 
partner’s sexual history or because 
HPV is common. 
 
“If you're sexually active, then 
probably a high risk.  If you're not 
sexually active, then I guess you're 
kind of okay. I think I'm a low risk. I'm 
not sexually active.” (P30) 
 
With Vaccine: All but one said the 
risk would decline; the one who said 
no change stated her risk was already 
low to begin with. 
 
“I think it's lower than it was before I 
got the vaccine.” (P36)  
 
“Yeah, I mean, I still think I'm at low 
risk because I have the vaccine.  It's 
an extra safety net for me.” (P3) 
 
 
Motivation – Risk perceptions – Perceived severity. Perceived severity of outcomes 
associated with HPV was assessed by questioning participants about how they perceived the 
consequences of HPV. There were no salient group differences among sampling groups, rather 
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three primary consequences emerged. The first outcome focused on by participants was cervical 
cancer, or more generally cancer (N=45). This was seen as the most severe outcome associated  
with HPV attributed to the fact that it is life-threatening, serious, has significant treatment costs, 
and fatal.  
 
“I would say, well if it was, if it was as bad as cervical cancer, I would say the 
consequences would be awful. Um, potentially life threatening, would be the best 
way I could put that.” (P48, Vaccinated, Married/Living with Partner) 
 
Some women even drew on experiences of knowing others who suffered through cancer to 
emphasize the severity of this disease. Others mentioned that cervical cancer would ultimately 
affect their fertility and potential to have children in the future. 
The second outcome described was genital warts; however, sometimes this was referred 
to as just warts or conflated it with herpes (N=40). The general sentiment was, “…genital warts, 
I've seen pictures and it does not look very pleasant.” (P17, Unvaccinated, Married/Living with 
Partner) In comparison to cancer, women reported that it was not as serious as cervical cancer, 
but still serious due to it being uncomfortable, cosmetically displeasing, and painful. “Well, I 
mean to me the scariest one is cervical cancer, and plus I don’t know anyone that wants warts.” 
(P15, Vaccinated, Married/Living with Partner) Others mentioned that they would not have to 
want to disclose having genital warts to a partner and that it would affect their sex life.  
 
“I mean I guess especially it's not appealing if you're trying to engage in any type 
of sexual activity with anybody.  But if you would be self-conscious and you would 
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feel not clean with yourself, you know.  It's not a good thing to feel like you have.  
It's not something that you would wanna advertise or anything like that.” (P25, 
Vaccinated, Long-term Monogamous) 
 
Finally, some participants described the emotional responses of having HPV (N=9). 
Psychosocial reactions included loss of trust in partners, the stigma of having a sexually 
transmitted infection, and being self-conscious. These emotional responses were primarily a 
reflection of how others, specifically future or current sexual partners, would perceive them with 
an HPV diagnosis. 
 
“…you know, diagnosed some psychological or emotional I guess turmoil of 
sorts; and so have to deal with, "Oh, I have an STD," and not seeing it's pretty, 
uh, negative in our culture.” (P23, Unvaccinated, Long-term Monogamous) 
 
 A comment made by one participant put into context how some women may perceive 
HPV in the realm of sexually transmitted infections. She stated,  
 
“I feel like it's, it's – in a way, I just feel like it's HIV's little sister. Like it's just, 
it's just you can get – you can get it so many times until you actually get the HIV.  
So it's definitely – it's like a chance.  You can a chance to like get yourself 
together; and it's just a red flag.  Like, "Hey, you have to protect yourself. You 
have HPV, now you have to protect yourself, you know, right before you, you 
know, things can get out of hand.” (P26, Vaccinated, Single and Dating) 
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This indicates that HPV may be a surrogate for sexual behavior that may place a woman at more 
risk for other, perceived more serious, sexually transmitted infections.  
Behavioral skills – Procedural knowledge. In order to elicit the behavioral skills 
needed to get the HPV vaccine series, participants were asked to describe the steps for getting it. 
For unvaccinated women, this was a hypothetical situation of what they thought would be 
involved. For vaccinated women, they recalled the process. Overall the groups were similar in 
displaying procedural knowledge for getting the HPV vaccine. For the vaccinated women, 
approximately half of participants said they went to a regularly scheduled annual exam or other 
healthcare appointment where the HPV vaccine was discussed. It was at these visits that the 
women decided to get the vaccine then based on conversations with healthcare providers or other 
staff. In contrast, the other half made specific appointments to get the HPV vaccine; however, 
this was usually the result of another cue to action for getting the vaccine. Most women 
described speaking to their healthcare provider about the vaccine prior to initiating the series. 
 
“I went to my healthcare provider because, in order to go to college, I had to get 
a couple more vaccines.  And he said that there was another vaccine that was 
available for me to have in case I became sexually active or already was.  And, he 
told me a little bit about it.  He told me about what it prevents, such as, you know, 
cancers, genital warts.  I told him to give me the need-to-know information and 
all the cons, and I remember he said auto-immune disease was a con.  And, I 
decided it's better safe than sorry, and because I do believe in vaccines, I decided 
to go ahead with it.” (P3, Vaccinated, Single) 
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The majority stated they used insurance coverage to pay for the vaccine; only three said they 
received the vaccine for free and another said her mother covered the payment.  
Women who were vaccinated were in different stages of getting the follow-up shots. Of 
the women who reported completing the vaccine series (N=16), these women made follow-up 
appointments in advance and typically had an immunization-only appointment. Unvaccinated 
women mentioned that in order to successfully complete the vaccine series, they would need to 
schedule follow-up appointment in advance. 
In comparison, women who were unvaccinated reflected on the steps they would need to 
take if they hypothetically decided to get the HPV vaccine. Women said they would go to a 
scheduled annual exam or schedule a specific visit for the vaccine, then ask for more information 
from their healthcare provider to clarify that the vaccine was right for them.  
 
“So I would go to the gynecologist and then I would be talking with them at my 
appointment and then one of us would say, ‘Hey, do you want to get – you can get 
a HPV vaccine?’ Or if they didn’t ask me this time I would bring it up because 
I’ve been thinking about it a lot and then I would say, ‘Should I get the vaccine?’   
Or actually I’d say something I want ‘cause it sounds like I probably do really 
want it and so I’d say, ‘I want to get the vaccine.  Should I now – is it good for 
me?’  And then I would ask them like how we would go about doing this, like 
when will I get the first shot or what – and then I’d ask what maybe the 
complications are, like people’s side effects they’ve had from the vaccine.  And 
that would be – that would be it.  I either get it or I wouldn’t.” (P35, 
Unvaccinated, Single and Dating) 
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Most women said their insurance would cover the vaccine, but there were seven women who 
said they would need to figure out their finances to cover the expense. Finally, they stated they 
would need to schedule follow-up visits for the additional shots. These steps were essentially the 
same as the vaccinated group indicating that the unvaccinated have the procedural knowledge to 
get the HPV vaccine. 
Behavioral skills – Facilitators. Women were asked to describe factors that would make 
the vaccination process easier for them, considering the steps needed to get the vaccine (Figure 
7). For vaccinated women, this involved reflection on events that had occurred, while 
unvaccinated women described what they believe would facilitate the process. Interestingly, 
women in the unvaccinated group were able to describe more facilitators compared to the 
vaccinated group, 39 and 30, respectively. This may be due to women in the unvaccinated group 
describing hypothetical scenarios for themselves and women generally, whereas the vaccinated 
women reflected on their individual experiences. 
All groups of women described logistics and convenience as the primary facilitator for 
HPV vaccination (N=19). This included items such as time off of work, distance to the 
provider’s office, easy scheduling, vaccine only appointments, and efficiency of the office. 
Additionally low cost of the vaccine or insurance coverage was also a facilitator (N=23). Women 
in the unvaccinated group were more interested in the cost aspect compared to vaccinated 
women.  
All groups of women emphasized that a trusting relationship or reassurance from a 
healthcare provider would help/helped the decision-making process (N=13). These women 
described an evaluation process to determine if the vaccine was right for them and a reliance on a 
healthcare provider’s judgement. As one participant stated, “Just the reassurance from talking to 
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the doctor” (P4, Vaccinated, Long-term Monogamous) made the process easier. Additionally, 
women also described having a regularly seen healthcare provider or a provider they could trust 
as a facilitator.  Support from influential others agreeing with the decision for the vaccine was 
also reported (N=4); these influential others included parents and partners. 
Since unvaccinated women were still undecided or decided against getting the HPV 
vaccine, when describing facilitators for vaccination, some women mentioned the desire to have 
more information or awareness about the vaccine (N=5). This is another opportunity for a 
healthcare provider to have a role in the decision-making process.  
There were a few facilitators that were described that were unrealistic. Women stated 
they would rather the shot be in a pill format or that there were fewer shots (N=5). This is similar 
to the negative attributes described about the HPV vaccine. 
 
 
Figure 7. Frequency of Facilitators for HPV Vaccination by Vaccination Status 
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Behavioral skills – Barriers. Similar to the facilitators for the HPV vaccination process, 
women were asked to also describe perceived barriers (hypothetical or actual). Unvaccinated 
women had 33 accounts of describing barriers compared to vaccinated women at 19 (Figure 8).  
This is largely attributed to 40% of the vaccinated women stating that there were no barriers to 
vaccination, which may be due to the recall of the process.  
Logistics continued to be of prime importance to the young adult women across 
vaccination status (N=15). Again, this included factors such as time, convenience, and 
accessibility. However, in this scenario 15 unvaccinated women described insurance or cost as a 
potential barrier, while only one vaccinated woman described the insurance process. Again, this 
is likely due to the fact that vaccinated women were able to overcome this obstacle and no longer 
see it as a barrier, while unvaccinated women were describing what they perceive to be future 
obstacles. 
Lack of healthcare provider support or recommendation was not seen as a significant 
barrier (N=3); rather healthcare provider input appears to be more of a positive factor. Lack of 
support from influential others was also seen as a barrier (N=4); these important others included 
parents and partners. Only one vaccinated woman described wanting to receive more information 
prior to getting the vaccine as a factor that made the process difficult. Finally, many of the 
barriers described were opposite of the facilitators listed; however, there were a few new items, 
including fear of needles (N=6) and fear of side effects (N=5). 
Macro factors – Healthcare interaction. Women were asked how many times they 
visited a healthcare provider in the last year. Almost all women (N=41) reported seeing at least 
one physician in the past year, typically a gynecologist or general practitioner for an annual 
appointment. Women who did not see a doctor in the last year mentioned that they only see a   
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Figure 8. Frequency of Barriers for HPV Vaccination by Vaccination Status 
 
doctor when they are sick. Among this group of women with low healthcare interaction (N=9), a 
third was women who were unvaccinated and single only. These women reported not being 
currently sexually active, which may contribute to their low utilization of healthcare services 
from a gynecologist.  
Macro factors – Health insurance. According to the survey administered prior to the 
interview, a total of six participants did not have insurance at the time of the interview. There 
were two vaccinated participants without health insurance, and four unvaccinated participants 
without health insurance. The majority of participants, 58%, had some form of private insurance 
(N=29). The remaining had Medicaid (N=8), school-sponsored (N=4), and other (N=3). 
Macro factors – Social and cultural factors. Finally, participants were asked to share 
any social or cultural factors that influenced their decision or opinion about the HPV vaccine. 
This concept was difficult for women to articulate, and as result they were probed about 
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government involvement, vaccine discussions in our culture, and media messages. There were no 
group differences in these factors; in fact, the items listed by women were very individualized. 
Only eight women could not list any social or cultural factors that influenced their opinion about 
the HPV vaccine (N=3 unvaccinated and N=5 vaccinated).  
Societal norms regarding views on medicine and vaccines in the United States were 
discussed. Women reported having a distrust in the American medical system and/or a focus on 
natural and holistic medicine (N=8). Many of the women’s preferences for holistic and natural 
remedy stemmed from their culture or upbringing. Similarly, a couple of women reported the 
skepticism they had for new medicine and lack of information on long-term outcomes (N=2). 
 
“Just that I come from a family that’s more into like holistic remedies and cures 
for things. We don’t really go to the doctor or take a whole lot of medicine, um, 
things like that, so I’m always leery of vaccines and vaccinations.” (P15, 
Vaccinated, Married/Living with Partner)  
 
Yet despite these preferences for natural medicine, women still recognized the importance of the 
HPV vaccine for prevention of disease. 
 
“I think, I think definitely I've, I've carried it on [traditional medicine] in the 
sense like I don't, I don't take over-the-counter stuff when I'm sick or, you know, 
things like that.  But definitely things that are more out of my control like, you 
know, getting an STI, or like if, if I can prevent something like that, then I'll 
definitely try to because it's like, it's like my life being in somebody else's hands, 
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it's not really my life in my own hands.” (P25, Vaccinated, Long-term 
Monogamous) 
 
 Additionally, there were HPV vaccine specific societal attitudes that impacted the 
participants’ opinions about the HPV vaccine. These HPV vaccine factors included (1) 
connection of the vaccine to sex, abstinence, and stigma (N=4); (2) lack of awareness in society 
of this vaccine (N=2); (3) non-required vaccine indicating its lack of importance (N=2); and (4) 
negative reputation of the vaccine (N=1).  
 The most prominent theme discussed by women was the anti-vaccination movement 
(N=11). These women reported not agreeing with the movement, but recognized that it 
contributes to negative views of the HPV vaccine. As one woman stated, there are polarizing 
opinions on vaccination in our society,  
 
“Society’s view of vaccinations, like I just think it’s like half and half, like half of 
them say it’s very good, half of them say it’s super bad.” (P11, Unvaccinated, 
Single and Dating).   
 
 Finally, women described media messages they had viewed about the HPV vaccine and 
vaccines generally. Among these messages, there were negative (N=6), positive (N=4), and 
mixed or incomplete messages (N=2). Two specific media campaigns/advertisements were 
described, these included “One Less” and “Tell Someone.” One participant also mentioned an 
episode of the HBO television show, Girls, mentioning HPV and its relation to sexual activity. 
Most women reported a level of skepticism of the mass media messages that were presented. 
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“I haven’t seen many – like a lot of media promoting HPV except here in like the 
- and with pamphlets and like the - student health services that’s advocating for it. 
But I’ve seen a lot of like stuff against it saying that it causes autism in kids and 
stuff like that since that has been disproven.” (P41, Vaccinated, Long-term 
Monogamous) 
 
Summary of IMB Factors for HPV Vaccine Decision-Making 
 The research questions for this phase aimed to compare informational needs, motivations, 
and behavioral skills for HPV vaccination across vaccination status (i.e., vaccinated and 
unvaccinated) and relationship statuses (i.e., married/living with partner, long-term 
monogamous, single and dating, and single). During these comparisons, it was clear that there 
were no significant differences across these groups for the following constructs: Information: 
Knowledge, Preferences, and Trust; Motivation: Attitudes about Vaccines, Social Motivation, 
Reasons for Non-Vaccination at a Younger Age, and Perceived Severity; Behavioral Skills: 
Procedural Knowledge; and Macro Factors: Healthcare Interaction, Insurance, and 
Social/Cultural Factors (Figure 9).  
 When comparing across vaccination status, there were differences between vaccinated 
and unvaccinated women for Motivation: Attitudes about HPV Vaccine, Motivation: Reason for 
(Non-)Vaccination Now, and Behavioral Skills: Facilitators and Barriers. Finally, differences 
were observed across relationship status categories (i.e., In a relationship; Single and Dating; and 
Single Only) for Motivation: Perceived Risk of HPV and Motivation: Reason for (Non-) 
Vaccination Now. 
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Figure 9: IMB Model for HPV Vaccination among Young Women  
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Chapter 5: Discussion 
 
Overview 
 HPV vaccination has been available for the prevention of HPV-related disease among 
females since 2006 (Markowitz et al., 2007). While targeted toward young adolescents aged 11 
and 12 years, the rate of uptake among this group continues to be below optimal (Healthy People 
2020, 2015c; Stokley et al., 2014). As a result, unvaccinated young adult women continue to fall 
in the catch-up age range of 18 to 26 years for HPV vaccination. Unfortunately, approximately 
only a third of 18 to 26 year old women have received the HPV vaccine resulting in a large 
proportion of women who cannot benefit from this type of prevention for HPV-related disease 
(Schmidt & Parsons, 2014).  
 In order to improve HPV vaccine rates among this catch-up range of women, it is 
necessary to examine groups who continue to have low rates. Repeatedly in the literature, 
married women or women in relationships are identified as having lower HPV vaccine uptake 
rates compared to women who are single (Anhang Price et al., 2011; Bernat et al., 2013; Ford, 
2011; Joseph et al., 2014; Laz et al., 2013; Liddon, Hood, et al., 2012; Liddon, Leichliter, et al., 
2012; Lindley et al., 2013; Rahman et al., 2013; Schmidt & Parsons, 2014; Wei et al., 2013; 
Williams et al., 2013; Zimet et al., 2010). However, until now, it was unknown the particular 
reasons for this disparity.  
 This study aimed to understand the information, motivation, and behavioral skills 
influenced by relationship status for HPV vaccine decision-making among young adult women.   
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This was achieved through a two phase, mixed methods research study.  Phase I comprised a 
quantitative analysis of a nationally representative dataset to examine how interest in HPV 
vaccination and primary reasons for no interest in HPV vaccination differed by relationship 
status among young adult women. Phase II expanded upon this premise, by conducting in-depth 
interviews with young adult women to understand their HPV vaccine decision-making process, 
specifically their informational needs, motivations, behavioral skills and the influential macro 
factors. Women were stratified by relationship status and vaccination status to allow for 
qualitative comparisons between groups.  
 
Relationship Status and HPV Vaccination 
  
 Phase I – Reasons for Non-Interest in HPV Vaccination 
 Using data from the National Health Interview Survey, this study found that married 
women were approximately 40% less likely to be interested in HPV vaccination compared to 
never married women and women living with a partner. This confirmed the hypothesis that 
women who were married would be less likely to be interested in HPV vaccination compared to 
other relationship status groups. These findings are similar to other studies examining marital 
status and HPV vaccination interest using epidemiological data (Anhang Price et al., 2011; 
Bernat et al., 2013; Ford, 2011; Joseph et al., 2014; Laz et al., 2013; Liddon, Hood, et al., 2012; 
Liddon, Leichliter, et al., 2012; Lindley et al., 2013; Rahman et al., 2013; Schmidt & Parsons, 
2014; Wei et al., 2013; Williams et al., 2013; Zimet et al., 2010); however, this study utilized 
more specific categorizations of relationship status, specifically dividing non-married to never 
married and living with a partner. No significant differences were observed when comparing 
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married and widowed, divorced, or separated relationship status groups. This may be due to the 
latter group once being in a marital relationship. 
 Moreover, while previous research examined how relationship status (i.e., married, not 
married) was associated with interest in the HPV vaccine, it did not evaluate the reasons for non-
interest in vaccination (Schmidt & Parsons, 2014). Using the NHIS dataset, differences in 
primary reasons for non-vaccination were observed by relationship status category, confirming 
the study’s hypothesis. Belief that they did not need the HPV vaccine was the primary reason for 
non-vaccination among all relationship status groups, yet it was highest among the married 
women (48%). This may be attributed belief that they are perceived not at risk for HPV in this 
relationship status, and therefore do not need the HPV vaccine (Schmidt & Parsons, 2014). 
 Additionally, married women were more likely to cite lack of doctor recommendation as 
a primary reason for non-vaccination compared to other relationship status groups. Previous 
research has indicated that healthcare providers may have a bias that reduces their 
recommendation for HPV vaccination to young adult female patients in relationships (Zimet et 
al., 2011). While lack of doctor recommendation and perceived lack of need of the HPV vaccine 
were key factors for married women, other relationship status groups were more likely to list 
worried about the safety of the vaccine; 15.2% and 14.9%, respectively compared to 3.9%. 
  
 Phase II –Relationship Status, Risk Perception, and HPV Vaccine Decision-Making 
 The primary purpose of conducting Phase II was to elucidate the connection between 
relationship status and HPV vaccination decision-making. Women in long-term relationships 
reported that their current relationship status impacted their decisions not to receive the HPV 
vaccine. Women attributed their decision not to receive the vaccine to current monogamy and 
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few sexual partners. Moreover, these women described their perceived risk for HPV as low and 
indicated that their risk for HPV would not significantly change with the vaccine due to it 
already being quite low. This connects to what is seen in the quantitative literature that women in 
relationships are less likely to receive the HPV vaccine, and how previous researchers 
hypothesized this was attributed to risk perceptions (Anhang Price et al., 2011; Laz et al., 2013; 
Lindley et al., 2013; Schmidt & Parsons, 2014; Wei et al., 2013).  
 Similarly, women in this sample who were in relationships and vaccinated stated that 
their risk for HPV was low for comparable reasons. However, these women were less likely to 
state that their relationship status impacted their decision for vaccination, rather reasons for 
vaccination varied widely for this group. One of the primary themes among these cues to action 
for HPV vaccination was a realization of high risk for HPV or HPV-related outcomes, which was 
in the form of being diagnosed for HPV or an abnormal Pap, having a family history of cancer, 
or changing relationship or sexual status (e.g., becoming sexually active or moving in with 
partner). This indicates that while relationship status serves as a primary barrier to HPV 
vaccination for women in relationships, significant cues to action that permit women to realize 
actual risk for HPV can facilitate the vaccination process.  As of yet, no interventions have been 
developed for this population to address this specific barrier. 
 Unvaccinated women who were single and dating reported that their relationship status 
did not impact their decision for non-vaccination. In fact, these women had more accurate 
perceptions of their risk for HPV compared to women in relationships who were unvaccinated.  
Women who were single and dating were more likely to question why they had not yet received 
the HPV vaccine. Similarly, women who were single and dating and vaccinated reported a more 
accurate risk perception for HPV and that their decision for the vaccine was not based on their 
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relationship status. Both groups of women acknowledged the advantage of getting the HPV 
vaccine was the uncertainty of future sexual partners. Women who were single and dating were 
more heterogeneous than the other relationship status categories. This particular group’s 
variability is often overlooked in other study designs since they are lumped into the “single” or 
“never married” category (Anhang Price et al., 2011; Ford, 2011; Laz et al., 2013; Liddon, Hood, 
et al., 2012; Liddon, Leichliter, et al., 2012; Lindley et al., 2013; Rahman et al., 2013; Schmidt & 
Parsons, 2014; Wei et al., 2013; Williams et al., 2013).  
 In contrast, women who were unvaccinated and single only perceived themselves at zero 
risk for HPV, which was attributed to lack of sexual activity.  Most of these women recognized 
their potential risk for HPV once commencing a relationship or sexual activity; however, stated 
they would wait until that point to receive the vaccine. Cohen and Head (2013) reported a similar 
argument from young adult women who were not sexually active. While these women stated that 
their current relationship status did not impact their decision to get the HPV vaccine, the fact that 
they were single and not sexually active was their primary reason for not getting the vaccine 
now. Thus, in a sense, these women’s relationship statuses were the primary barrier for not 
getting the HPV vaccine, much like women who were in relationships and unvaccinated. Gerend, 
Shepherd, and Shepherd (2013) evaluated the multidimensional nature of perceived barriers to 
HPV vaccination among young adult women. This study found one of the barrier dimensions 
was perceived lack of need, which included the clustering of not sexually active and 
monogamous relationship. In contrast, women who were single and vaccinated stated that their 
relationship status did not impact their decision for vaccination, but much like women in 
relationships and vaccinated, they had a variety of cues to action for getting the vaccine, 
including recommendations from providers and parents. 
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 These findings suggest that among unvaccinated young adult women, women were 
framing their risk for HPV and perceived need for the HPV vaccine based on their current 
relationship statuses. Yet, there was some discussion of the potential need or lack of need if 
relationship statuses were to change in the future among unvaccinated women. For example, 
women in relationship said that the vaccine would be more important if they were no longer in a 
monogamous partnership. In contrast, women who were single and dating said the vaccine would 
be less important if they did enter a long-term monogamous relationship.  While these women 
were cognizant of the potential change in risk for HPV based on changing relationships, these 
were not motivating factors when the women evaluated their potential risk for HPV. In other 
words, women were evaluating their current risk for HPV, rather than recognizing the potential 
for that risk to change in the future. The low risk perceptions of women in relationships due to 
monogamy observed in this study are similar to the HIV risk perceptions among women in close 
relationships. The concept of knowing their partner and engaging in monogamy supersede any 
other risk behaviors the couple may be engaging in, for example, sex without condoms 
(Misovich et al., 1997). These findings should be considered in the context of the potential 
lifetime risk for HPV among a woman, which underscores the need for HPV vaccination. The 
average lifetime risk of HPV among women with one opposite sex partner is 85% (Chesson, 
Dunne, et al., 2014). Recent evidence suggests the prevalence of HPV is approximately 17% 
among heterosexual couples who did not have any other sexual partners (Burchell et al., 2014).  
 
Triangulation 
 The findings from Phases I and II were complementary and both confirmed the 
hypothesis the relationship status is influential to HPV vaccination among young adult women. 
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The findings from Phase I described differences in reasons for non-interest in HPV vaccination 
based on relationship status groups using a nationally generalizable and large sample. While this 
suggested that differences do exist by relationships status, this survey was limited by not 
expanding upon the reasons for non-interest and non-vaccination. Phase II’s qualitative 
methodology permitted an in-depth understanding of reasons for not receiving the HPV vaccine 
among a smaller sample of young adult women. To assist in the comparison between phases, the 
relationship status categories from Phase I were redefined to be Married or Living with a Partner 
and Never Married to mirror the relationship status categories from Phase II (see Table 19, Page 
97).  
 The quantitative data indicated that more women who were Married or Living with a 
Partner reported “does not need vaccine” compared to Never Married women (45.3% and 34.7%, 
respectively). This is similar to the findings among unvaccinated women in Phase II that women 
who were married or living with a partner reported not needing the vaccine due to monogamy or 
other protective sexual practices in their relationship. In contrast, women who were single and 
dating were more likely to state that they were unaware of the vaccine as a reason for non-
vaccination. 
 Another key difference observed between the relationship status groups from the survey 
data were women who were Married or Living with a Partner reported a lack of doctor 
recommendation more often compared to Never Married women (9.5% and 6.3%, respectively). 
In the interview sample, vaccinated young adult women were asked their reasons for receiving 
the HPV vaccine as a young adult. Women who were single and dating or single only were more 
likely to report a doctor recommendation as a cue to vaccination, whereas women in 
relationships did not cite this as a reason.  
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 These results provide evidence of the importance of mixed methodology for public health 
research, especially for a complicated topic, such as HPV vaccination. The qualitative data 
supplemented the quantitative results by expanding upon the reasons for non-vaccination with 
narratives from the target population. Furthermore, these narratives were not constricted to 
closed-ended questions, but based on the diverse perspectives of the participants. Moreover, 
while the quantitative and qualitative painted a picture of the barriers to HPV vaccination, the 
qualitative data enriched these findings by also evaluating the facilitators to vaccination among 
already vaccinated women. However, there are limitations to these comparisons due to 
differences in samples and recruiting methods, as well as categorizations of relationship status. 
The quantitative data were more restricted in relationship status types for an 18 to 26 year old 
population, whereas the interview sampling disentangled the “Never Married” group into three 
distinct strata (i.e., Long-term Monogamous, Single and Dating, and Single Only), which was 
found to have significant variability in responses.  
 
Informational Needs 
 Knowledge about a health behavior is often recognized as a key step in the behavior 
change process (Brewer & Rimer, 2008). Awareness about the HPV vaccine was found to be a 
significant predictor of interest in HPV vaccination among young adult women in the NHIS 
sample (PR = 1.58, 95% CI 1.46-2.05). In examining the primary reasons for non-interest in 
vaccination, not knowing enough about the vaccine was only reported by 13% of sample. 
Women in the Phase II sample had adequate knowledge about HPV and the HPV vaccine. 
Compared to a 2008 sample of college women using the same knowledge scale, the 2015 sample 
had higher scores, 14.1 and 15.3, respectively (Daley, Vamos, et al., 2010). This coincides with 
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other literature indicating that awareness about the HPV vaccine have increased over time 
(Schmidt & Parsons, 2014). 
 In the Phase II sample, women demonstrated a surface level awareness and knowledge of 
HPV and the HPV vaccine, but had difficulty elaborating on details. Women were generally 
aware of what HPV was and that it could cause cervical cancer. However, they were more 
uncertain about other outcomes associated with HPV, such as genital warts or other HPV-related 
cancers. This may be due to the heightened focus on the link between HPV and cervical cancer 
through popular media campaigns rather than on outcomes with more sexual connotations 
(Pisciotta, 2012). An additional area where women were lacking information was the mode of 
transmission of HPV. In the interviews, women stated that HPV was transmitted sexually; 
however, were generally unable to elaborate on modes of transmission (i.e., vaginal-penile, oral, 
skin to skin). Previous research among young adult women has also documented the lack of 
knowledge regarding routes of HPV transmission (Sandfort & Pleasant, 2009).  If women are 
unaware of these modes of transmission, they may have the false belief that protected sex with a 
condom alone may prevent HPV, therefore underestimating their risk for acquiring the virus. 
 Of most concern were the misperceptions women have about the timing and target 
population for the HPV vaccine. A subset of the vaccinated and unvaccinated women both 
reported that HPV vaccination should occur after onset of sexual activity. Similarly, 
approximately 7% of the NHIS sample reported that they did not need the vaccine because they 
were not sexually active. This is contrary to the evidence supporting that the vaccine is most 
effective prior to exposure to HPV and onset of sexual activity (Markowitz et al., 2014). 
Moreover, it perpetuates the public’s focus on the connection of this vaccination with sexual 
activity of adolescents and young adults (Zimet, Rosberger, Fisher, Perez, & Stupiansky, 2013). 
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Additionally, despite the introduction and approval of a 9-valent vaccine immediately prior to the 
commencement of data collection (Food and Drug Administration, 2015; Petrosky et al., 2015), 
none of the participants described this change in vaccine availability. It is anticipated that health 
messages surrounding the HPV vaccine will become increasingly complicated with options of a 
quadrivalent and 9-valent vaccine.  
 Despite many of these misperceptions about HPV and the HPV vaccine, women reported 
hearing about the HPV vaccine from a variety of sources, such as healthcare providers, family 
members, partners, TV, and the Internet. Among these sources, women stated that they trusted 
their healthcare provider the most for information about HPV and the vaccine. It is important to 
identify the agent most trusted as previous research has indicated the more valued the 
information source, the more likely the woman may be to prioritize that specific information 
(Redmond et al., 2010; Worsley, 1989).  Moreover, it is evident from the literature how valuable 
a provider recommendation for the HPV vaccine can be, especially for young adult women 
(Rosenthal et al., 2011).  
 Women also reported that they would prefer to learn more information in the future about 
HPV and the vaccine from a healthcare provider and the Internet. Internet sources, while easily 
accessible by this population, may also produce negative and mixed messages about the HPV 
vaccine (Ruiz & Barnett, 2015). Other modes of information were less consistently cited as 
sources of HPV vaccination information, including the television and radio. Identifying the 
information-seeking preferences of this demographic can inform the agents or modes used in 
future health interventions.  
 
Motivation 
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 Motivating factors for HPV vaccination, which included attitudes, social influences, and 
risk perceptions, were explored. Significant differences in motivations were observed for 
attitudes about the HPV vaccine between vaccinated and unvaccinated women. Additionally, risk 
perception varied based on relationship status, as previously described. 
  
 Attitudes 
 Overall, women reported positive attitudes about vaccines generally, stating that they 
protected the population and personal health from diseases. Surrogate markers for attitudes about 
other vaccines were measured in the NHIS sample; specifically women who had received a flu 
shot in the last 12 months or received the Hepatitis B vaccine were more likely to be interested in 
the HPV vaccine. This is supported by previous research as well (Anhang Price et al., 2011; Jain 
et al., 2009; Laz et al., 2013; Rahman et al., 2013; Schmidt & Parsons, 2014; Wei et al., 2013). 
 Yet, women in the interview sample differed in attitudes about the HPV vaccine based on 
vaccination status. Women who were vaccinated had more favorable opinions about the HPV 
vaccine compared to women who were unvaccinated. This may reflect true differences in 
attitudes impacting vaccine behavior, or may be indicative of changes in attitudes after engaging 
in the behavior. Higher perceived importance and positive attitudes about the HPV vaccine have 
been cited as being associated with vaccination or intent for vaccination among young adult 
women (Bendik et al., 2011; Bennett et al., 2012; Dillard, 2011; Ratanasiripong et al., 2013; 
Rosenthal et al., 2011; Schaefer Ziemer & Hoffman, 2013). However, similar retrospective 
adjustments have been reported in the literature for risk perceptions and recall bias (Brewer et 
al., 2007). Thus, the differences in attitudes about the HPV vaccine between vaccination groups 
may be attributed to experience with the vaccine. Women who were unvaccinated cited more 
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often that side effects were a negative aspect about the vaccine; however, these women were 
unable to describe these side effects in any detail. This is congruent with the NHIS sample, 
which estimated that 12% of unvaccinated young adult women were worried about the safety of 
the HPV vaccine. In contrast, women who had received the vaccine were able to describe any 
side effects experienced, such as pain at the injection site, which is reported in the literature as a 
common side effect with this vaccine (Reiter, Brewer, Gottlieb, McRee, & Smith, 2009a). 
 An explanation for the disparity observed between the attitudes about vaccines generally 
and the attitudes about the HPV vaccine may be attributed to women classifying the HPV 
vaccine as a separate type of vaccine. For instance, women stated it is not similar to required 
vaccines, such as the MMR vaccine, but is more important than completely optional vaccines, 
such as the influenza vaccine. Analogous perceptions have been reported by providers who 
administer adolescent vaccines; specifically, that the HPV vaccine is more burdensome to 
discuss with patients compared to other required vaccines (e.g., Tdap and meningococcal) 
(Gilkey et al., 2015). 
 
 Social Motivation 
 There were no major differences between social motivators for HPV vaccination across 
vaccination status and relationship status. The key motivator was/is a healthcare provider. 
Previous literature repeatedly emphasizes the importance of a healthcare provider 
recommendation for HPV vaccination initiation (Daley, Vamos, et al., 2010; Klosky et al., 2015; 
Licht et al., 2010; Marchand et al., 2012; Rosenthal et al., 2011; Zimet et al., 2010); however, 
this study also elicited the salience of a trusting or established relationship with a healthcare 
provider. This confirms findings from Joseph et al. (2014) that a diverse sample of young adult 
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women reported trust in a provider was important for HPV vaccine decision-making; however, 
while it significantly predicted intent for vaccination, it was not statistically significant for 
receipt of the HPV vaccine. Moreover, in this study, some women reported that providers 
reassured them that the vaccine was best for them, and personalized it to their particular 
circumstances. While this may appear as a facilitator to HPV vaccination, it can also negatively 
affect HPV decision-making for this particular population. Women in college may not wish to 
establish care with a new provider and prefer returning “home” to see a provider they have a 
relationship with. Thus, while in college, women may not see a trusted provider due to logistics 
and thus do not receive this recommendation during the catch-up years for HPV vaccination.  
 Additional influential others included friends, family members, and spouses. Previous 
literature studying young adult college women has found peer norms impactful for HPV 
vaccination (Hopfer & Clippard, 2011); however, in this study, peers were less important than 
other agents. Peers were only seen as significant if they could share their experiences with HPV 
vaccination as a model that it was safe and acceptable. Family members, specifically mothers, 
were also important in encouraging or discouraging vaccination, which is previously found in the 
literature (Cohen & Head, 2013; Hopfer & Clippard, 2011). However, this study found that 
mothers’ roles in the HPV vaccination process were more salient during adolescence compared 
to young adulthood. Moreover, women reflected that their mothers were one of the primary 
barriers to vaccination in adolescence. In comparison, the NHIS sample found that a family 
member or spouse against the HPV vaccine was a primary reason for non-vaccination in less 
than 2% of the sample. Therefore, these agents may not necessarily be barriers to vaccination, 
but rather facilitators.  
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 The final group examined as social motivators were partners. Interestingly, women 
reported that these were not significant agents in HPV vaccination decision-making, in fact, 
partners tended to be indifferent. Moreover, women reported that they thought their partners 
should be vaccinated as well, while some women stated it was important to receive the vaccine 
to protect their partner’s health. Both of these statements are consistent with previous literature 
(Harper, Alexander, et al., 2014; Patel et al., 2013). This coincides with the notion that sexual 
health prevention practices are often relegated to women’s health. Women often take on the 
sexual and reproductive health prevention behaviors (e.g., birth control pills) to keep the 
heterosexual partnership safe. This may also be the product of societal norms of masculine 
hegemony resulting in men believing they do not need protection (Evans, Frank, Oliffe, & 
Gregory, 2011). Perhaps this is a consequence of the feminization of the HPV vaccine, which 
ultimately over-identified the vaccine as a women’s rather than men’s health behavior (Daley, 
Buhi, Vamos, et al., 2012).  
 Previous literature among university women has indicated that attitudes toward HPV 
vaccination and perceptions of social support predicted intention of HPV vaccination (Fisher, 
Kohut, Salisbury, & Salvadori, 2013), which is supported by this study. However, one factor that 
is understudied in the current literature emerged, the idea that HPV vaccination is a personal 
decision. Women repeatedly mentioned that while outside information or people were 
influential, women ultimately wanted to make the decision on their own with all the available 
information. In other words, women were deciding if the vaccine was right for them. This 
personalization of the vaccine for individual use has implications for future health messages 
targeted at this newly autonomous group of young adults. Women desire to know that the HPV 
vaccine is best for their health given their medical and social history. This contradicts the 
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literature that reports social norms from peers and family members being influential for HPV 
vaccine decision-making (Allen et al., 2009; Bennett et al., 2012; Hopfer & Clippard, 2011; 
Ratanasiripong et al., 2013; Schaefer Ziemer & Hoffman, 2013). While these multiple spheres of 
influence may be significant, women wish to reconcile the overwhelming amounts information 
and perspectives with their own beliefs and judgement.  
 
 Reasons for Non-Vaccination as an Adolescent 
 Since the HPV vaccine has been available for females since 2006 and this study’s sample 
comprised females 18 to 26 years old, women were questioned about the reasons they did not 
receive the HPV vaccine as an adolescent, as these factors may influence current HPV 
vaccination behavior. Major reasons were lack of awareness of the HPV vaccine and parental 
beliefs about the HPV vaccine. For many of these women, lack of awareness perpetuated until 
young adulthood. Similarly, approximately 30% of the NHIS 2010 sample of women had not 
heard of the HPV vaccine. However, parental influence, while significant in adolescence, does 
not have the same weight in young adulthood. This provides evidence to the statement that 
young adulthood is a period of autonomous decision-making for sexual and reproductive health. 
Furthermore it emphasizes the need to continue to target women in the catch-up range for HPV 
vaccination, since their parents’ beliefs may have been an obstacle to vaccination at an earlier 
age. 
 
 Reasons for (Non-) Vaccination as a Young Adult 
 Vaccination decision-making in young adulthood revealed that parental beliefs were no 
longer primary drivers in this process. In examining the primary reasons for non-vaccination 
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among unvaccinated women, two key themes emerged: (1) lack of awareness of the vaccine, and 
(2) perceptions of low risk for HPV. As previously stated, the perceptions related to risk of HPV 
varied based on relationship status groups, which impacted reasoning for not needing the vaccine 
at that time. The lack of awareness of the HPV vaccine was a significant barrier to vaccination 
among this sample, while similarly it affected interested in HPV vaccination in the NHIS sample. 
These two barriers were also previously identified in the literature as contributing to low uptake 
of the HPV vaccine (Anhang Price et al., 2011; Cohen & Head, 2013; Gelman et al., 2013; 
Hodge et al., 2011; Hopfer & Clippard, 2011; Joseph et al., 2014; Laz et al., 2013; 
Ratanasiripong et al., 2013; Schaefer Ziemer & Hoffman, 2013; Schmidt & Parsons, 2014). 
 In contrast, women who were vaccinated cited a variety of reasons for getting the HPV 
vaccine as a young adult. These cues to action, while quite heterogeneous, could be simplified to 
addressing the primary barriers: lack of awareness and perceptions of low risk for HPV. For 
some women, a recommendation from another individual or awareness generally contributed to 
uptake of the vaccine. For others, it was the realization of the actual risk for HPV in their 
lifetime, which stemmed from HPV diagnosis, family history of cancer, becoming sexually 
active, or other changes in relationship status.  
 
 Consequences 
 Similar to the findings from the informational needs, the majority of women focused on 
cervical cancer as the primary consequence to HPV. Again, this may be attributed to popular 
media and health messages’ focus on this connection (Pisciotta, 2012). Women repeatedly 
mentioned cervical cancer to be the most severe outcome, while genital warts were seen as 
inconvenient and aesthetically displeasing. Correspondingly, previous studies have found that the 
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perceived severity of cervical cancer predicted HPV vaccination (Bendik et al., 2011; Krakow et 
al., 2015). Findings from the knowledge survey confirm that women were less aware of HPV’s 
connection to genital warts (60%) compared to cervical cancer (94%). 
 An additional consequence reported by a smaller proportion of the sample was the 
emotional responses to an HPV diagnosis. Previous literature has reported on emotional 
responses expressed by women who are HPV positive, including anger, self-blame, fear, and 
stigma (Daley, Perrin, et al., 2010; Perrin et al., 2006). This consequence may be even more 
salient in women compared to men since women have screening tests throughout their adult lives 
to identify the presence of HPV (US Preventive Services Task Force, 2014a), whereas a 
comparable test is not approved for use among men. Therefore, women may experience these 
emotional responses on a greater scale due to increased testing. Yet, Daley, Buhi, Marhefka, et 
al. (2012) found in a natural history study of HPV infection in men, that men who tested positive 
for HPV experienced more negative emotional responses compared to HPV negative men. The 
only instance where the emotional responses to HPV may be similar across sexes is with the 
presence of genital warts, which may cause shame and affect self-esteem (Jeynes, Chung, & 
Challenor, 2009), or potentially oropharyngeal cancer. 
 
Behavioral Skills 
 Vaccinated and unvaccinated women had similar procedural knowledge for obtaining the 
HPV vaccine. This is reassuring to confirm that unvaccinated women are aware of the process 
for accessing, financing, and following up with the HPV vaccine. Additionally, women reported 
similar facilitators to vaccination, including ease of logistics, cost/insurance, and healthcare 
provider established or trusted. Yet, unvaccinated women desired additional information prior to 
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vaccination. Another facilitator described was a fewer number of shots for the vaccine series. 
This is reassuring as current research is evaluating the efficacy of a two-dose rather than three-
dose vaccine (Markowitz et al., 2014), which may ease the vaccination process for women. 
 In contrast, unvaccinated women reported more barriers to vaccination, such as cost and 
insurance. However, the frequency of barriers reported in this group may be inflated compared to 
vaccinated women due addressing a hypothetical situation, whereas vaccinated women recalled 
the situation. Some of the barriers described by unvaccinated women were stated in reference to 
women generally, not necessarily personally experienced barriers. In the NHIS sample of 
unvaccinated women, the cost of the vaccine as a reason for non-vaccination was only cited by 
3% of the sample. Yet, the presence of cost and lack of insurance coverage as a barrier to 
vaccination is congruent with previous literature among this population (Anhang Price et al., 
2011; Dempsey et al., 2011; Ford, 2011; Head & Cohen, 2012; Hodge et al., 2011; Jain et al., 
2009; Joseph et al., 2014; Laz et al., 2013; Lindley et al., 2013; Rahman et al., 2015; Tiro et al., 
2012; Wei et al., 2013; Zimet et al., 2010).  
 
Macro Factors 
 The macro factors assessed in this study were healthcare interaction, economic factors 
(i.e., insurance coverage and poverty level), and social and cultural factors. 
 
 Healthcare Interaction  
 The interview sample reported high levels of healthcare interaction; visiting a 
gynecologist or general practice physician approximately once a year. This indicates that access 
to a healthcare provider is not an issue; rather these women have many clinical opportunities to 
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discuss the HPV vaccine with providers. In fact, women mentioned needing to go to a healthcare 
appointment for annual exams for preventive screening, such as Pap tests, as well as getting birth 
control refills. Florida data from 2008-2009 indicate that approximately 24% of women reported 
using short-acting reversible methods of contraception, such as pills, injectable, patches, and 5% 
using long-acting reversible methods, such as intrauterine devices, and implants (Hernandez, 
Sappenfield, Clark, & Thompson, 2012), all of which requires some level of healthcare 
interaction. These simultaneous sexual and reproductive health behaviors may offer the 
opportunity for increased vaccination among catch-up young adult women. However, one barrier 
reported among college women was the desired to return to a familiar or trusted healthcare 
provider “back home.” This may reduce the number of annual visits in the catch-up period for 
some women since the logistics are less feasible. Efforts are needed to understand how to engage 
college women with health services available in a university setting, which would ultimately 
decrease logistical barriers for vaccine uptake. 
 
 Economic 
 Additionally, most women in the sample reported having some form of insurance 
coverage, which may also contribute to the high healthcare interaction for this sample. Insurance 
has been found to be a significant barrier in the literature (Anhang Price et al., 2011; Dempsey et 
al., 2011; Ford, 2011; Hodge et al., 2011; Jain et al., 2009; Laz et al., 2013; Lindley et al., 2013; 
Rahman et al., 2015; Tiro et al., 2012; Wei et al., 2013; Zimet et al., 2010), because without 
insurance, there is a high out-of-pocket cost for the HPV vaccine (American Cancer Society, 
2014b; Planned Parenthood, 2014). In contrast, insurance coverage was not a significant 
predictor of HPV vaccine interest in the NHIS sample. In addition, certain economic factors may 
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contribute to HPV vaccination in young adult women. In the NHIS sample, being less than 100% 
of the poverty ratio was a significant predictor for interest HPV vaccination. This may be 
attributed to the impending changes in Medicaid Eligibility across the United States at the time 
of the survey (2010), which would create a national Medicaid minimum eligibility of 133% of 
the federal poverty level (Centers for Medicare and Medicaid, n.d.). Additionally, young adults 
were permitted to stay on their parent’s insurance coverage until age 26, as of 2010 ("Patient 
Protection and Affordable Care Act," 2010). Previous research has reported that low income or 
being below the federal poverty level was associated with non-vaccination among young adult 
women (Chao et al., 2010; Jain et al., 2009; Laz et al., 2013; Rahman et al., 2013; Wei et al., 
2013). With the changing healthcare landscape and availability of health coverage for young 
adults, it is anticipated that insurance coverage for this demographic will increase (Claxton, 
Levitt, Brodie, Garfield, & Damico, 2014; Rudowitz, Snyder, Smith, Gifford, & Ellis, 2014). 
   
 Social and Cultural Factors 
 One of the more nebulous factors reported by women were the social and cultural factors 
impacting HPV vaccination. These may be more difficult for participants to recall since they are 
in the periphery of their influence. The most prominent theme that emerged throughout the 
interviews was the discussion of the anti-vaccination movement. As a result, the discussion about 
vaccines became politicized with participants stating they were “pro-vaccine” or did not 
understand people who were “anti-vaccine.” The social context of this movement is necessary to 
consider for this health behavior as public commentary and figures (e.g., celebrities) can have an 
influence on a preventive behavior (Bean, 2011; Hoffman & Tan, 2015). 
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 Some women described media messages about the HPV vaccine that they have seen. The 
majority were characterized as negative or mixed/incomplete messages. Similarly, a content 
analysis of web media has revealed the majority of the HPV vaccine webpages also have a 
negative spin (Ruiz & Barnett, 2015). Moreover, popular media, such as the television show 
Girls on HBO, may provide unfocused or problematic messages about HPV and HPV 
vaccination (Rogers, 2015). Overall, the women reported a level of skepticism of the messages 
seen. While mass media campaigns or other sources of media may be used as a tool to reach a 
broad audience, this may not necessarily be the best option to target young adult women. 
 Finally, the NHIS sample revealed that region of the United States impacted interest in 
HPV vaccination. While previous literature has indicated that the South region has lower uptake 
in the HPV vaccine (Rahman et al., 2013; Schmidt & Parsons, 2014), this analysis found that 
women living in the Midwest were less likely than women living in the South to be interested in 
the HPV vaccine.  
 
Strengths and Limitations 
 For any research project, the strengths and limitations of the study design must be 
evaluated in context of the results reported.  For this study, these were be assessed by phase of 
the study due to the mixed method design. 
 
 Phase I – Validity and Reliability 
Utilizing the NHIS 2010 dataset for a secondary data analysis had advantages to achieve 
this research aim. First, the survey used a nationally-representative sample based on the 
population characteristics from the U.S. Census. The analysis procedures incorporated the 
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primary sampling units, strata and clustering variables to appropriately weight the survey data 
according to the complex sampling design. Thus, the external validity of this sample could 
extend to the larger United States population of unvaccinated women 18 to 26 years of age. 
 Despite the benefits of conducting a secondary data analysis (e.g., feasibility, 
generalizability), there were limitations. First, given that this was a cross-sectional survey, there 
was the concern for issues with self-report for responses, specifically for HPV vaccination, one 
of the sub-setting variables used to develop the samples for analysis. Previous studies have 
estimated the reliability of self-report of HPV vaccination. One study has shown that the 
sensitivity for recall among adolescent girls 13 to 17 years to only be 54%, and for mothers of 
those girls 76%. Alternatively, the specificity was 100% (Stupiansky, Zimet, Cummings, 
Fortenberry, & Shew, 2012). A study conducted among women 18 to 26 years old reported that 
there was 94.5% agreement between recall and electronic medical records for the first dose of the 
HPV vaccine series (Kharbanda et al., 2013).  The remaining variables included in the analysis 
were also self-reported and may have suffered from recall bias by the individual. Moreover, the 
reliability of these survey questions was not reported on publically available reports from the 
National Center for Health Statistics. However, the questions are periodically revised by experts 
in health statistics and health content areas (Centers for Disease Control and Prevention & 
National Center for Health Statistics, 2012). Also, because these data were from a secondary 
source, the analysis was limited to the population who had the option to respond to the 
psychosocial questions about the HPV vaccine, which were women un-interested in the vaccine. 
As a result, a comparison of vaccinated to un-vaccinated women was not within the scope of this 
analysis. 
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An additional limitation of this dataset was the response rate. While participants were 
drawn from a random sample, nearly 40% refused to participate. In 2009, the nonresponse bias 
for the sample adult and sample child files were assessed. In the sample adult file, non-
respondents were more likely to be younger and Hispanic, but have a similar health status. As a 
result of this analysis, an adjustment was made and implemented in the 2010 NHIS file weights 
to account for nonresponse bias associated with geographic area, sex, age, and race/ethnicity 
(Moriarity, 2009). Another issue faced was the large amount of missing data for the income 
variable in the NHIS 2010 dataset. To address this issue, the NHIS has developed imputed values 
for income based on demographic and health-related variables (Division of Health Interview 
Statistics & National Center for Health Statistics, 2011b). As a result, multiple imputation was 
used in the analysis to estimate income’s impact on HPV vaccine intention.  
 An additional limitation of using secondary, cross-sectional data was the ability to assess 
causality between the exposure and outcome. While women may report no interest in the HPV 
vaccine while in a particular relationship status, this only infers an association between 
relationship status and HPV vaccination interest. Additional qualitative research elucidated 
women’s specific decision-making for HPV non-vaccination. 
The statistical analysis methods also must be considered. This study used logistic 
regression to estimate the odds ratio. While this is the most commonly used methodology for 
measuring the strength of association in cross-sectional data (Szklo & Nieto, 2007b), this 
particular analysis was limited by the fact that the outcome variable of interest may not be rare 
(i.e., ~35%) (Schmidt & Parsons, 2014). The odds ratio asymptotically approaches the relative 
risk with small probabilities; however, when an event is not rare (>10%), then the odds ratio will 
overestimate the relative risk (Szklo & Nieto, 2007a). To assist in this overestimation of the 
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relative risk, an ad hoc adjustment of the odds ratio was used to derive a closer estimate of the 
relative risk by accounting for the prevalence (Zhang & Yu, 1998). 
The final statistical consideration was the use of survey-weighting procedures and the 
availability of Exact tests in the statistical software program. The primary reasons for non-
interest in HPV vaccination compared to relationship status revealed multiple cells with 
frequencies less than five. While chi square tests are not equipped to handle small cell numbers 
(Rosner, 2006), Fishers Exact test is not available in SAS 9.4 with survey-weighting procedures 
(SAS Institute Inc., 2015). As a result, smaller categories were combined into an “other” 
category to permit the use of a chi square test. This ultimately resulted in a reduction in the 
variability of responses for reason for non-vaccination.  
 
Phase II - Trustworthiness of Data  
Qualitative methodology does not have the traditional methods for assessment of validity 
and reliability. Rather data can be assessed for trustworthiness, the truth value of the findings, 
using the following criteria: credibility, dependability, confirmability, and transferability (Ulin, 
Robinson, & Tolley, 2005) In this context, the credibility of the interpretations of the data was 
assessed by looking for negative cases for emerging hypotheses in the data, as well as seeking 
explanations for inconsistencies in the data from outside sources (e.g., Phase I results). 
Dependability refers to the ability to replicate the process for obtaining the results, which was 
documented throughout the research process and reported in dissemination pieces. Due to the 
subjective nature of data analysis, it was important for the researcher to be reflexive throughout 
the project. This occurred through writing memos during the interview and analysis processes, as 
well as debriefing with committee members and colleagues. Additionally, having a second coder 
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establish the reliability of the coding process (kappa = 0.88) improved the dependability of the 
analysis process. Confirmability of the results was achieved by utilizing an audit trail for all 
research processes (e.g., raw data, data analysis process, memos). Finally, transferability is the 
degree to which the results can be applied or transferred to groups of people beyond this project. 
Results are more likely to be transferable when utilizing a theoretical framework to guide the 
research, making it more likely to be adaptable to other populations (Ulin et al., 2005). To assist 
in the transferability of the results, the IMB Model was used as a guiding theoretical framework. 
To assist in the evaluation of the transferability of the results, the characteristics of the final 
sample was assessed to allow for comparison with other types of populations (Denscombe, 
2010). The student population at the University of South Florida is more racially/ethnically 
diverse than most universities in the United States. Data from the NCHA 2013-14 surveys 
indicate that USF had more black and Hispanic respondents (11.3% and 21.1%, respectively) 
compared to the reference group (6.6% and 13.9%, respectively). Furthermore, these racial and 
ethnic groups have increased at the University of South Florida  from 2011 to 2014 (University 
of South Florida, n.d.-a). Among the eligible sample completing the initial survey, 19% of 
respondents were Hispanic and 19% were black. It may be that these results are only transferable 
to similar college populations and not representative of women 18 to 26 years in the general 
population. Moreover, the data from the knowledge questions will most likely be different in this 
college population compared to a general population since one study found that knowledge about 
the HPV vaccine was strongly associated with college educational attainment (Kennedy et al., 
2011).  
Using qualitative methods to answer the proposed research question was an appropriate 
scientific approach. The research question asked “why” and “how”, which qualitative 
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methodology permits a greater level of detail and depth compared to quantitative methodology 
(Hennink et al., 2011b). Additionally, this approach was an extension of what has been 
previously documented using survey-based research indicating that married or monogamous 
women are less likely to be vaccinated (Anhang Price et al., 2011; Bernat et al., 2013; Ford, 
2011; Joseph et al., 2014; Laz et al., 2013; Liddon, Hood, et al., 2012; Liddon, Leichliter, et al., 
2012; Lindley et al., 2013; Rahman et al., 2013; Schmidt & Parsons, 2014; Wei et al., 2013; 
Williams et al., 2013; Zimet et al., 2010). This form of data collection was suitable for 
investigating how people make decisions, their personal beliefs and perceptions, motivations for 
behavior, and for sensitive issues (Hennink et al., 2011a). Furthermore, this design of having two 
segments for the sample allowed for a description of the variability of HPV informational needs, 
motivations, and behavioral skills across these groups, rather than quantifying the variation, 
which is typical of quantitative research. 
 An additional benefit of conducting in-depth interviews was the less-restrictive form of 
data collection. The open-ended nature allowed for participants to add additional information 
that may have not been explicitly asked for, thus permitting the generation of new findings. The 
iterative process of qualitative data analysis allowed for adjustments to interview guide material 
throughout the study to account for emergent findings (Hennink et al., 2011b). These 
characteristics are typically not attributes of quantitative methodologies. Additionally, this study 
design permitted women to self-identify their relationship status without any specific criteria. 
Through the in-depth interview, descriptions about length of time, monogamy, and sexual 
behavior were gathered to provide context to these relationship status categories, which may be 
beneficial for future studies.  
161 
While the knowledge scale was not the main focus of this research phase, the study 
benefited from utilizing an HPV knowledge scale that had high reliability with an intraclass 
correlation coefficient equivalent to α = 0.92. Moreover, this knowledge scale has been 
previously applied among a college sample of women, confirming the content validity of the 
scale (Daley, Vamos, et al., 2010). 
This methodology was the most appropriate for the research question; however, there are 
limitations that must be considered. Firstly, a major criticism of qualitative data analysis is the 
subjectivity of the process, that is argued to affect the internal validity of the findings (Hennink 
et al., 2011b). In order to make any potential subjectivity transparent, I engaged in reflexivity, 
which is self-reflection on the research throughout the research project (Hennink et al., 2011b). 
By documenting the potential biases I have as a researcher, this helped me be more aware of any 
subjective bias introduced in the study. For example, I am a public health, female researcher who 
perceives vaccination as a benefit to the public’s health. Also, I have received the HPV vaccine, 
underscoring my personal preference for this vaccination. During interviews, participants 
sometimes asked my personal opinion about the HPV vaccine; however, I asked that we wait 
until the end of the interview to discuss information about me. This was an attempt to not allow 
my beliefs to influence the participants’ perceptions of the HPV vaccine. 
The mode of the interview administration via telephone may have impacted the social 
desirability bias of the data collected. Compared to questionnaires, telephone interviewing has 
been found to underestimate severity of health status due to respondents reporting better health 
outcomes (Brewer, Hallman, Fiedler, & Kipen, 2004). However, a comparison of perceived risk 
for cancer was compared for interview administered telephone surveys and  mailed surveys 
found there was no difference between these modes of data collection (Persoskie, Leyva, & 
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Ferrer, 2014). To ameliorate the effect of social desirability bias on the data collection process, 
the researcher attempted to establish rapport with the participants. This was implemented by 
demonstrating gratitude to the participant for their time and honesty of their answers. Moreover, 
the more sensitive questions regarding HPV risk were layered in the middle of the interview to 
allow time for the participant to be more comfortable with the interviewer. 
An additional potential source of bias that may have been present in this study is 
sampling bias. Recruitment materials (Appendix A) stated the purpose of this study was to “… 
investigat[e] the knowledge, attitudes and opinions of young adult women about HPV 
vaccination.” As a result, women included in the sample may have had more of an interest or 
more knowledge of the HPV vaccine compared to non-participants. Additionally, recruitment in 
this phase was stratified only by vaccination status and relationship status in order to assess the 
variability in HPV vaccine decision-making among these groups. This stratification alone may 
prevent equivalent comparisons of known risk factors or associated sociodemographic factors for 
HPV vaccination (e.g., age, sexual orientation), which may slightly bias these results. 
Findings from the qualitative data indicated that there may have been recall bias for 
women who already received the HPV vaccine. Certain constructs, such as attitudes about the 
HPV vaccine and barriers to vaccination, may have been adjusted for women after receiving the 
HPV vaccine compared to unvaccinated women. While the research design advertised that 
women could be eligible to participate if they received the first dose of the vaccine within the 
last six months, it became clear during the interview process that many women did not accurately 
recall this length of time. Once the study concluded, it was determined that overall the 
vaccinated women received at least one of the three doses for the vaccine in the last year, rather 
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than the first dose in the last six months. Conducting the follow-up interviews after the survey 
was permitted the elucidation of this difference.  
 One interesting finding in two of the interviews was women reporting that the HPV 
vaccine was required for admittance to the university or living in residence halls. These women 
were probed to describe the vaccine and the purpose of the vaccine to ensure it was the HPV 
vaccine they were referencing. Additionally, these women were asked to clarify if it was the 
HPV vaccine and not the meningococcal vaccine, which is often required for living on campus. 
Everything stated by the participants indicated that they received the HPV vaccine with the 
exception that it was required, which was incorrect. During the analysis, the USF Student Health 
Services webpage was reviewed to determine if any confusion could occur for students. While 
the webpage clearly delineates those vaccines required for documentation (e.g., MMR, Hepatitis 
B, and Meningitis if living on campus), it does provide information on the HPV vaccine in 
addition to these other vaccines (University of South Florida, n.d.-b). Future work should 
examine how college entry policies could impact HPV vaccination behavior for catch-up groups. 
The goal of Phase II was to compare the informational needs, motivations, and behavioral 
skills for HPV vaccination among young adult women across relationship status groups and 
vaccination status groups in congruence with the research questions proposed (Table 2). While 
conducting these comparisons, it was evident that women who were married/living with a partner 
or in a long-term monogamous relationship shared similar factors for HPV vaccination. Thus, 
these two sampling groups were consolidated into one group for the analysis. It was 
hypothesized that the single and dating, and single only groups would also be similar; however, 
it was evident that these two sampling groups were distinct in their factors contributing to HPV 
vaccination. As a result there were uneven numbers in the sampling categories for the data 
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analysis. However, this study underscored the importance of finer categorizations of relationship 
status for scientific study. Previous research has stratified samples by sexual activity (active or 
never active) (Hopfer & Clippard, 2011); yet this oversimplification removes the heterogeneity 
present within these groups as evidenced by this study. 
 
Implications  
 This research study established that relationship status plays an integral role in HPV 
vaccine decision-making for young adult women. Primarily, it identified that women’s risk 
perceptions regarding HPV were moderated by their relationship status; specifically, women in 
long-term relationships were less likely to see themselves at risk for HPV due to monogamy. A 
potential mechanism to address this discrepancy between actual and perceived risk is the use of 
health literacy. Health literacy is the process of finding, understanding, evaluating, 
communicating and using health information to make informed health decisions (Coleman et al., 
2011). Returning to the IMB Model, women in this study were found to have adequate levels of 
knowledge regarding HPV and HPV vaccination, such as identifying HPV as sexually 
transmitted, the potential ways to prevent HPV, and that a vaccine does exist. Moreover, the 
women also reported having the behavioral skills necessary to perform the behavior, such as 
procedural knowledge and facilitators. The high level of healthcare interaction and insurance 
coverage also facilitates the ability of these women to have opportunities for vaccination. 
However, the motivations for vaccination served as obstacles, specifically risk perceptions. 
Therefore, the missing step in the health literacy process is the accurate evaluation of this health 
information regarding risk for HPV and how it applies to women’s personal health (Coleman et 
al., 2011).  
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 A key social motivator identified by women was the healthcare provider. While previous 
literature reports that a healthcare provider recommendation is an essential step in the HPV 
vaccination process (Rosenthal et al., 2011), this study expanded these findings by emphasizing 
the importance of provider reassurance that the vaccine is best for the individual. Healthcare 
providers can be agents in the health literacy process to assist women in evaluating the true risk 
for HPV, not only based on current relationship status, but also future risk for HPV.  Currently, 
US Preventive Services Task Force recommends sexually transmitted infection behavioral 
counseling for sexually active adolescents and adults. This comprises providing essential health 
information about STIs and transmission, assessing individual risk for STIs, and skill building 
(e.g., condoms, communication, and goal-setting) (US Preventive Services Task Force, 2014b). 
While this type of behavioral counseling is recommended generally for all STIs, specific health 
messages are required for HPV, as well as for the HPV vaccine, for women not already 
vaccinated. These messages can assist women in understanding individual risk for HPV in the 
context of relationship status and potential future risk. 
 While healthcare providers are integral to the health literacy process for young adult 
women and HPV vaccination, an assessment regarding current provider practices and HPV 
vaccination should occur. Previous research has reported that providers have biases regarding 
prioritization of HPV vaccination and young adult female patients’ relationship statuses (Zimet 
et al., 2011); however, these were based on hypothetical scenarios. As such, it may be necessary 
for healthcare providers to be recipients, in addition to agents, of health literacy to equip them 
with the skills needed to assist patients in the evaluation process for the HPV vaccine (Vamos, 
2011). Moreover, research with healthcare providers could identify the tools or methods that 
would facilitate this process with patients, for example, patient decision-making aids, 
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informational brochures, Internet websites, brief motivational interviewing or eHealth 
technology. Previous research reported that providers rely on secondary sources (e.g., handouts) 
to facilitate HPV vaccine discussions and also preferred to follow professional organization 
recommendations (Vadaparampil et al., 2013). Integrating previous findings with formative 
consumer-based research can inform the development of resources that would be acceptable and 
feasible for providers in a clinic setting. 
 Ultimately tailoring health messages to young adult women’s specific risk misperceptions 
about HPV can promote patient-centered, individualized care to reassure women about the HPV 
vaccine. This connects with the women’s reported desire for personal decision-making about 
HPV vaccination. By reinforcing the health literacy process, women will ultimately be able to 
make an informed decision based on all evidence. The findings from this mixed-methods study 
provide the formative research to inform future intervention development. In fact, this study 
design aligns with the elicitation phase of the IMB Model intervention development sequence 
(Fisher & Fisher, 2002). These findings can be used in future research in three specific manners: 
(1) develop a quantitative instrument guided by the IMB Model to assess risk perceptions and 
relationship status as a barrier to HPV vaccination among a larger sample and more diverse 
population (e.g., community sample, 4-year college sample, 2-year college sample); (2) develop 
health messages from the qualitative responses from women regarding their risk perceptions for 
HPV and perceived need for the vaccine; and (3) evaluate developed health messages in multiple 
settings. The proposed quantitative survey should include a measure of sexual behaviors to 
compare actual and perceived risk for HPV. It can also be utilized to evaluate future 
interventions. Findings from future research with the target population and healthcare providers 
can inform the development of theory-based interventions using IMB Model and Intervention 
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Mapping methodologies (Bartholomew et al., 1998; Fisher & Fisher, 2002) (Figure 10). In 
addition to planning and preparing for future research endeavors, a dissemination plan has been 
developed to share these results with scientific and community audiences (Appendix C). 
 
 
Figure 10: Proposed Future Research to Improve HPV Vaccination 
  
 Additionally, this proposed future research aligns with a number of public health 
priorities, including Healthy People 2020 objectives to: (1) Improve the health literacy of the 
population; (2) Increase the proportion of patients whose doctor recommends personalize health 
information resources to help them manage their health; (3) increase the proportion of persons 
who report that their health care providers always involved them in decisions about their health 
care as much as they wanted; (4) reduce the proportion of females with HPV infection; (5) 
reduce invasive uterine cervical cancer cases; and (6) reduce the death rate from cancer of the 
uterine cervix (Healthy People 2020, 2015a, 2015b, 2015c, 2015d).  
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 A final issue to address is the need for continued targeted efforts to improve HPV 
vaccination rates among young adult women in the United States. The two major barriers 
identified for HPV vaccination as an adolescent were unawareness of the vaccine and parental 
refusal. As unvaccinated adolescents transition into young adulthood, they should be given the 
opportunity to make individual health decisions to prevent HPV and HPV-related diseases, 
outside the prevue of their parents’ beliefs. Future research aimed at improving HPV vaccination 
among young adult women aligns with the Centers for Disease Control and Prevention call for 
additional research to increase HPV vaccine coverage by engaging patients and providers to 
eliminate missed clinical opportunities (Markowitz et al., 2014). Thus, young adults should not 
be discounted from continued research on HPV vaccination. 
 
Conclusion  
 This study found that relationship status impacts HPV vaccine decision-making and 
reasons for non-vaccination among young adult women. Specifically, it operates by modifying 
risk perceptions for HPV and perceived need for the HPV vaccine, which serve as barriers to 
vaccination. Young adult women have the knowledge and behavioral skills necessary to access 
and understand the importance of HPV vaccination, as well as the reinforcing macro factors in 
place. However, women are unable to accurately perceive their individual risk for HPV, resulting 
in impaired motivation for vaccination. A potential mechanism to address this issue is the use of 
health literacy. Future research should integrate health literacy techniques with healthcare 
providers serving this population to assist in the evaluation process for risk of HPV among 
young adult women. This will facilitate shared decision-making and patient-provider 
communication surrounding the HPV vaccine.  
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 If current trends in HPV vaccination continue in the United States, there will continue to 
be a substantial proportion of women who are in the catch-up range of 18 to 26 years old, yet are 
not vaccinated. Continued research is needed to target this specific group of unvaccinated 
women who have the opportunity to make autonomous sexual and reproductive health decisions.  
By promoting HPV vaccination among young adult women, it will ultimately reduce the 
morbidity and mortality of HPV-related diseases, including genital warts and HPV-related 
cancers. 
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APPENDIX A: PHASE II RECRUITMENT EMAIL LANGUAGE 
 
IRB # 
Study Title: HPV Vaccination among Young Adult Women 
PI: Erika Thompson, MPH 
 
Volunteers Needed for Research Study 
Description:  We are investigating the knowledge, attitudes and opinions of young adult women 
about HPV vaccination. Your participation would take about 5 minutes to complete an initial 
online survey. You would then be contacted to schedule a follow-up 30 minute telephone or 
Skype interview at a time that is convenient for you. 
Who Can Participate? 
 female,  
 age 18 to 26 years,  
 student at the University of South Florida, and 
 meets one of these criteria: 
o has not received any HPV vaccine shots 
o has received the first HPV vaccine shot within the last 6 months 
Incentives for Participation: Participants who schedule and complete the telephone/Skype 
interview will receive a $10 gift card. 
How to Participate? Start the process by clicking on this link to complete the initial short 
survey. 
HYPERLINK FOR SURVEY 
To learn more, contact the Principal Investigator, Erika Thompson at XXX-XXX-XXXX or at 
ethomps1@health.usf.edu.  
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APPENDIX B: PHASE II INSTRUMENTS 
 
Eligibility Survey 
Thank you for your interest in the HPV Vaccination among Young Adult Women study. To 
determine if you are eligible to participate, please complete the following questions. 
 
1. What is your gender? 
a. Female 
b. Male 
c. Transgender 
d. Other 
 
2. What is your current age? ______ 
 
3. A vaccine to prevent the human papilloma virus or HPV infection is available and is 
called the cervical cancer or genital warts vaccine, HPV shot, Gardasil or Cervarix. Have 
you EVER received an HPV vaccine shot? 
a. No (Continue to Question 6) 
b. Yes (Continue to question 4) 
c. Don’t know (End survey) 
 
4. Did you receive your first HPV vaccine shot in the last 6 months? 
a. No (End survey) 
b. Yes (Continue to question 5) 
c. Don’t know (End survey) 
 
5. (Question 4 = Yes) Thinking back to when you received your first dose of the HPV 
vaccine, please identify your relationship status at that time: 
a. Married or living with a partner 
b. Single, but in a long-term monogamous relationship 
c. Single and dating 
d. Singe, but not in a relationship or dating 
 
6. (Question 3 = No) Please identify your current relationship status: 
a. Married or living with a partner 
b. Single, but in a long-term monogamous relationship 
c. Single and dating 
d. Singe, but not in a relationship or dating 
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Informed Consent 
Informed Consent to Participate in Research 
Information to Consider Before Taking Part in this Research Study 
 
IRB Study #  
 
You are being asked to take part in a research study. Research studies include only people who 
choose to take part. This document is called an informed consent form. Please read this 
information carefully and take your time making your decision. Ask the researcher or study staff 
to discuss this consent form with you, please ask him/her to explain any words or information 
you do not clearly understand.  We encourage you to talk with your family and friends before 
you decide to take part in this research study.  The nature of the study, risks, inconveniences, 
discomforts, and other important information about the study are listed below. 
We are asking you to take part in a research study called:  
HPV Vaccination among Young Adult Women 
The person who is in charge of this research study is Erika Thompson.  This person is called the 
Principal Investigator.  However, other research staff may be involved and can act on behalf of 
the person in charge. Erika Thompson is being guided in this research by Dr. Ellen Daley.  If you 
have any questions about this research please contact Erika Thompson at 
ethomps1@health.usf.edu (XXX-XXX-XXXX) or Dr. Ellen Daley at email address.  
 
The research will be conducted via an online survey and a follow-up telephone or Skype 
interview.  
 
 
Purpose of the study 
The purpose of this study is to assess and understand the information needs, motivations, and 
skills required for HPV vaccination among college females. You are being asked to participate 
because you are enrolled at the University of South Florida and met the eligibility criteria. 
Study Procedures 
 If you take part in this study, you will be asked to spend approximately 5-minutes 
answering questions about your knowledge of HPV and HPV vaccination. There are no 
right or wrong answers to any of the questions.  Your responses will be averaged with the 
responses of other participants. All responses will remain anonymous and individual 
responses will not be identified.  
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No identifiable information, including your name or email address, will be associated 
with your responses. However, you will be asked to report information on your age, 
gender, race/ethnicity, relationship status, and sexual orientation. In order to schedule a 
follow-up interview, you will be asked to provide your name, email, and telephone 
number. These items will not be connected to any of the information you share. 
 
 You will only complete the survey once. There will only be a follow-up interview.  
 
This research is being conducted at the University of South Florida, during March to 
April 2015.  
Total Number of Participants 
About 48 individuals will take part in this study at USF.  
Alternatives 
You do not have to participate in this research study.  
Benefits 
We are unsure if you will receive any benefits by taking part in this research study.   
Risks or Discomfort 
This research is considered to be minimal risk.  That means that the risks associated with this 
study are the same as what you face every day.  There are no known additional risks to those 
who take part in this study. 
Compensation 
You will receive a $10 gift card for participating in the survey and interview for this study. 
Cost 
There will be no additional costs to you as a result of being in this study.  However, routine 
medical care for your condition (care you would have received whether or not you were in this 
study) will be charged to you or your insurance company.  You may wish to contact your 
insurance company to discuss this further. 
Conflict of Interest Statement 
While we are conducting the research study, we cannot let you see or copy the research 
information we have about you.  After the research is completed, you have a right to see the 
information about you, as allowed by USF policies. 
Privacy and Confidentiality 
We will keep your study records private and confidential.  Certain people may need to see your 
study records.  By law, anyone who looks at your records must keep them completely 
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confidential.  The only people who will be allowed to see these records are: 
 The research team, including the Principal Investigator, Co-Investigators, study advisors, 
and all other research staff.   
 Certain government and university people who need to know more about the study.  For 
example, individuals who provide oversight on this study may need to look at your 
records. This is done to make sure that we are doing the study in the right way.  They also 
need to make sure that we are protecting your rights and your safety.   
 The USF Institutional Review Board (IRB) and its related staff who have oversight 
responsibilities for this study, staff in the USF Office of Research and Innovation, USF 
Division of Research Integrity and Compliance, and other USF offices who oversee this 
research. 
 It is possible that unauthorized individuals could gain access to your responses. 
Confidentiality will be maintained to the degree permitted by the technology used. No 
guarantees can be made regarding the interception of data sent via the Internet. However, 
your participation in this online survey involves risks similar to a person’s everyday use 
of the Internet. If you complete and submit an anonymous survey and later request your 
data be withdrawn, this may not be possible as the researcher may not be unable to 
extract anonymous data from the database. 
We may publish what we learn from this study.  If we do, we will not include your name.  We 
will not publish anything that would let people know who you are.   
Voluntary Participation / Withdrawal 
You should only take part in this study if you want to volunteer.  You should not feel that there is 
any pressure to take part in the study.  You are free to participate in this research or withdraw at 
any time.  The decision to participate or not to participate in the study will not affect your student 
status (e.g., course grades, etc).  
New information about the study 
During the course of this study, we may find more information that could be important to you.  
This includes information that, once learned, might cause you to change your mind about being 
in the study.  We will notify you as soon as possible if such information becomes available. 
 
You can get the answers to your questions, concerns, or complaints  
If you have questions about your rights as a participant in this study, general questions, or have 
complaints, concerns or issues you want to discuss with someone outside the research, call the 
USF IRB at (813) 974-5638.  
 
 
By completing the survey, you are agreeing to participate in research.  
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Demographic Questions 
Thank you for agreeing to participate in this study. All of your responses will be confidential. 
Please complete the following questions. 
 
1. Which category(ies) best describes your race? (Check all that apply) 
a. American Indian/Alaskan Native 
b. Asian 
c. Native Hawaiian/Pacific Islander 
d. Black or African American 
e. White or Caucasian 
f. Other: _____________ 
 
2. Are you Hispanic or Latina? 
a. Yes 
b. No 
 
3. Are you an international student? 
a. Yes 
b. No 
 
4. What is your primary source of health insurance? 
a. Private 
b. School-sponsored 
c. Medicaid 
d. Other: _____________ 
e. Don’t have insurance 
f. Not sure if I have insurance 
 
5. What sexual orientation do you most identify with? (Check one) 
a. Bisexual 
b. Homosexual 
c. Heterosexual 
d. Unsure 
e. Other:___________ 
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Knowledge Questions 
For each of the following questions, please answer True or False as a response. If you are unsure, 
you can select Unsure. Please do not use any outside resources to assist you in answering these 
questions. 
1. There are many types of HPV (T) 
2. Antibiotics can cure HPV (F) 
3. Only men can get HPV (F) 
4. Using a condom decreases the chance of HPV transmission (T) 
5. There is a vaccine for women that prevents certain types of HPV (T) 
6. You can have HPV without knowing it (T) 
7. HPV can be cured (F) 
8. Some types of HPV cause cervical cancer (T) 
9. HPV can cause HIV/AIDS (F) 
10. You can always tell when someone else have HPV (F) 
11. HPV can cause abnormal Pap smears in women (T) 
12. HPV can cause herpes (F) 
13. HPV can affect a woman’s ability to get pregnant (F) 
14. HPV is a virus (T) 
15. HPV can cause genital warts (T) 
16. HPV is spread on toilet seats (F) 
17. Only women can get HPV (F) 
18. HPV is a sexually transmitted infection (T) 
19. Transmission of HPV can occur through sexual contact with another person (T) 
20. HPV can be passed to a newborn at birth (T) 
21. Even if you do not see a wart, you can transmit HPV (T) 
22. HPV is a bacterial infection (F) 
23. Most HPV infections clear up within a short time (T) 
 
 
24. Where have you heard about the HPV vaccine? (Check all that apply) 
a. Healthcare provider  
b. Family 
c. Friends/Peers 
d. Partner/Spouse 
e. Radio 
f. Television 
g. Internet 
h. Other source: __________________ 
i. I have not heard about the HPV vaccine until today 
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Interview Guide  
 
Hello, my name is Erika Thompson, and I am a researcher and doctoral candidate at the 
University of South Florida. May I please speak to ___________. 
 
Thank you for completing the initial survey for this study and agreeing to participate in this 
interview. This interview should only take about 30 to 40 minutes. As you may recall, you 
consented to this interview when you initially completed the survey. Your participation is 
completely voluntary and we can stop the interview at any time. Everything you state will be 
confidential and not linked to your name or any other identifiers. Finally, there is no right or 
wrong answer to each of these questions. I just ask that you answer the questions as honestly as 
you can. 
 
Would you mind if I audio-recorded our conversation? 
 
So to start, what do you think about the HPV vaccine? 
 
Construct Sub-Group Interview Question 
Information: 
Knowledge 
All What are some of the things you know about HPV? 
     [Probe: Transmission 
     Probe: Outcomes – cancer, genital warts, herpes, HIV 
     Probe: Curability and length of infection] 
     Added after pilot testing 
 
What are some of the things you know about the HPV 
vaccine? 
     [Probe: Who can get it? 
     Probe: When should you get it? 
     Probe: Any negative effect associated with it?] 
     Added after pilot testing 
 
[People mention __[insert from knowledge 
questionnaire]____ about HPV (HPV vaccine). What do you 
think about this statement? Why?]  Removed after pilot testing 
 
[I see you mentioned on your survey that you heard of the 
HPV vaccine from _____________. Is there one of these 
sources that your trust the most?] Added after pilot testing 
 
[If you wanted to receive more information about the HPV 
vaccine, where would you want to get it from?] Added after 
pilot testing 
Human papillomavirus or HPV is a sexually transmitted infection. The HPV vaccine can protect 
females and males against types of HPV that can cause genital warts and cancers, such as 
cervical cancer. The vaccine includes three doses or three shots provided over the course of six 
months typically. 
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Motivation: 
Personal 
Unvaccinated How do you feel about vaccines in general? 
    Probe: How important do you think they are? Why? 
 
How do you feel about the HPV vaccine? 
     Probe: How important do you think it is? Why? 
 
What are some good things about getting the vaccine? Why? 
 
What are some bad things about getting the vaccine? Why? 
 
What are the reasons for not getting HPV vaccinated? 
 
Why didn’t you get the vaccine when you were younger? 
Vaccinated How do you feel about vaccines in general? 
    Probe: How important do you think they are? Why? 
 
How do you feel about the HPV vaccine? 
     Probe: How important do you think it is? Why? 
 
What are some good things about getting the vaccine? Why? 
 
What are some bad things about getting the vaccine? Why? 
 
What are some of the reasons why you decided to get the 
vaccine now? 
 
Why didn’t you get the vaccine when you were younger? 
Motivation: 
Social 
Unvaccinated Which people in your life do you think would impact your 
decision to get the vaccine? 
    Probe: How would they impact your decision? (Positive or     
    negative) 
    Probe: Parents, peers, partners, providers? 
 
Based on your response to the initial survey, I see that you are 
in a [relationship category]. Can you talk a little bit about your 
current relationship status? 
     Probe: Length of time? 
     Probe: Mutually monogamous? (if applicable) 
     Probe: Future together? (if applicable) 
 
How does your current relationship status impact your 
decision to be HPV vaccinated? Why? 
 
How do you think it might change if your relationship status 
changes in the future? 
Vaccinated Which people in your life do you think impacted your 
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decision to get the vaccine? 
    Probe: How did they impact your decision? (Positive or     
    negative) 
    Probe: Parents, peers, partners, providers? 
 
Based on your response to the initial survey, I see that you 
were in a [relationship category] at the time you were 
vaccinated. Can you talk a little bit about your relationship 
status at that time? 
     Probe: Length of time? Still in this relationship? 
     Probe: Mutually monogamous? (if applicable) 
     Probe: Future together? (if applicable) 
 
How did your relationship status at that time impact your 
decision to be HPV vaccinated? Why? 
Motivation: 
Perceived 
Vulnerability 
Unvaccinated What do you think your risk of HPV is, without the vaccine? 
     Probe: What influences this risk? 
     Probe: Does your relationship status impact this risk? 
 
Do you think your risk would change if you got the vaccine? 
     Probe: How so? 
 
What do you think are the consequences of getting HPV? 
     Probe: How serious is the condition?; How severe is the  
     condition?; How significant is the condition? 
Vaccinated What do you think your risk of HPV is, without the vaccine? 
     Probe: What influences this risk? 
     Probe: Did your relationship status impact this risk? 
 
Do you think your risk has changed now that you got the 
vaccine? 
     Probe: How so? 
 
What do you think are the consequences of getting HPV?  
     Probe: How serious is the condition?; How severe is the  
     condition?; How significant is the condition? 
 
Behavioral 
skills 
Unvaccinated Walk me through the steps you would need to do to get the 
HPV vaccine. 
    Probe: access, communicate, complete 
 
What would make it easy to get the vaccine? 
 
What would make it difficult to get the vaccine? 
    Probe: How confident do you feel to overcome these   
    barriers? 
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Vaccinated Walk me through the steps you took to get the HPV vaccine. 
    Probe: access, communicate, complete 
 
What made it easy to get the vaccine? 
 
What made it difficult to get the vaccine? 
    Probe: How confident did you feel to overcome these   
    barriers? 
Macro factors All How frequently do you visit your healthcare provider? 
     Probe: How often did you go in the last year? 
 
You have mentioned [list here] barriers and facilitators to 
HPV vaccination, are there any other social or cultural factors 
that impact your opinion or ability to get the vaccine? 
     Probe: Distrust government or pharmaceuticals 
     Probe: Media messages 
     Probe: Vaccine culture 
 
Insurance status question in demographics section.  
 
Is there anything else you would like to share with me about HPV or HPV vaccination? 
Thank you for your participation and contribution to this research. 
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APPENDIX C: DISSEMINATION PLAN 
1. Manuscripts 
Brief Title Target Journals 
(Impact Factor) 
Description 
IMB Model Findings American Journal of 
Public Health (4.552) 
 
Vaccine (3.624) 
 
Health Education and 
Behavior (2.229) 
The purpose is to compare the information, 
motivation, behavioral skills, and macro factors 
for HPV vaccination between vaccinated and 
unvaccinated women. Methods will be from 
Phase II of the dissertation. 
Risk Perceptions American Journal of 
Public Health (4.552) 
 
American Journal of 
Preventive Medicine 
(4.527) 
 
Women’s Health 
Issues (2.330) 
The purpose is to describe how relationship 
status impacts risk perceptions and perceived 
need of the HPV vaccine. Methods will be from 
Phase II of the dissertation. 
NHIS 2010 Analysis Sexually Transmitted 
Diseases (2.594) 
 
The focus on this paper is to describe the 
differences in primary reasons for non-
vaccination by relationship status. This 
manuscript will likely be a Brief Report. 
HPV Knowledge and 
Information 
Health Education and 
Behavior (Impact 
Factor 2.229) 
 
Women’s Health 
Issues (2.330) 
The purpose of this paper is to compare how 
knowledge items are measured for the 
quantitative and qualitative components of 
Phase II.  
 
2. Conference Abstracts 
Brief Title Conference Description 
IMB Model Findings American Academy 
of Health Behavior 
2016 
 
Due: Sept 19 2015 
The purpose is to compare the information, 
motivation, behavioral skills, and macro factors 
for HPV vaccination between vaccinated and 
unvaccinated women. Methods will be from 
Phase II of the dissertation. 
Risk Perceptions Society for the The purpose is to describe how relationship 
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Scientific Study of 
Sexuality 2015 
 
Due: Sept 1 2015 
status impacts risk perceptions and perceived 
need of the HPV vaccine. Methods will be from 
Phase II of the dissertation. 
NHIS 2010 Analysis American Public 
Health Association 
2016 
 
Due: Feb 2016 
The focus on this abstract is to describe the 
differences in primary reasons for non-
vaccination by relationship status. This 
manuscript will likely be a Brief Report. 
HPV Knowledge and 
Information 
American Public 
Health Association 
2016 
 
Due: Feb 2016 
The purpose of this abstract is to compare how 
knowledge items are measured for the 
quantitative and qualitative components of 
Phase II.  
HPV Vaccine 
Attitudes 
American Public 
Health Association 
2016 
 
Due: Feb 2016 
The purpose of this abstract is to describe how 
women frame the HPV vaccine as a separate 
vaccine from required and optional 
vaccinations, as well as reconcile these attitudes 
with the anti-vaccination movement. 
 
3. Community Reports 
An executive summary of the findings from this dissertation will be drafted and shared with the 
USF Student Health Services staff. This report will translate the research into implications for 
practice. 
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